

Abiraterone and Increased Survival in Metastatic Prostate Cancer

New England Journal of Medicine

364, 1995-2005

DOI: [10.1056/nejmoa1014618](https://doi.org/10.1056/nejmoa1014618)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current status of immunological therapies for prostate cancer. <i>Current Opinion in Urology</i> , 2010, 20, 241-246.	0.9	45
2	New Pharmacotherapies in the Treatment of Advanced Prostate Cancer. <i>Clinical Medicine Insights Urology</i> , 2010, 4, CMU.S5075.	0.4	0
3	Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 4133-4160.	1.8	1,117
4	Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 13728-13733.	3.3	303
5	New Hormonal Therapies for Castration-Resistant Prostate Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2011, 40, 625-642.	1.2	18
6	The changing therapeutic landscape of castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 597-610.	12.5	137
7	Towards a New Era in Care for Metastatic Castrate-Resistant Prostate Cancer. <i>British Journal of Medical and Surgical Urology</i> , 2011, 4, S1-S1.	0.2	0
8	Abiraterone Acetate. <i>Drugs</i> , 2011, 71, 2067-2077.	4.9	25
9	Pharmacotherapeutic Management of Locally Advanced Prostate Cancer. <i>Drugs</i> , 2011, 71, 1019-1041.	4.9	34
10	Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. <i>Asian Journal of Andrology</i> , 2011, 13, 783-784.	0.8	9
11	Abiraterone acetate. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 573-574.	21.5	33
12	Recent advances in the therapy of castration-resistant prostate cancer: The price of progress. <i>Maturitas</i> , 2011, 70, 194-196.	1.0	13
13	New Data, New Paradigms for Treating Prostate Cancer Patientsâ€™VI: Novel Hormonal Therapy Approaches. <i>Urology</i> , 2011, 78, S494-S498.	0.5	11
14	Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration-refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel. <i>Urology</i> , 2011, 78, 1125-1130.	0.5	33
15	New and emerging agents for the treatment of castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 1-8.	0.8	54
16	End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice. <i>Journal of Clinical Oncology</i> , 2011, 29, 3695-3704.	0.8	202
17	Mathematical modeling of prostate cancer progression in response to androgen ablation therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19701-19706.	3.3	62
18	New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours. <i>Breast Cancer Research</i> , 2011, 13, 318.	2.2	9

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer. <i>Drug, Healthcare and Patient Safety</i> , 2011, 3, 107.	1.0	14
20	Current Options and Future Directions in Castrate Resistant Prostate (CRPC). , 0, , .		0
21	Genitourinary Oncology: Current Status and Future Challenges. <i>Frontiers in Oncology</i> , 2011, 1, 32.	1.3	9
22	Industry Update: The latest developments in therapeutic delivery. <i>Therapeutic Delivery</i> , 2011, 2, 975-985.	1.2	0
23	Hormonal therapy for cancer. <i>Medicine</i> , 2011, 39, 723-727.	0.2	6
24	TMPRSS2-ERG Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate. <i>European Urology</i> , 2011, 60, 897-904.	0.9	176
25	Circulating Tumour Cells as Surrogate Biomarkers in Castration-Resistant Prostate Cancer Trials. <i>European Urology</i> , 2011, 60, 905-907.	0.9	5
26	Beefing up Prostate Cancer Therapy with Performance-Enhancing (Anti-) Steroids. <i>Cancer Cell</i> , 2011, 20, 7-9.	7.7	6
27	Secondary Hormonal Therapy in Men With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2011, 9, 95-103.	0.9	15
28	Circulating Tumors Cells as Biomarkers. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 438-450.	1.0	76
29	Debating controversies in the management of advanced prostate cancer. <i>Trends in Urology & Men's Health</i> , 2011, 2, 39-41.	0.2	0
32	Clinical implications of the 5 α -androstane-3-one pathway for castration-resistant prostate cancer. <i>Future Oncology</i> , 2011, 7, 1239-1241.	1.1	3
33	The unfolding treatment landscape for men with castration-resistant prostate cancer. <i>Clinical Investigation</i> , 2011, 1, 1533-1544.	0.0	2
35	Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer. <i>Current Medicinal Chemistry</i> , 2011, 18, 4440-4453.	1.2	22
36	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 766-768.	13.9	35
37	Expanding Treatment Options for Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 2055-2058.	13.9	80
38	Abiraterone prolongs survival in metastatic prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 515-516.	12.5	7
39	Recent advances in second-line treatment of castration-resistant prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2011, 5, 199-205.	0.5	3

#	ARTICLE	IF	CITATIONS
40	Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1665-1675.	3.0	120
41	Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3. <i>Clinical Cancer Research</i> , 2011, 17, 6218-6228.	3.2	53
42	GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2011, 17, 7174-7182.	3.2	31
43	Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics. <i>Clinical Cancer Research</i> , 2011, 17, 6634-6640.	3.2	46
44	The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1677-1684.	1.9	64
45	Clusterin Is a Critical Downstream Mediator of Stress-Induced YB-1 Transactivation in Prostate Cancer. <i>Molecular Cancer Research</i> , 2011, 9, 1755-1766.	1.5	63
46	Chemotherapy-Based Treatment for Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 3686-3694.	0.8	76
47	Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants. <i>Clinical Cancer Research</i> , 2011, 17, 5913-5925.	3.2	528
48	Prostate Cancer: Evolution or Revolution?. <i>Journal of Clinical Oncology</i> , 2011, 29, 3595-3598.	0.8	10
49	Circulating Tumor Cells as Biomarkers in Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 3903-3912.	3.2	219
50	Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. <i>British Journal of Cancer</i> , 2011, 105, 1628-1634.	2.9	44
51	Abiraterone increases overall survival in men with castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2011, 8, 351-351.	1.9	2
52	Forty Years of Translational Cancer Research. <i>Cancer Discovery</i> , 2011, 1, 383-390.	7.7	17
53	Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2011, 3, 3449-3460.	1.7	2
54	Revisiting the Role of Antiandrogen Strategies in Ovarian Cancer. <i>Oncologist</i> , 2011, 16, 1413-1421.	1.9	19
55	Alternatively spliced androgen receptor variants. <i>Endocrine-Related Cancer</i> , 2011, 18, R183-R196.	1.6	337
56	Novel Therapeutic Strategies for Metastatic Prostate Cancer in the Post-Docetaxel Setting. <i>Oncologist</i> , 2011, 16, 1487-1497.	1.9	26
57	Management of Castration-Resistant Prostate Cancer: A Global Approach. <i>Current Oncology</i> , 2012, 19, 32-36.	0.9	2

#	ARTICLE	IF	CITATIONS
58	Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e31s-e37s.	2.5	78
60	Hitting old targets better and identifying new targets. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 70-72.	12.5	10
61	Emerging Targeted Therapies for Castration-Resistant Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 73.	1.5	20
62	Genomic and epigenomic alterations in prostate cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 128.	1.5	13
63	Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate. <i>Canadian Urological Association Journal</i> , 2012, 6, 183-186.	0.3	3
65	Activin A Stimulates AKR1C3 Expression and Growth in Human Prostate Cancer. <i>Endocrinology</i> , 2012, 153, 5726-5734.	1.4	37
66	Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 507-516.	1.8	234
67	Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions. <i>Nucleic Acids Research</i> , 2012, 40, 10765-10779.	6.5	108
68	Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer. <i>Cancers</i> , 2012, 4, 193-217.	1.7	41
69	Redefining Hormone Sensitive Disease in Advanced Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-6.	0.6	14
70	Targeting the Androgen Receptor in the Management of Castration-Resistant Prostate Cancer: Rationale, Progress, and Future Directions. <i>Current Oncology</i> , 2012, 19, 22-31.	0.9	35
71	Patient Preference and the Impact of Decision-Making Aids on Prostate Cancer Treatment Choices and Post-Intervention Regret. <i>Current Oncology</i> , 2012, 19, 37-44.	0.9	56
72	Management of Advanced Prostate Cancer in Senior Adults: The New Landscape. <i>Oncologist</i> , 2012, 17, 16-22.	1.9	19
73	Metastatic Prostate Adenocarcinoma Diagnosed in a Colonic Polyp. <i>Journal of Clinical Oncology</i> , 2012, 30, e160-e162.	0.8	4
74	Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 644-646.	0.8	122
75	Fast and Flawed or Scientifically Sound: The Argument for Administering Oral Oncology Drugs During Fasting. <i>Journal of Clinical Oncology</i> , 2012, 30, 888-889.	0.8	13
76	Abiraterone in Prostate Cancer: A New Angle to an Old Problem. <i>Clinical Cancer Research</i> , 2012, 18, 1848-1854.	3.2	51
77	Overall Survival: Patient Outcome, Therapeutic Objective, Clinical Trial End Point, or Public Health Measure?. <i>Journal of Clinical Oncology</i> , 2012, 30, 1750-1754.	0.8	63

#	ARTICLE	IF	CITATIONS
78	Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors. <i>Cancer Research</i> , 2012, 72, 6142-6152.	0.4	175
79	Active surveillance for prostate cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 243-250.	1.1	41
80	Use of radionuclides in metastatic prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 310-315.	0.5	14
81	Combining immunological and androgen-directed approaches. <i>Current Opinion in Oncology</i> , 2012, 24, 258-265.	1.1	23
82	The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 272-277.	1.1	21
83	Overcoming castration resistance in prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 167-174.	0.9	13
84	The androgen/androgen receptor axis in prostate cancer. <i>Current Opinion in Oncology</i> , 2012, 24, 251-257.	1.1	110
85	MicroRNAs and Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 253-261.	1.0	35
86	Current status of immunological approaches for the treatment of prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 197-202.	0.9	14
88	Novel agents for the management of castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 175-182.	0.9	7
89	Emerging novel therapies for advanced prostate cancer. <i>Therapeutic Advances in Urology</i> , 2012, 4, 3-12.	0.9	26
90	Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2012, 23, 1803-1808.	0.6	120
91	A Changing Landscape in Castration-Resistant Prostate Cancer Treatment. <i>Frontiers in Endocrinology</i> , 2012, 3, 85.	1.5	13
92	Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. <i>Drug Design, Development and Therapy</i> , 2012, 6, 13.	2.0	98
93	Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. <i>Annals of Oncology</i> , 2012, 23, 1085-1094.	0.6	29
94	Latest advances in the medical treatment of cancer: a 2011 snapshot. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 3-8.	1.4	0
95	A Comment on the International Society of Geriatric Oncology Guidelines: Evidence-Based Advice for the Clinical Setting. <i>Oncologist</i> , 2012, 17, 31-35.	1.9	7
96	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. <i>Annals of Oncology</i> , 2012, 23, 2943-2947.	0.6	224

#	ARTICLE	IF	CITATIONS
97	Efficacy of Cetuximab in Metastatic Castration-Resistant Prostate Cancer Might Depend on EGFR and PTEN Expression: Results from a Phase II Trial (SAKK 08/07). <i>Clinical Cancer Research</i> , 2012, 18, 6049-6057.	3.2	36
98	AACR Cancer Progress Report 2012. <i>Clinical Cancer Research</i> , 2012, 18, S1-S100.	3.2	28
99	Nuclear Export Signal of Androgen Receptor (NESAR) Regulation of Androgen Receptor Level in Human Prostate Cell Lines via Ubiquitination and Proteasome-Dependent Degradation. <i>Endocrinology</i> , 2012, 153, 5716-5725.	1.4	26
100	Androgen Deprivation Therapy as Primary Treatment for Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 360-365.	1.8	32
101	A Phase II Pharmacodynamic Study of Preoperative Figitumumab in Patients with Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3407-3413.	3.2	47
102	Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer. <i>Cancer Discovery</i> , 2012, 2, 995-1003.	7.7	257
104	Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer. <i>Future Oncology</i> , 2012, 8, 1239-1251.	1.1	23
105	Enzalutamide in Prostate Cancer after Chemotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 2448-2449.	13.9	9
106	Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1-3.	1.1	15
107	Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. <i>Therapeutic Advances in Urology</i> , 2012, 4, 85-101.	0.9	14
108	Redefining the therapeutic landscape for CRPC. <i>Nature Reviews Urology</i> , 2012, 9, 63-64.	1.9	16
111	The evolution of antiandrogens: MDV3100 comes of age. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 131-133.	1.1	8
112	The role of abiraterone in the management of metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 429-437.	1.1	2
113	Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. <i>Cancer Biology and Therapy</i> , 2012, 13, 1001-1008.	1.5	6
114	Sipuleucel-T for the treatment of metastatic prostate cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 509-519.	1.4	16
116	MDV3100 for the treatment of prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 227-233.	1.9	29
118	Pro-survival and anti-apoptotic properties of androgen receptor signaling by oxidative stress promote treatment resistance in prostate cancer. <i>Endocrine-Related Cancer</i> , 2012, 19, R243-R253.	1.6	60
119	Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2012, 107, 592-597.	2.9	17

#	ARTICLE	IF	CITATIONS
120	Enzalutamide in metastatic CRPC—old dog, new tricks. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 613-614.	12.5	3
121	Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 75-86.	2.0	20
122	Multitargeted Tyrosine Kinase Inhibition Produces Discordant Changes Between 99mTc-MDP Bone Scans and Other Disease Biomarkers: Analysis of a Phase II Study of Sunitinib for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1670-1675.	2.8	14
123	Gene Expression Signature Predicting High-Grade Prostate Cancer Responses to Oxaliplatin. <i>Molecular Pharmacology</i> , 2012, 82, 1205-1216.	1.0	4
124	Dual Targeting of the Akt/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model. <i>Cancer Research</i> , 2012, 72, 4483-4493.	0.4	79
125	Abiraterone Inhibits 3 β -Hydroxysteroid Dehydrogenase: A Rationale for Increasing Drug Exposure in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3571-3579.	3.2	87
126	Advanced prostate cancer—a case for adjuvant differentiation therapy. <i>Nature Reviews Urology</i> , 2012, 9, 595-602.	1.9	32
127	Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1661-1671.	1.9	59
128	Treatment Given Near the End of Life in Castration-Resistant Prostate Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2012, 29, 536-540.	0.8	4
129	Post-docetaxel therapy in castration resistant prostate cancer — the forest is growing in the desert. <i>Therapeutic Advances in Urology</i> , 2012, 4, 107-111.	0.9	2
130	Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone. <i>Journal of Clinical Oncology</i> , 2012, 30, 637-643.	0.8	168
131	Challenges in Recognizing Treatment-Related Neuroendocrine Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, e386-e389.	0.8	185
132	Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. <i>Journal of Endocrinology</i> , 2012, 212, 99-110.	1.2	118
133	Collaboration of Kras and Androgen Receptor Signaling Stimulates EZH2 Expression and Tumor-Propagating Cells in Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 4672-4681.	0.4	30
134	Treatment-Induced Bone Loss and Fractures in Cancer Patients Undergoing Hormone Ablation Therapy: Efficacy and Safety of Denosumab. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S8511.	0.6	26
135	Proof of Concept to Clinical Confirmation: Evolving Clinical Trial Designs for Targeted Agents. <i>ISRN Oncology</i> , 2012, 2012, 1-6.	2.1	0
136	Tumor biomarkers: PSA and beyond. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 1865-1869.	1.4	5
137	Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. <i>Endocrine-Related Cancer</i> , 2012, 19, 305-319.	1.6	56

#	ARTICLE	IF	CITATIONS
138	The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-11.	0.6	24
139	Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment. <i>Prostate Cancer</i> , 2012, 2012, 1-11.	0.4	79
140	Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. <i>Advances in Urology</i> , 2012, 2012, 1-12.	0.6	14
141	Management of High-Risk Localized Prostate Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-11.	0.6	13
142	Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. <i>Annals of Oncology</i> , 2012, 23, 1241-1249.	0.6	51
143	A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2012, 23, 2714-2719.	0.6	30
144	Androgen Receptor Splice Variants Activate Androgen Receptor Target Genes and Support Aberrant Prostate Cancer Cell Growth Independent of Canonical Androgen Receptor Nuclear Localization Signal. <i>Journal of Biological Chemistry</i> , 2012, 287, 19736-19749.	1.6	194
145	Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2012, 30, 88-109.	0.8	87
146	Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study. <i>Clinical Cancer Research</i> , 2012, 18, 2352-2359.	3.2	7
147	Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. <i>Therapeutic Advances in Urology</i> , 2012, 4, 167-178.	0.9	56
148	Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1016-1024.	0.9	13
149	Overcoming Drug Resistance and Treating Advanced Prostate Cancer. <i>Current Drug Targets</i> , 2012, 13, 1308-1323.	1.0	94
150	Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling. <i>Case Reports in Oncology</i> , 2012, 5, 154-158.	0.3	0
151	Abiraterone Acetate Withdrawal Syndrome: Does It Exist?. <i>Case Reports in Oncology</i> , 2012, 5, 385-387.	0.3	21
152	Identification and Characterization of MEL-3, a Novel AR Antagonist That Suppresses Prostate Cancer Cell Growth. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1257-1268.	1.9	13
153	Overcoming docetaxel resistance in prostate cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 329-340.	1.4	114
154	Novel strategies in the treatment of castration-resistant prostate cancer (Review). <i>International Journal of Oncology</i> , 2012, 40, 1313-20.	1.4	19
155	Therapeutic Additions and Possible Deletions in Oncology in 2011. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 15-17.	2.3	8

#	ARTICLE	IF	CITATIONS
156	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of Clinical Practice. Clinical Practice (London, England), 2012, 9, 241-246.	0.1	0
157	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of Clinical Practice. Clinical Practice (London, England), 2012, 9, 619-621.	0.1	0
158	New Perspectives in the Therapy of Castration Resistant Prostate Cancer. Current Drug Targets, 2012, 13, 1676-1686.	1.0	34
159	Evolving role of chemotherapy in castration-resistant prostate cancer. Clinical Practice (London,) Tj ETQq1 1 0.784314 rgBT /Overlock	0.1	0
160	Abiraterone acetate in castration-resistant prostate cancer. Anti-Cancer Drugs, 2012, 23, 247-254.	0.7	7
161	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 1081-1087.	2.3	208
162	The 5 α -Androstane-3 β -Dione Pathway to Dihydrotestosterone in Castration-Resistant Prostate Cancer. Journal of Investigative Medicine, 2012, 60, 504-507.	0.7	39
163	Human Steroid Biosynthesis for the Oncologist. Journal of Investigative Medicine, 2012, 60, 495-503.	0.7	54
164	Abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer: review of clinical data. Clinical Investigation, 2012, 2, 707-713.	0.0	4
165	Prostate cancer overview. Part 2: metastatic prostate cancer. British Journal of Nursing, 2012, 21, S23-S28.	0.3	11
166	The future of adjuvant therapy for renal cell carcinoma. Clinical Practice (London, England), 2012, 9, 451-462.	0.1	3
167	Immunotherapy and cancer "making the past prologue. Clinical Investigation, 2012, 2, 873-881.	0.0	0
168	Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood, 2012, 120, 3030-3038.	0.6	107
169	New pharmacological treatments for prostate cancer. NursePrescribing, 2012, 10, 498-502.	0.1	0
170	Abiraterone acetate for metastatic castration-resistant prostate cancer post-docetaxel. Clinical Investigation, 2012, 2, 995-1002.	0.0	0
171	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine, 2012, 367, 1187-1197.	13.9	3,847
172	New Agents for the Management of Castration-Resistant Prostate Cancer. Annals of Pharmacotherapy, 2012, 46, 1518-1528.	0.9	13
173	MicroRNA Regulation of Oncolytic Adenovirus 6 for Selective Treatment of Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2012, 11, 2410-2418.	1.9	24

#	ARTICLE	IF	CITATIONS
174	Cabazitaxel in metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1129-1136.	1.1	23
175	Management of castration-resistant prostate cancer: a call to urologists. <i>BJU International</i> , 2012, 110, 772-774.	1.3	4
176	Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, E635-40.	1.3	23
177	Prostate cancer treatment: the times they are a' changin'. <i>BJU International</i> , 2012, 110, 1408-1411.	1.3	3
178	Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). <i>BJU International</i> , 2012, 110, 1580-1588.	1.3	44
179	Prostate cancer: germline prediction for a commonly variable malignancy. <i>BJU International</i> , 2012, 110, E809-18.	1.3	10
180	UK PROSTATE CHARITIES MERGE. <i>BJU International</i> , 2012, 110, 1098-1099.	1.3	0
181	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 549-573.	4.2	96
182	Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 101-108.	2.3	63
183	A new era for castrate resistant prostate cancer: A treatment review and update. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 343-354.	0.5	20
184	The Role of Genetic Markers in the Management of Prostate Cancer. <i>European Urology</i> , 2012, 62, 577-587.	0.9	92
185	Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. <i>Cancer Research</i> , 2012, 72, 2176-2182.	0.4	240
186	Measuring Oncogenic Signaling Pathways in Cancer with PET: An Emerging Paradigm from Studies in Castration-Resistant Prostate Cancer. <i>Cancer Discovery</i> , 2012, 2, 985-994.	7.7	16
187	The complexity of prostate cancer: genomic alterations and heterogeneity. <i>Nature Reviews Urology</i> , 2012, 9, 652-664.	1.9	167
188	Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. <i>Nature</i> , 2012, 482, 116-119.	13.7	284
189	Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 3457-3462.	0.4	518
190	Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. <i>Lancet Oncology</i> , The, 2012, 13, 189-195.	5.1	79
191	Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 509-517.	5.1	390

#	ARTICLE	IF	CITATIONS
192	Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?. <i>Lancet Oncology</i> , The, 2012, 13, e259-e269.	5.1	58
193	Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 549-558.	5.1	100
194	Current management of prostate cancer: dilemmas and trials. <i>British Journal of Radiology</i> , 2012, 85, S28-S40.	1.0	4
197	Cabazitaxel Rechallenge at Prostate-Specific Antigen Relapse After Previous Cabazitaxel and Docetaxel Chemotherapy: Case Report. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 207-209.	0.9	1
198	The Role of IMiDs Alone or in Combination in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 141-146.	0.9	13
199	Prolonged Therapy With Cabazitaxel in an Octogenarian With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 274-276.	0.9	3
200	Intracranial Meningeal Carcinomatosis in Metastatic Castration Resistant Prostate Cancer: Will Extension of Survival Increase the Incidence?. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 271-273.	0.9	4
202	Treatment Decisions for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Chemotherapy: The Role of Cabazitaxel in the Continuum of Care. <i>European Urology</i> , 2012, 62, 1201-1204.	0.9	14
203	Posttreatment Prostate Specific Antigen Nadir Predicts Prostate Cancer Specific and All Cause Mortality. <i>Journal of Urology</i> , 2012, 187, 2068-2073.	0.2	21
204	The Effect of 5-Aminolevulinic Acid and Its Derivatives on Protoporphyrin IX Accumulation and Apoptotic Cell Death in Castrate-resistant Prostate Cancer Cells. <i>Urology</i> , 2012, 80, 1391.e1-1391.e7.	0.5	6
205	Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. <i>EPMA Journal</i> , 2012, 3, 3.	3.3	23
206	Pelvic malignancies in older patients: New drugs in the elderly?. <i>Journal of Geriatric Oncology</i> , 2012, 3, S22-S23.	0.5	0
207	Ketoconazole in Taiwanese castration-resistant prostate cancer patients: Evaluation of response rates, durations, and predictors. <i>Urological Science</i> , 2012, 23, 48-51.	0.2	3
208	Moving Toward Personalized Medicine in Castration-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 483-490.	0.8	6
209	Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 583-591.	0.8	5
210	Management of Cancer in the Older Adult. <i>Clinics in Geriatric Medicine</i> , 2012, 28, 33-49.	1.0	12
211	Abiraterone and Increased Survival in Metastatic Prostate Cancer. <i>Yearbook of Urology</i> , 2012, 2012, 78-79.	0.1	1
212	Management of advanced prostate cancer in senior adults: The new therapeutic landscape. <i>Journal of Geriatric Oncology</i> , 2012, 3, S11.	0.5	0

#	ARTICLE	IF	CITATIONS
213	Cancer and Age: General Considerations. <i>Clinics in Geriatric Medicine</i> , 2012, 28, 1-18.	1.0	63
214	Biology of Castration-Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 435-452.	0.8	28
215	Advances in uro-oncology "Oncoforum": The best of 2011. <i>Actas Urológicas Españolas (English)</i> 111, 107-110.	0.2	11
216	ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment. <i>Cancer Research</i> , 2012, 72, 1494-1503.	0.4	573
217	Current and emerging treatments in the management of castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 951-964.	1.1	25
218	Prostate cancer overview. Part 2: metastatic prostate cancer. <i>British Journal of Nursing</i> , 2012, 21, S23-S28.	0.3	1
219	Distinct Epigenetic Mechanisms Distinguish ERG Fusion-Positive and -Negative Prostate Cancers. <i>Cancer Discovery</i> , 2012, 2, 979-981.	7.7	8
220	Minor Activities and Transition State Properties of the Human Steroid Hydroxylases Cytochromes P450c17 and P450c21, from Reactions Observed with Deuterium-Labeled Substrates. <i>Biochemistry</i> , 2012, 51, 7064-7077.	1.2	31
221	Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors. <i>Urology</i> , 2012, 79, 644-649.	0.5	50
222	Editorial Comment. <i>Urology</i> , 2012, 80, 180-181.	0.5	0
223	Life after failure of traditional androgen deprivation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, S10-S14.	0.8	8
224	Prostate cancer vaccines in clinical trials. <i>Expert Review of Vaccines</i> , 2012, 11, 857-868.	2.0	30
225	Why RECIST Works and Why It Should Stay Counterpoint. <i>Cancer Research</i> , 2012, 72, 5151-5157.	0.4	28
226	Enzalutamide: A Major Advance in the Treatment of Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2012, 367, 1256-1257.	13.9	20
227	Synthesis of halogenated pregnanes, mechanistic probes of steroid hydroxylases CYP17A1 and CYP21A2. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 128, 38-50.	1.2	8
228	Androgen deprivation therapy in combination with radiotherapy for high-risk clinically localized prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 129, 179-190.	1.2	14
229	Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012, 129, 115-128.	1.2	107
230	Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases. <i>Cancer Letters</i> , 2012, 323, 135-146.	3.2	88

#	ARTICLE	IF	CITATIONS
231	New treatment options for patients with metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 340-345.	3.4	10
232	Converting Cancer Therapies into Cures: Lessons from Infectious Diseases. <i>Cell</i> , 2012, 148, 1089-1098.	13.5	159
233	Telomere and Microtubule Targeting in Treatment-Sensitive and Treatment-Resistant Human Prostate Cancer Cells. <i>Molecular Pharmacology</i> , 2012, 82, 310-321.	1.0	16
234	Prostate cancerâ€™ from steroid transformations to clinical translation. <i>Nature Reviews Urology</i> , 2012, 9, 721-724.	1.9	17
235	Steroid biosynthesis and prostate cancer. <i>Steroids</i> , 2012, 77, 719-726.	0.8	96
236	Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. <i>Trials</i> , 2012, 13, 168.	0.7	121
237	Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. <i>Journal of Hematology and Oncology</i> , 2012, 5, 35.	6.9	35
238	Diethylstilbestrol in castrationâ€™resistant prostate cancer. <i>BJU International</i> , 2012, 110, E727-35.	1.3	26
239	To Market, To Marketâ€™2011. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 499-569.	0.5	23
240	Luteinizing Hormone (LH)â€™Releasing Hormone Agonist Reduces Serum Adrenal Androgen Levels in Prostate Cancer Patients: Implications for the Effect of LH on the Adrenal Glands. <i>Journal of Andrology</i> , 2012, 33, 1233-1238.	2.0	22
241	Management of Metastatic Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2012, 72, 1011-1028.	4.9	31
242	Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. <i>British Journal of Cancer</i> , 2012, 107, 840-846.	2.9	51
243	AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. <i>Oncogene</i> , 2012, 31, 4759-4767.	2.6	177
244	Isolated, disseminated and circulating tumour cells in prostate cancer. <i>Nature Reviews Urology</i> , 2012, 9, 448-463.	1.9	32
245	Nouvelles hormonothÃ©rapies dans le cancer de la prostate. <i>ProgrÃ©s En Urologie - FMC</i> , 2012, 22, F110-F114.	0.2	0
246	NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen. <i>Lancet Oncology</i> , The, 2012, 13, 762-763.	5.1	8
247	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 983-992.	5.1	1,182
248	Abiraterone acetate for metastatic prostate cancer. <i>Lancet Oncology</i> , The, 2012, 13, 958-959.	5.1	2

#	ARTICLE	IF	CITATIONS
249	Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. <i>Lancet Oncology</i> , The, 2012, 13, 1210-1217.	5.1	254
251	Castration-resistant prostate cancer: Where are we going?. <i>Actas Urológicas Españolas (English)</i> Tj ETQq1 1 0.784314 rgBT /Overlo	0.2	1
252	A Model of the Cost-effectiveness of Intensity-modulated Radiotherapy in Comparison with Three-dimensional Conformal Radiotherapy for the Treatment of Localised Prostate Cancer. <i>Clinical Oncology</i> , 2012, 24, e159-e167.	0.6	19
253	Abiraterone increases survival in metastatic prostate cancer. <i>Community Oncology</i> , 2012, 9, 240-242.	0.2	2
254	Regulation of cholesterol biosynthesis and cancer signaling. <i>Current Opinion in Pharmacology</i> , 2012, 12, 710-716.	1.7	74
255	Discovery of small molecule cancer drugs: Successes, challenges and opportunities. <i>Molecular Oncology</i> , 2012, 6, 155-176.	2.1	447
256	Advanced Clinical States in Prostate Cancer. <i>Urologic Clinics of North America</i> , 2012, 39, 561-571.	0.8	21
257	Optimal Management of Recurrent Prostate Cancer in Older Patients. <i>Drugs and Aging</i> , 2012, 29, 871-883.	1.3	8
258	Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer. <i>Drugs and Aging</i> , 2012, 29, 243-248.	1.3	5
259	Radium-223 Chloride. <i>Drugs in R and D</i> , 2012, 12, 227-233.	1.1	5
262	Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 293-303.	1.1	8
263	Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 305-313.	1.1	29
264	The role of enzalutamide in the treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2012, 8, 1073-1081.	1.1	3
265	Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity. <i>Immunotherapy</i> , 2012, 4, 577-580.	1.0	15
266	Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario. <i>Future Oncology</i> , 2012, 8, 1585-1595.	1.1	12
267	Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. <i>PLoS ONE</i> , 2012, 7, e30062.	1.1	108
268	Modulators of Prostate Cancer Cell Proliferation and Viability Identified by Short-Hairpin RNA Library Screening. <i>PLoS ONE</i> , 2012, 7, e34414.	1.1	28
269	Constitutive and Treatment-Induced CXCL8-Signalling Selectively Modulates the Efficacy of Anti-Metabolite Therapeutics in Metastatic Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e36545.	1.1	17

#	ARTICLE	IF	CITATIONS
271	The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. <i>Cancer Management and Research</i> , 2012, 4, 183.	0.9	67
272	Is the Bench Getting Closer to the Bedside in the War on Cancer? A Quick Look at Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2012, 3, 53.	1.5	5
274	Targeted Nanoparticles for Cancer Therapy. , 0, , .		16
275	Use of androgen deprivation therapy in prostate cancer: indications and prevalence. <i>Asian Journal of Andrology</i> , 2012, 14, 177-186.	0.8	44
276	Testosterone and the prostate. , 0, , 268-291.		3
277	State-of-the-Art Management for the Patient with Castration-Resistant Prostate Cancer in 2012. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 289-291.	1.8	7
278	Castration-resistant prostate cancer: systemic therapy in 2012. <i>Clinics</i> , 2012, 67, 389-394.	0.6	24
279	Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2012, 38, 717-727.	0.7	10
280	Management of bone metastases in refractory prostate cancer – role of denosumab. <i>Clinical Interventions in Aging</i> , 2012, 7, 363.	1.3	26
281	Paracrine hedgehog increases the steroidogenic potential of prostate stromal cells in a Gli&Edependent manner. <i>Prostate</i> , 2012, 72, 817-824.	1.2	17
282	Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure. <i>Prostate</i> , 2012, 72, 1223-1232.	1.2	21
283	Allelic loss of the loci containing the androgen synthesis gene, <i>StAR</i>, is prognostic for relapse in intermediate&Erisk prostate cancer. <i>Prostate</i> , 2012, 72, 1295-1305.	1.2	10
284	Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. <i>Prostate</i> , 2012, 72, 1478-1489.	1.2	18
285	Adaptive auto&Eregulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. <i>Prostate</i> , 2012, 72, 1491-1505.	1.2	96
286	Combinatorial drug therapy for cancer in the post-genomic era. <i>Nature Biotechnology</i> , 2012, 30, 679-692.	9.4	883
287	Therapeutic Options for Advanced Prostate Cancer: 2011 Update. <i>Current Urology Reports</i> , 2012, 13, 170-178.	1.0	13
288	Chemical castration and anti&Eandrogens induce differential gene expression in prostate cancer. <i>Journal of Pathology</i> , 2012, 227, 336-345.	2.1	29
289	Castration&Eresistant prostate cancer: Many treatments, many options, many challenges ahead. <i>Cancer</i> , 2012, 118, 2583-2593.	2.0	41

#	ARTICLE	IF	CITATIONS
290	Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. <i>Cancer</i> , 2012, 118, 5709-5718.	2.0	89
291	De theoretische achtergrond van de nieuwe behandelingen bij castratieresistent prostaatcarcinoom (CRPC). <i>Tijdschrift Voor Urologie</i> , 2012, 2, 22-28.	0.1	0
292	Nieuwe hormonale manipulaties bij castratieresistent prostaatcarcinoom (CRPC). <i>Tijdschrift Voor Urologie</i> , 2012, 2, 38-41.	0.1	0
293	Cabazitaxel: de grote stap voorwaarts bij chemotherapie voor castratieresistent prostaatcarcinoom (CRPC)?. <i>Tijdschrift Voor Urologie</i> , 2012, 2, 45-49.	0.1	0
296	A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2012, 30, 1652-1659.	1.2	47
297	Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 189-200.	1.3	38
298	Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 174-188.	1.3	27
299	Castration-resistant metastatic prostate cancer: current status and treatment possibilities. <i>Clinical and Translational Oncology</i> , 2012, 14, 169-176.	1.2	18
300	SEOM clinical guidelines for treatment of prostate cancer. <i>Clinical and Translational Oncology</i> , 2012, 14, 520-527.	1.2	5
301	Advances in small molecule inhibitors of androgen receptor for the treatment of advanced prostate cancer. <i>World Journal of Urology</i> , 2012, 30, 311-318.	1.2	33
306	Advances in the management of high-risk localised and metastatic prostate cancer. <i>BJU International</i> , 2012, 109, 8-13.	1.3	11
307	Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 6-14.	0.9	28
308	Abiraterone acetate: redefining hormone treatment for advanced prostate cancer. <i>Drug Discovery Today</i> , 2012, 17, 221-226.	3.2	37
309	Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2012, 61, 363-369.	0.9	34
310	Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. <i>European Urology</i> , 2012, 61, 11-25.	0.9	206
311	The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2012, 61, 639-647.	0.9	28
312	Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2012, 61, 549-559.	0.9	159
313	Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2012, 61, 950-960.	0.9	69

#	ARTICLE	IF	CITATIONS
314	Progress of molecular targeted therapies for prostate cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 140-152.	3.3	29
315	Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 3492-3497.	1.0	52
316	A Wealth of New Options: A Case Presentation of the Management of Castration-Recurrent Prostate Cancer. <i>Seminars in Oncology</i> , 2012, 39, 1-8.	0.8	5
317	Sipuleucel-T for the Treatment of Advanced Prostate Cancer. <i>Seminars in Oncology</i> , 2012, 39, 245-252.	0.8	22
318	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. <i>Seminars in Oncology</i> , 2012, 39, 296-304.	0.8	75
319	Targeting the Androgen receptor: 70 years on and still relevant. <i>International Journal of Clinical Practice</i> , 2012, 66, 726-727.	0.8	0
320	Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 31-42.	0.7	4
321	Androgen action and metabolism in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012, 360, 3-13.	1.6	153
322	Novel endocrine aspects of prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012, 360, 1-2.	1.6	4
323	Clinical development of novel therapeutics for castration-resistant prostate cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 299-308.	157.7	40
324	Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). <i>BJU International</i> , 2012, 110, 328-335.	1.3	22
325	Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers. <i>BJU International</i> , 2012, 110, 840-845.	1.3	9
326	Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, 1149-1155.	1.3	10
327	Metastatic castrate-resistant prostate cancer: dawn of a new age of management. <i>BJU International</i> , 2012, 110, 1110-1114.	1.3	12
328	Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade. <i>BJU International</i> , 2012, 110, 1252-1256.	1.3	5
329	Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. <i>BJU International</i> , 2012, 110, E461-8.	1.3	30
330	New developments in castrate-resistant prostate cancer. <i>BJU International</i> , 2012, 109, 22-32.	1.3	38
331	Drivers for change in the management of prostate cancer – Guidelines and new treatment techniques. <i>BJU International</i> , 2012, 109, 33-41.	1.3	19

#	ARTICLE	IF	CITATIONS
332	The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, E575-82.	1.3	28
333	Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience. <i>BMC Urology</i> , 2012, 12, 3.	0.6	7
334	Beyond Castration—Defining Future Directions in the Hormonal Treatment of Prostate Cancer. <i>Hormones and Cancer</i> , 2012, 3, 3-13.	4.9	17
340	Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 333-339.	1.2	18
341	Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 89.	1.8	84
342	Recent advances revolutionize treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2013, 9, 1133-1144.	1.1	18
343	Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials. <i>Quality of Life Research</i> , 2013, 22, 2777-2786.	1.5	10
345	Prostate cancer therapy: going forwards by going backwards. <i>Lancet Oncology</i> , The, 2013, 14, 104-105.	5.1	43
347	Monitoring the Clinical Outcomes in Advanced Prostate Cancer: What Imaging Modalities and Other Markers Are Reliable?. <i>Seminars in Oncology</i> , 2013, 40, 375-392.	0.8	34
348	Radium-223 for the treatment of prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 379-387.	1.9	15
349	New treatment options for castration-resistant prostate cancer. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 856-865.	0.5	6
350	Cell mates: paracrine and stromal targets for prostate cancer therapy. <i>Nature Reviews Urology</i> , 2013, 10, 441-451.	1.9	32
351	Interplay Between Genomic Alterations and Androgen Receptor Signaling During Prostate Cancer Development and Progression. <i>Hormones and Cancer</i> , 2013, 4, 61-69.	4.9	42
352	Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis. <i>BMC Cancer</i> , 2013, 13, 150.	1.1	14
353	Androgen receptors in hormone-dependent and castration-resistant prostate cancer. , 2013, 140, 223-238.		273
354	Impact of Genetic Targets on Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, v-vi.	0.8	1
355	Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 217-223.	1.8	1
356	New Agents in the Arsenal to Fight Castrate-Resistant Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 239-248.	1.8	10

#	ARTICLE	IF	CITATIONS
357	Tasquinimod: A Novel Angiogenesis Inhibitor—Development in Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 65-68.	1.8	6
358	Targeting the Adrenal Gland in Castration-Resistant Prostate Cancer: A Case for Orteronel, a Selective CYP-17 17,20-Lyase Inhibitor. <i>Current Oncology Reports</i> , 2013, 15, 105-112.	1.8	22
359	Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 113-118.	1.8	13
361	Multidisciplinary care in patients with prostate cancer: room for improvement. <i>Supportive Care in Cancer</i> , 2013, 21, 2327-2333.	1.0	13
363	Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2013, 30, 727-747.	1.3	14
364	The Future of Systemic Therapies for Localised Prostate Cancer. <i>Clinical Oncology</i> , 2013, 25, 506-513.	0.6	6
365	Non-castrate Metastatic Prostate Cancer: Have the Treatment Options Changed?. <i>Seminars in Oncology</i> , 2013, 40, 337-346.	0.8	20
366	Transcription Factor KLLN Inhibits Tumor Growth by AR Suppression, Induces Apoptosis by TP53/TP73 Stimulation in Prostate Carcinomas, and Correlates With Cellular Differentiation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E586-E594.	1.8	32
367	The utility of prostate-specific antigen in the management of advanced prostate cancer. <i>BJU International</i> , 2013, 112, 548-560.	1.3	46
368	New treatment developments applied to elderly patients with advanced prostate cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 578-583.	3.4	21
369	The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 585-596.	2.0	26
370	A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 537-544.	1.1	75
371	Effect of abiraterone acetate plus prednisone on the pharmacokinetics of dextromethorphan and theophylline in patients with metastatic castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 237-244.	1.1	24
372	Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer. <i>World Journal of Urology</i> , 2013, 31, 261-266.	1.2	5
373	Association of legumain expression pattern with prostate cancer invasiveness and aggressiveness. <i>World Journal of Urology</i> , 2013, 31, 359-364.	1.2	62
374	Translational Molecular Imaging of Prostate Cancer. <i>Current Radiology Reports</i> , 2013, 1, 216-226.	0.4	14
375	Efficacy, Patient-Reported Outcomes (PROs), and Tolerability of the Changing Therapeutic Landscape in Patients with Metastatic Prostate Cancer (MPC): A Systematic Literature Review. <i>Value in Health</i> , 2013, 16, 872-890.	0.1	15
376	Picking the Optimal Duration of Hormonal Therapy in Men With High-Risk and Locally Advanced Prostate Cancer Treated With Radiotherapy. <i>Seminars in Radiation Oncology</i> , 2013, 23, 206-214.	1.0	7

#	ARTICLE	IF	CITATIONS
379	A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer. <i>Cell</i> , 2013, 154, 1074-1084.	13.5	257
383	Metabolic and Prostate-Specific Antigen Response After Abiraterone Acetate Withdrawal: A New Clinical Scenario for Castration-Resistant Prostate Cancer?. <i>Clinical Genitourinary Cancer</i> , 2013, 11, e10-e14.	0.9	5
384	Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. <i>Scientific Reports</i> , 2013, 3, 1528.	1.6	64
385	Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial. <i>Urology</i> , 2013, 81, 1297-1302.	0.5	211
386	The androgen receptor remains front and centre. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 126-128.	12.5	22
387	Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer. <i>Steroids</i> , 2013, 78, 851-859.	0.8	24
388	Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 229-237.	0.9	23
389	A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1711-1716.	2.9	49
390	Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis. <i>Prostate</i> , 2013, 73, 1636-1650.	1.2	35
391	2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 117-124.	5.1	195
392	Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability. <i>Cancer Research</i> , 2013, 73, 5206-5217.	0.4	64
393	Advancing Precision Medicine for Prostate Cancer Through Genomics. <i>Journal of Clinical Oncology</i> , 2013, 31, 1866-1873.	0.8	84
394	Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade. <i>Cell</i> , 2013, 155, 1309-1322.	13.5	801
395	Molecular Pathways: Blockade of the PRLR Signaling Pathway as a Novel Antihormonal Approach for the Treatment of Breast and Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1644-1650.	3.2	46
396	Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time. <i>Journal of Clinical Oncology</i> , 2013, 31, 3800-3806.	0.8	196
397	Abiraterone Acetate: A Review of Its Use in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2013, 73, 2077-2091.	4.9	47
398	Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 213-223.	13.9	2,723
399	Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways. <i>Journal of Clinical Oncology</i> , 2013, 31, 1592-1605.	0.8	249

#	ARTICLE	IF	CITATIONS
400	Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. <i>Annals of Oncology</i> , 2013, 24, 1802-1807.	0.6	288
401	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). <i>Annals of Oncology</i> , 2013, 24, 1807-1812.	0.6	310
402	A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2013, 73, 4599-4605.	0.4	82
403	Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2013, 49, 3821-3830.	1.3	183
404	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1193-1199.	5.1	142
405	Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. <i>Oncogene</i> , 2013, 32, 5501-5511.	2.6	646
406	Management of Patients with Castration-Resistant Disease. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1243-1260.	0.9	2
407	Imaging in Prostate Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1163-1187.	0.9	8
408	Optimizing Bone Health and Minimizing Skeletal Morbidity in Men with Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1261-1283.	0.9	5
409	Management of Hormone-Sensitive Metastatic Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1221-1241.	0.9	4
410	Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. <i>EJNMMI Research</i> , 2013, 3, 64.	1.1	41
411	Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy. <i>International Journal of Clinical Oncology</i> , 2013, 18, 711-717.	1.0	20
412	Molecular Classification of Prostate Cancer Progression: Foundation for Marker-Driven Treatment of Prostate Cancer. <i>Cancer Discovery</i> , 2013, 3, 849-861.	7.7	120
414	A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time. <i>BMC Cancer</i> , 2013, 13, 613.	1.1	17
415	Evolution of the Treatment Paradigm for Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Advances in Therapy</i> , 2013, 30, 1041-1066.	1.3	7
416	Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy. <i>Medical Oncology</i> , 2013, 30, 719.	1.2	14
419	Molecular Pathogenesis and Progression of Prostate Cancer. <i>Seminars in Oncology</i> , 2013, 40, 244-258.	0.8	96
420	Are urologists ready to manage castration-resistant disease?. <i>Nature Reviews Urology</i> , 2013, 10, 133-134.	1.9	3

#	ARTICLE	IF	CITATIONS
421	Phase II Trial Assessing Granulocyte-macrophageâ€”Colony Stimulating Factor, Ketoconazole Plus Mitoxantrone in Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatments. <i>Cancer Investigation</i> , 2013, 31, 177-182.	0.6	6
422	Multimodality Therapy for Patients With High-Risk Prostate Cancer: Current Status and Future Directions. <i>Seminars in Oncology</i> , 2013, 40, 308-321.	0.8	22
423	Managing the Risks of Cardiac Therapy in Cancer Patients. <i>Seminars in Oncology</i> , 2013, 40, 210-217.	0.8	3
424	Nasty or Nice? Findings from a UK Survey to Evaluate the Impact of the National Institute for Health and Clinical Excellence (NICE) Clinical Guidelines on the Management of Prostate Cancer. <i>Clinical Oncology</i> , 2013, 25, 178-189.	0.6	8
425	Cabazitaxel for the Second-Line Treatment of Metastatic Hormone-Refractory Prostate Cancer: A NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2013, 31, 479-488.	1.7	29
426	Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelialâ€”mesenchymal transition. <i>Expert Review of Endocrinology and Metabolism</i> , 2013, 8, 403-416.	1.2	0
427	Defining the optimal approach to the patient with postradiation prostateâ€”specific antigen recurrence using outcome data from a prospective randomized trial. <i>Cancer</i> , 2013, 119, 3280-3286.	2.0	5
428	Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3525-3530.	0.8	223
429	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 323-327.	2.0	10
430	Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions. <i>Expert Review of Vaccines</i> , 2013, 12, 1219-1234.	2.0	8
431	Tackling the Bone with Alpha Emitters in Metastatic Castration-resistant Prostate Cancer Patients. <i>European Urology</i> , 2013, 63, 198-200.	0.9	10
432	New and Emerging Therapies for Bone Metastases in Genitourinary Cancers. <i>European Urology</i> , 2013, 63, 309-320.	0.9	42
433	Re: Impact of Circulating Cholesterol Levels on Growth and Intratumoral Androgen Concentration of Prostate Tumors. <i>European Urology</i> , 2013, 63, 178-179.	0.9	1
434	Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 134, 75-79.	1.2	15
435	Objective assessment of cancer genes for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 35-50.	21.5	111
436	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.	13.9	2,412
437	Adaptation or selectionâ€”mechanisms of castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2013, 10, 90-98.	1.9	103
438	Prostate cancer: ESMO Consensus Conference Guidelines 2012. <i>Annals of Oncology</i> , 2013, 24, 1141-1162.	0.6	137

#	ARTICLE	IF	CITATIONS
439	Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2013, 19, 699-709.	3.2	54
440	Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 70-83.	1.4	9
441	The Action of Cytochrome <i>c</i> ₅ on CYP2E1 and CYP2C19 Activities Requires Anionic Residues D58 and D65. <i>Biochemistry</i> , 2013, 52, 210-220.	1.2	27
442	Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. <i>BJU International</i> , 2013, 111, 44-52.	1.3	67
443	Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines. <i>Cancer Research</i> , 2013, 73, 483-489.	0.4	570
444	Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 134, 80-91.	1.2	33
445	Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. <i>Journal of Neuro-Oncology</i> , 2013, 111, 163-167.	1.4	25
446	Mini-review: Foldosome regulation of androgen receptor action in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2013, 369, 52-62.	1.6	52
447	Luteinizing hormone-releasing hormone (LHRH) receptor agonists vs antagonists: a matter of the receptors?. <i>BJU International</i> , 2013, 111, 1021-1030.	1.3	15
448	Improving outcomes in high-risk prostate cancer with radiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2013, 18, 333-337.	0.3	15
449	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1307-1316.	5.1	205
450	Management of prostate cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. <i>Lancet Oncology</i> , The, 2013, 14, e524-e534.	5.1	42
451	Re: Effect of Abiraterone Acetate and Prednisone Compared with Placebo and Prednisone on Pain Control and Skeletal-related Events in Patients with Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis of Data from the COU-AA-301 Randomised Trial. <i>European Urology</i> , 2013, 63, 1132-1133.	0.9	3
452	Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment. <i>European Journal of Oncology Nursing</i> , 2013, 17, S1-S6.	0.9	8
453	Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. <i>Lancet Oncology</i> , The, 2013, 14, 760-768.	5.1	256
454	Re: Axel Heidenreich, David Pfister. Treatment Decisions for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Chemotherapy: The Role of Cabazitaxel in the Continuum of Care. <i>Eur Urol</i> 2012;62:1201-4. <i>European Urology</i> , 2013, 64, e62-e64.	0.9	0
455	Castration-resistant Prostate Cancer: Where We Stand in 2013 and What Urologists Should Know. <i>European Urology</i> , 2013, 64, 260-265.	0.9	35
456	Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: Implications for prior therapy in clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1457-1463.	0.8	11

#	ARTICLE	IF	CITATIONS
457	Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer. <i>Urology</i> , 2013, 82, 410-415.	0.5	17
458	Safety and Efficacy of Maintenance Therapy With a Nonspecific Cytochrome P17 Inhibitor (CYP17i) After Response/Stabilization to Docetaxel in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 78-84.	0.9	2
459	Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. <i>European Urology</i> , 2013, 64, 300-306.	0.9	85
460	Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. <i>Cancer Treatment Reviews</i> , 2013, 39, 966-973.	3.4	37
461	Actualizaci3n en c4ncer de pr3stata. <i>Medicine</i> , 2013, 11, 1578-1587.	0.0	1
462	Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 238-250.e1.	0.9	26
463	Chemotherapy and Targeted Therapies: Are We Making Progress in Castrate-Resistant Prostate Cancer?. <i>Seminars in Oncology</i> , 2013, 40, 361-374.	0.8	15
464	A Phase II Trial of Tamsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 397-406.	0.9	52
465	Progress in emerging therapies for advanced prostate cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 275-289.	3.4	60
466	Contemporary Issues in Radiotherapy for Clinically Localized Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 1137-1162.	0.9	4
468	Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 893-900.	5.1	139
469	Biochemical and Objective Response to Abiraterone Acetate Withdrawal: Incidence and Clinical Relevance of a New Scenario for Castration-resistant Prostate Cancer. <i>Urology</i> , 2013, 82, 1090-1093.	0.5	22
470	Efficacy of Oxaliplatin Plus Pemetrexed in Chemotherapy Pretreated Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 416-422.	0.9	7
472	Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition. <i>Actas Urol3gicas Espa±olas (English Edition)</i> , 2013, 37, 292-304.	0.2	7
473	Luteinizing Hormoneâ€“Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 375-384.	0.9	65
474	Angiogenesis and anti-angiogenic therapy in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 122-131.	2.0	34
475	Prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 253-262.	2.0	12
476	Hsp90: Still a viable target in prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 211-218.	3.3	32

#	ARTICLE	IF	CITATIONS
477	Validation and clinical utility of prostate cancer biomarkers. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 225-234.	12.5	83
478	Abiraterone acetate for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 91-96.	0.9	29
479	Novel Therapies for the Treatment of Advanced Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 109-126.	1.3	18
480	Management of cancer treatment-induced bone loss. <i>Nature Reviews Rheumatology</i> , 2013, 9, 365-374.	3.5	77
481	Androgen-Responsive Gene Expression in Prostate Cancer Progression. , 2013, , 135-153.		2
482	Impact of Genetic Targets on Prostate Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, 359-383.	0.8	2
484	Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 342-349.	0.8	27
486	'Old' and 'new' drugs for the treatment of cancer pain. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 425-433.	0.9	6
487	AKR1C3 as a target in castrate resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 137, 136-149.	1.2	117
488	Tubulin: an example of targeted chemotherapy. <i>Future Medicinal Chemistry</i> , 2013, 5, 339-352.	1.1	67
489	Locally Advanced Prostate Cancer: Current Controversies and Optimisation Opportunities. <i>Clinical Oncology</i> , 2013, 25, 499-505.	0.6	10
490	Ex vivo culture of human prostate tissue and drug development. <i>Nature Reviews Urology</i> , 2013, 10, 483-487.	1.9	111
491	Metabolic and toxicological considerations of newly approved prostate cancer drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 835-846.	1.5	4
492	Cabazitaxel Plus Prednisone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel: Results from the German Compassionate-use Programme. <i>European Urology</i> , 2013, 63, 977-982.	0.9	70
493	Management of Castrate Resistant Prostate Cancer—Recent Advances and Optimal Sequence of Treatments. <i>Current Urology Reports</i> , 2013, 14, 174-183.	1.0	16
494	PTEN in Prostate Cancer. , 2013, , 87-137.		2
495	Truncated Androgen Receptor Splice Variants in Prostate Cancer. , 2013, , 351-382.		2
496	Commentary on: Abiraterone in Metastatic Prostate Cancer Without Previous Chemotherapy. <i>Urology</i> , 2013, 81, 1121-1122.	0.5	0

#	ARTICLE	IF	CITATIONS
497	Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review. <i>Clinical Oncology</i> , 2013, 25, 406-430.	0.6	38
498	Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer. <i>Molecular Endocrinology</i> , 2013, 27, 708-714.	3.7	64
499	Steroidal 5 α -reductase and 17 β -hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 137, 199-222.	1.2	50
500	Castration-Resistant Prostate Cancer: AUA Guideline. <i>Journal of Urology</i> , 2013, 190, 429-438.	0.2	206
501	A randomized, double-blind, placebo-controlled, Phase II study with and without enzalutamide in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 1044-1050.	1.2	14
502	Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2013, 138, 248-256.	1.2	36
503	Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5) α -ketoacyl-CoA synthetase. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 2429-2446.	2.9	78
504	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 13-33.	1.1	81
505	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. <i>Current Opinion in Pharmacology</i> , 2013, 13, 486-496.	1.7	55
506	Androgens and prostate cancer; pathogenesis and deprivation therapy. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2013, 27, 603-616.	2.2	71
507	Androgen and Androgen Receptor-Directed Therapy as Initial Treatment for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 861-871.		0
508	Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer. <i>Annual Review of Medicine</i> , 2013, 64, 1-13.	5.0	42
509	Preoperative therapy for localized prostate cancer: A comprehensive overview. <i>Maturitas</i> , 2013, 74, 3-9.	1.0	5
510	Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2013, 20, R83-R99.	1.6	272
511	Radium-223 Chloride: Extending Life in Prostate Cancer Patients by Treating Bone Metastases. <i>Clinical Cancer Research</i> , 2013, 19, 5822-5827.	3.2	37
512	α -Emitting radium-223: additional choices, more unknowns. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 612-613.	12.5	1
513	Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan. <i>International Journal of Clinical Oncology</i> , 2013, 18, 306-313.	1.0	11
514	Advances in Prostate Cancer Chemoprevention: A Translational Perspective. <i>Nutrition and Cancer</i> , 2013, 65, 12-25.	0.9	15

#	ARTICLE	IF	CITATIONS
515	Downregulation of Androgen Receptor Transcription by Promoter G-Quadruplex Stabilization as a Potential Alternative Treatment for Castrate-Resistant Prostate Cancer. <i>Biochemistry</i> , 2013, 52, 1429-1436.	1.2	23
516	Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9® Lead to Promotion versus Suppression of Prostate Cancer Metastasis. <i>Journal of Biological Chemistry</i> , 2013, 288, 19359-19369.	1.6	106
517	Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 325-330.e1.	0.9	54
518	Avances en la prevención y el tratamiento de las metástasis óseas en cáncer de próstata. Papel de la inhibición de RANK/RANKL. <i>Actas Urológicas Españolas</i> , 2013, 37, 292-304.	0.3	12
519	Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. <i>European Journal of Cancer</i> , 2013, 49, 3648-3657.	1.3	77
520	Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer. <i>Endocrinology</i> , 2013, 154, 4010-4017.	1.4	68
521	Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer. <i>Drugs</i> , 2013, 73, 1417-1430.	4.9	39
522	Abiraterone Acetate in Combination with Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer: U.S. Food and Drug Administration Drug Approval Summary. <i>Clinical Cancer Research</i> , 2013, 19, 6650-6656.	3.2	55
524	AERIO News in brief. <i>Oncologie</i> , 2013, 15, 543-547.	0.2	2
525	Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2013, 31, 760-768.	1.2	297
526	The prognostic significance of loss of the androgen receptor and neuroendocrine differentiation in prostate biopsy specimens among castration-resistant prostate cancer patients. <i>Molecular and Clinical Oncology</i> , 2013, 1, 257-262.	0.4	39
527	Pharmacogenetics- and pharmacogenomics-based rational clinical trial designs in oncology. <i>Personalized Medicine</i> , 2013, 10, 859-869.	0.8	2
528	Prostate cancer vaccines: an old yet novel target, the androgen receptor. <i>Expert Review of Vaccines</i> , 2013, 12, 249-251.	2.0	1
529	Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. <i>Annals of Oncology</i> , 2013, 24, 1017-1025.	0.6	81
530	Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules. <i>Oncology</i> , 2013, 84, 92-99.	0.9	9
531	Molecular Biomarkers for Patients with Castration-Resistant Prostate Cancer. , 2013, , 71-80.		0
532	Abiraterone in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1457-1459.	13.9	34
533	Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?. <i>British Journal of Cancer</i> , 2013, 108, 9-13.	2.9	52

#	ARTICLE	IF	CITATIONS
534	Androgen deprivation treatment in prostate cancer. <i>BMJ, The</i> , 2013, 346, e8555-e8555.	3.0	13
535	Tasquinimod: a novel drug in advanced prostate cancer. <i>Future Oncology</i> , 2013, 9, 1271-1281.	1.1	10
536	Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1740-1747.	0.8	184
537	Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. <i>OncoTargets and Therapy</i> , 2013, 6, 9.	1.0	9
538	Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 357-367.	2.0	4
539	Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy. <i>Case Reports in Oncology</i> , 2013, 6, 325-330.	0.3	2
540	Emerging Molecularly Targeted Therapies in Castration Refractory Prostate Cancer. <i>Prostate Cancer</i> , 2013, 2013, 1-12.	0.4	18
541	Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 7757-7770.	1.8	122
542	Perturbation Biology: Inferring Signaling Networks in Cellular Systems. <i>PLoS Computational Biology</i> , 2013, 9, e1003290.	1.5	128
543	A Urologic Oncology Roundtable Discussion: How to Choose Among the Available Therapies for the Treatment of Castration-Resistant Prostate Cancer. <i>Postgraduate Medicine</i> , 2013, 125, 114-116.	0.9	1
544	The European Medicines Agency Review of Abiraterone for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Adult Men After Docetaxel Chemotherapy and in Chemotherapy-Naïve Disease: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. <i>Oncologist</i> , 2013, 18, 1032-1042.	1.9	13
545	The Androgen Receptor, Androgen Synthesis, and New Designer Antiandrogens for Metastatic Castration-Resistant Prostate Cancer. <i>American Journal of Therapeutics</i> , 2013, 20, 128-131.	0.5	1
546	The changing landscape in metastatic castration-resistant prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2013, 7, 243-248.	0.5	4
547	A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. <i>Anti-Cancer Drugs</i> , 2013, 24, 743-753.	0.7	47
548	The Changing Natural History of Metastatic Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 19-24.	1.0	37
549	Castrate-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 201-207.	0.9	6
550	Agents That Target Androgen Synthesis in Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 34-42.	1.0	17
551	Potential Predictive Biomarkers for Individualizing Treatment for Men With Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 25-33.	1.0	13

#	ARTICLE	IF	CITATIONS
552	Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 79-89.	1.0	106
553	Targeting the Apoptosis Pathway in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 79-89.	1.0	43
554	Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 252-260.	1.1	35
555	Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. <i>Annals of Oncology</i> , 2013, 24, 2402-2408.	0.6	126
556	Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2013, 18, 163-173.	1.9	145
557	Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1729-1737.	3.0	150
558	Castration Therapy Results in Decreased Ki67 Levels in Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1547-1556.	3.2	62
559	Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Previously Received Docetaxel: U.S. Food and Drug Administration Drug Approval Summary. <i>Clinical Cancer Research</i> , 2013, 19, 6067-6073.	3.2	40
560	SULT2B1b Sulfotransferase: Induction by Vitamin D Receptor and Reduced Expression in Prostate Cancer. <i>Molecular Endocrinology</i> , 2013, 27, 925-939.	3.7	36
561	Prevalence of Pain and Analgesic Use in Men With Metastatic Prostate Cancer Using a Patient-Reported Outcome Measure. <i>Journal of Oncology Practice</i> , 2013, 9, 223-229.	2.5	29
562	Phase II Study of Lutetium-177 Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5182-5191.	3.2	370
563	PPP2R2C Loss Promotes Castration-Resistance and Is Associated with Increased Prostate Cancer-Specific Mortality. <i>Molecular Cancer Research</i> , 2013, 11, 568-578.	1.5	41
564	Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2013, 18, 558-567.	1.9	26
565	Bazedoxifene Exhibits Antiestrogenic Activity in Animal Models of Tamoxifen-Resistant Breast Cancer: Implications for Treatment of Advanced Disease. <i>Clinical Cancer Research</i> , 2013, 19, 2420-2431.	3.2	127
566	Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3944-3950.	0.8	83
567	Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2791-2798.	0.8	111
568	Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers. <i>Cancer Discovery</i> , 2013, 3, 1245-1253.	7.7	421
569	Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-Type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. <i>Cancer Research</i> , 2013, 73, 2926-2926.	0.4	5

#	ARTICLE	IF	CITATIONS
570	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013, 24, vi106-vi114.	0.6	91
571	A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human $\hat{\pm}\hat{1}/2$ integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2013, 24, 329-336.	0.6	69
572	Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone. <i>Clinical Cancer Research</i> , 2013, 19, 215-224.	3.2	74
573	Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation. <i>PLoS ONE</i> , 2013, 8, e63563.	1.1	104
574	PSA, PCA3 and the philosophy of prostate cancer management. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 707-712.	1.4	10
575	Enzalutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 679-685.	0.9	18
576	Spongian Diterpenoids Inhibit Androgen Receptor Activity. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 621-631.	1.9	12
577	Novel cancer therapies: treatments driven by tumour biology. <i>Postgraduate Medical Journal</i> , 2013, 89, 652-658.	0.9	16
578	Novel chemotherapies in development for management of castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 220-229.	0.9	6
579	Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer. <i>Current Opinion in Urology</i> , 2013, 23, 208-213.	0.9	8
580	Tubulin-Targeted Agents Including Docetaxel and Cabazitaxel. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 59-65.	1.0	38
581	Targeted $\hat{\pm}$ -Particle Therapy of Bone Metastases in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 966-971.	0.7	46
582	Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. <i>Annals of Oncology</i> , 2013, 24, 31-38.	0.6	48
583	Androgen-responsive Serum Response Factor target genes regulate prostate cancer cell migration. <i>Carcinogenesis</i> , 2013, 34, 1737-1746.	1.3	37
584	TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17492-17497.	3.3	147
585	Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Na ^{ve} Prostate Cancer. <i>Frontiers in Oncology</i> , 2013, 3, 293.	1.3	20
586	CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 231.	0.3	15
587	Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S11670.	0.6	22

#	ARTICLE	IF	CITATIONS
588	Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S7256.	0.6	18
589	Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2013, 111, 1269-1280.	1.3	40
590	Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms. <i>Prostate Cancer</i> , 2013, 2013, 1-10.	0.4	33
591	Durable complete remission with abiraterone in castration resistant metastatic prostate cancer. <i>Acta Oncologica</i> , 2013, 52, 174-174.	0.8	1
592	Impact of pre-treatment prostate tissue androgen content on the prediction of castration-resistant prostate cancer development in patients treated with primary androgen deprivation therapy. <i>Andrology</i> , 2013, 1, 505-511.	1.9	17
593	Fighting Prostate Cancer with Radium-223 – Not Your Madame's Isotope. <i>New England Journal of Medicine</i> , 2013, 369, 276-278.	13.9	18
594	A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. <i>Xenobiotica</i> , 2013, 43, 379-389.	0.5	52
595	The current and future role of sequence-based analysis in prostate cancer treatment. <i>Personalized Medicine</i> , 2013, 10, 257-273.	0.8	0
596	Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. <i>Cancer</i> , 2013, 119, 4103-4110.	2.0	158
597	Survivorship™ in prostate cancer II: the need for ongoing patient support. <i>Trends in Urology & Men's Health</i> , 2013, 4, 29-31.	0.2	0
598	Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. <i>Annals of Oncology</i> , 2013, 24, 1813-1821.	0.6	481
599	The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2013, 119, 3636-3643.	2.0	17
600	Cofunded expanded access programmes for new oncology drugs: creating a two-tier system for Australian cancer patients?. <i>Internal Medicine Journal</i> , 2013, 43, 843-844.	0.5	5
601	Role of the androgen receptor in prostate cancer. <i>Trends in Urology & Men's Health</i> , 2013, 4, 26-30.	0.2	0
602	Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6997-7002.	3.3	210
603	Triptorelin in the management of prostate cancer. <i>Future Oncology</i> , 2013, 9, 93-102.	1.1	24
604	New Paradigms in Microtubule-Mediated Endocrine Signaling in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 555-566.	1.9	20
605	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013, 9, 889-897.	1.1	38

#	ARTICLE	IF	CITATIONS
606	Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?. <i>Future Oncology</i> , 2013, 9, 619-622.	1.1	2
607	Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 89-99.	1.1	5
608	Age is nothing but a number. <i>Nature Reviews Urology</i> , 2013, 10, 683-684.	1.9	1
609	First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 2579-2586.	2.9	78
610	Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers. <i>British Journal of Cancer</i> , 2013, 109, 1279-1286.	2.9	17
611	Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 1-6.	2.0	12
612	Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1079-1084.	2.9	18
613	Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 325-331.	2.9	34
614	Polymorphisms of the androgen transporting gene <i>SLCO2B1</i> may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 336-340.	2.0	41
615	Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. <i>Therapeutic Advances in Urology</i> , 2013, 5, 201-210.	0.9	38
616	AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function <i>In Vitro</i> and <i>In Vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1715-1727.	1.9	73
617	Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1335-1339.	3.2	70
618	The changing landscape in the treatment of metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 25-40.	1.4	40
619	Substrate-modulated Cytochrome P450 17A1 and Cytochrome b5 Interactions Revealed by NMR. <i>Journal of Biological Chemistry</i> , 2013, 288, 17008-17018.	1.6	85
620	Pathophysiology of Prostate Cancer. , 2013, , 1455-1464.		0
621	Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3353-3359.	3.2	80
622	Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore. <i>Annals of Oncology</i> , 2013, 24, 1717-1720.	0.6	1
623	Pleuropulmonary and Lymph Node Progression after Docetaxel - Benefits from Treatment with Cabazitaxel in Metastatic Prostate Cancer. <i>Case Reports in Oncology</i> , 2013, 6, 391-396.	0.3	0

#	ARTICLE	IF	CITATIONS
624	Abiraterone acetate for the treatment of castrate-refractory prostate cancer. <i>Aging Health</i> , 2013, 9, 9-23.	0.3	0
625	Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. <i>Clinical Investigation</i> , 2013, 3, 651-663.	0.0	0
626	Evidence from clinical trials for the use of valproic acid in solid tumors: focus on prostate cancer. <i>Clinical Investigation</i> , 2013, 3, 467-478.	0.0	6
627	Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2013, 20, 181-187.	0.7	10
628	Building on Sipuleucel-T for Immunologic Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2013, 20, 7-16.	0.7	18
629	The Osteoblastic and Osteoclastic Interactions in Spinal Metastases Secondary to Prostate Cancer. <i>Cancer Growth and Metastasis</i> , 2013, 6, CGM.S12769.	3.5	24
631	Update in Hematology and Oncology: Evidence Published in 2012. <i>Annals of Internal Medicine</i> , 2013, 158, 755.	2.0	0
632	Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice. <i>Prostate International</i> , 2013, 1, 125-132.	1.2	7
633	The relationship between vagal nerve activity and clinical outcomes in prostate and non-small cell lung cancer patients. <i>Oncology Reports</i> , 2013, 30, 2435-2441.	1.2	49
634	Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. <i>Clinical Medicine Insights Urology</i> , 2013, 7, CMU.S8337.	0.4	4
635	Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13958-13978.	1.8	45
636	Complete regression of advanced prostate cancer for ten years: A case report and review of the literature. <i>Oncology Letters</i> , 2013, 6, 590-594.	0.8	3
637	Partial response of liver metastases treated with abiraterone in castration-resistant prostate cancer: A case report. <i>Oncology Letters</i> , 2013, 5, 1877-1880.	0.8	4
638	Potential use of custirsen to treat prostate cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 785.	1.0	22
639	Challenges and Opportunities for Cancer Vaccines in the Current NSCLC Clinical Scenario. <i>Current Topics in Medicinal Chemistry</i> , 2013, 13, 2551-2561.	1.0	4
640	Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. <i>Core Evidence</i> , 2013, 8, 27.	4.7	22
641	Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. <i>Cancer Management and Research</i> , 2013, 5, 1.	0.9	101
642	Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. <i>Drug Design, Development and Therapy</i> , 2013, 7, 875.	2.0	33

#	ARTICLE	IF	CITATIONS
643	Budgetary Impact on a U.S. Health Plan Adopting Abiraterone Acetate Plus Prednisone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Managed Care Pharmacy</i> , 2013, 19, 799-808.	2.2	22
644	Hormonal therapy in metastatic prostate cancer: current perspectives and controversies. <i>Oncology Reviews</i> , 2013, 7, 6.	0.8	2
645	Do Fixed Patent Terms Distort Innovation?: Evidence from Cancer Clinical Trials. <i>SSRN Electronic Journal</i> , 0, , .	0.4	15
646	Therapeutic Options in Docetaxel-Refractory Metastatic Castration-Resistant Prostate Cancer: A Cost-Effectiveness Analysis. <i>PLoS ONE</i> , 2013, 8, e64275.	1.1	27
647	Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. <i>Canadian Urological Association Journal</i> , 2013, 7, 263.	0.3	31
648	New Therapeutics to Treat Castrate-Resistant Prostate Cancer. <i>Scientific World Journal, The</i> , 2013, 2013, 1-8.	0.8	22
649	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. <i>Tumori</i> , 2013, 99, 637-649.	0.6	18
650	Novel Therapeutic Settings in the Treatment of Castration- Resistant Prostate Cancer. , 2013, , .		0
651	Rational Categorization of the Pipeline of New Treatments for Advanced Cancer – Prostate Cancer as an Example. , 0, , .		0
652	Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic. , 2013, , .		0
653	Neuroendocrine Prostate Cancer. , 2014, , 2456-2463.		0
654	Glucocorticoids and prostate cancer treatment: friend or foe?. <i>Asian Journal of Andrology</i> , 2014, 16, 354.	0.8	37
656	Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer. <i>PLoS ONE</i> , 2014, 9, e103680.	1.1	11
657			

#	ARTICLE	IF	CITATIONS
662	Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 651.	0.9	6
663	Radium-223 in metastatic castration resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 348.	0.8	12
664	Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer. <i>Research and Reports in Urology</i> , 2014, 6, 97.	0.6	19
665	Roles for the Backdoor Pathway of Androgen Metabolism in Prostate Cancer Response to Castration and Drug Treatment. <i>International Journal of Biological Sciences</i> , 2014, 10, 596-601.	2.6	23
666	Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital. <i>Research and Reports in Urology</i> , 2014, 6, 121.	0.6	1
667	Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 520.	0.3	4
668	Review The use of luteinizing hormonereleasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer. <i>Wspolczesna Onkologia</i> , 2014, 2, 85-89.	0.7	0
669	Targeting Androgen Receptor Action for Prostate Cancer Treatment: Does the Post-Receptor Level Provide Novel Opportunities?. <i>International Journal of Biological Sciences</i> , 2014, 10, 576-587.	2.6	16
670	Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial. <i>Research and Reports in Urology</i> , 2014, 6, 71.	0.6	1
671	Androgen Signaling Pathway and the Development of Novel Drugs for the Management of Castration-Resistant Prostate Cancer. <i>Journal of the Nihon University Medical Association</i> , 2014, 73, 134-139.	0.0	0
672	Building on Prostate Cancer Working Group 2 to Change the Paradigm from Palliation to Cure. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e204-e212.	1.8	2
673	PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. <i>Asian Journal of Andrology</i> , 2014, 16, 378.	0.8	217
678	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3436-3448.	0.8	201
679	The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer. , 2014, , 319-356.		3
681	Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 23-27.	2.0	30
682	Phase I/II Trial of Orteronel (TAK-700)â€™an Investigational 17,20-Lyase Inhibitorâ€™in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1335-1344.	3.2	34
683	Can Targeting the Androgen Receptor in Localized Prostate Cancer Provide Insights Into Why Men With Metastatic Castration-Resistant Prostate Cancer Die?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3689-3691.	0.8	2
684	PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials. <i>Tumor Biology</i> , 2014, 35, 10601-10607.	0.8	23

#	ARTICLE	IF	CITATIONS
685	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 1755-1756.	13.9	134
686	No clear evidence of a clinical benefit of a sequential therapy regimen with abiraterone acetate and enzalutamide. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1135-1140.	1.1	26
687	Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. <i>Therapeutic Advances in Urology</i> , 2014, 6, 3-14.	0.9	50
688	A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1206-1215.	0.6	29
690	Progress and controversies: Radiation therapy for prostate cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 389-407.	157.7	44
691	Key papers in prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1379-1384.	1.1	9
692	Sustained Exposure to the Investigational Kisspeptin Analog, TAK-448, Down-Regulates Testosterone into the Castration Range in Healthy Males and in Patients With Prostate Cancer: Results From Two Phase 1 Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1445-E1453.	1.8	49
693	Gemcitabine+oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. <i>British Journal of Cancer</i> , 2014, 110, 2472-2478.	2.9	18
694	Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences. <i>British Journal of Cancer</i> , 2014, 111, 1249-1254.	2.9	66
695	Androgen dynamics and serum PSA in patients treated with abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 192-198.	2.0	32
696	Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 292-299.	2.0	10
697	Novel bone-targeting agents in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 112-118.	2.0	3
698	Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. <i>British Journal of Cancer</i> , 2014, 110, 551-555.	2.9	355
699	Pharmacological Inhibition of Myostatin and Changes in Lean Body Mass and Lower Extremity Muscle Size in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1967-E1975.	1.8	70
700	Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1283-1294.	1.1	11
701	Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2014, 17, 34-39.	2.0	85
702	Reply: Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2014, 110, 267-268.	2.9	1
703	Advances in systemic therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 2213-2226.	1.1	4

#	ARTICLE	IF	CITATIONS
704	Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. <i>Future Oncology</i> , 2014, 10, 985-993.	1.1	23
705	Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. <i>Urology Annals</i> , 2014, 6, 278.	0.3	3
706	Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2014, 25, 657-662.	0.6	94
707	ECF chemotherapy for liver metastases due to castration-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 353.	0.3	2
708	Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	8
709	Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy. <i>Core Evidence</i> , 2015, 10, 1.	4.7	48
710	Low Temperature Plasma: A Novel Focal Therapy for Localized Prostate Cancer?. <i>BioMed Research International</i> , 2014, 2014, 1-15.	0.9	41
711	From Bench to Bedside: Immunotherapy for Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	18
712	A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 583.	0.3	7
713	PMA induces androgen receptor downregulation and cellular apoptosis in prostate cancer cells. <i>Journal of Molecular Endocrinology</i> , 2014, 53, 31-41.	1.1	12
714	Dynamic Changes in Numbers and Properties of Circulating Tumor Cells and Their Potential Applications. <i>Cancers</i> , 2014, 6, 2369-2386.	1.7	23
715	A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study). <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1216-1226.	0.6	33
716	Lysine-Specific Demethylase 1 Has Dual Functions as a Major Regulator of Androgen Receptor Transcriptional Activity. <i>Cell Reports</i> , 2014, 9, 1618-1627.	2.9	115
718	Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 975-983.	1.1	43
719	The potential detrimental effect of corticosteroids in prostate cancer. <i>Future Oncology</i> , 2014, 10, 325-327.	1.1	2
720	Successes for UK cancer partnership. <i>Nature</i> , 2014, 510, 218-218.	13.7	2
721	Chemotherapeutic inhibitors in the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 11-22.	0.9	4
722	Surgery versus observation for localized prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 312-313.	1.9	4

#	ARTICLE	IF	CITATIONS
723	Targeting the androgen receptor in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 329-332.	1.1	1
724	Beyond abiraterone. <i>Cancer Biology and Therapy</i> , 2014, 15, 149-155.	1.5	8
725	Comparative Effectiveness Questions in Oncology. <i>New England Journal of Medicine</i> , 2014, 370, 1478-1481.	13.9	39
726	Androgenic biomarker profiling in human matrices and cell culture samples using high throughput, electrospray tandem mass spectrometry. <i>Prostate</i> , 2014, 74, 722-731.	1.2	21
727	GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 18261-18266.	3.3	114
728	Utility of FDG-PET in clinical neuroendocrine prostate cancer. <i>Prostate</i> , 2014, 74, 1153-1159.	1.2	55
730	"Charting a new course for prostate cancer" currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1253-1256.	1.1	7
731	Castrate-resistant prostate cancer: the future of antiandrogens. <i>Trends in Urology & Men's Health</i> , 2014, 5, 7-10.	0.2	0
732	The economics of abiraterone acetate for castration-resistant prostate cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 175-179.	0.7	15
733	Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone. <i>Prostate</i> , 2014, 74, 1462-1464.	1.2	3
734	Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. <i>Cancer</i> , 2014, 120, 968-975.	2.0	121
735	Molecular pathology and prostate cancer therapeutics: from biology to bedside. <i>Journal of Pathology</i> , 2014, 232, 178-184.	2.1	34
736	No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. <i>Cancer</i> , 2014, 120, 818-823.	2.0	112
737	AERIO news in brief. <i>Oncologie</i> , 2014, 16, 458-461.	0.2	0
738	Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. <i>Prostate</i> , 2014, 74, 1691-1696.	1.2	52
739	SEOM Clinical guidelines for the treatment of metastatic prostate cancer. <i>Clinical and Translational Oncology</i> , 2014, 16, 1060-1066.	1.2	11
740	Bone health in patients with prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 685-693.	0.2	1
741	Bladder outlet obstruction (<sc>BOO</sc>) in men with castration-resistant prostate cancer. <i>BJU International</i> , 2014, 114, 62-66.	1.3	11

#	ARTICLE	IF	CITATIONS
742	Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 205-215.	0.7	6
743	HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network. <i>EMBO Molecular Medicine</i> , 2014, 6, 651-661.	3.3	74
744	Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: A phase II bridging study in Korean and Taiwanese patients. <i>International Journal of Urology</i> , 2014, 21, 1239-1244.	0.5	11
745	Beyond the androgen receptor: New approaches to treating metastatic prostate cancer. Report of the 2013 Prostate Cancer Meeting. <i>Prostate</i> , 2014, 74, 314-320.	1.2	14
746	Use of Prednisone With Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2014, 19, 1231-1240.	1.9	78
747	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , 2014, 5, 5383.	5.8	522
748	Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. <i>Clinical Cancer Research</i> , 2014, 20, 6269-6276.	3.2	32
749	Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 951-961.	3.2	42
750	Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype. <i>Current Clinical Urology</i> , 2014, , 297-304.	0.0	0
751	Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, 903-914.	1.6	45
752	Adrenal Androgens and Androgen Precursors: Definition, Synthesis, Regulation and Physiologic Actions. , 2014, 4, 1369-1381.		80
753	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. <i>Scandinavian Journal of Urology</i> , 2014, 48, 268-275.	0.6	59
754	Androgen receptor antagonists for prostate cancer therapy. <i>Endocrine-Related Cancer</i> , 2014, 21, T105-T118.	1.6	116
755	Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1005-1013.	1.1	14
756	Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2014, 22, 3219-3226.	1.0	12
757	Comparing Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metastases. <i>Applied Health Economics and Health Policy</i> , 2014, 12, 547-557.	1.0	15
758	Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 51-61.	1.1	1
759	Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). <i>BMC Urology</i> , 2014, 14, 55.	0.6	27

#	ARTICLE	IF	CITATIONS
760	PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche. <i>Journal of Translational Medicine</i> , 2014, 12, 275.	1.8	25
761	Strategies for modern biomarker and drug development in oncology. <i>Journal of Hematology and Oncology</i> , 2014, 7, 70.	6.9	98
762	Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 219-231.	1.1	30
763	Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel. <i>Anti-Cancer Drugs</i> , 2014, 25, 1081-1088.	0.7	12
764	Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen. <i>Clinical Cancer Research</i> , 2014, 20, 4218-4227.	3.2	29
765	Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation. <i>American Journal of Surgical Pathology</i> , 2014, 38, 756-767.	2.1	439
766	Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 265-273.	1.1	6
767	Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. <i>Annals of Oncology</i> , 2014, 25, 429-434.	0.6	103
768	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1925-1934.	3.2	36
769	Molecular Pathways: Targeting ETS Gene Fusions in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4442-4448.	3.2	54
770	Differential Response to Abiraterone Acetate and Di-n-butyl Phthalate in an Androgen-Sensitive Human Fetal Testis Xenograft Bioassay. <i>Toxicological Sciences</i> , 2014, 138, 148-160.	1.4	44
771	Phase I study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer. <i>Cancer Science</i> , 2014, 105, 1313-1320.	1.7	15
772	Mechanisms of Resistance to Intermittent Androgen Deprivation in Patients with Prostate Cancer Identified by a Novel Computational Method. <i>Cancer Research</i> , 2014, 74, 3673-3683.	0.4	46
773	Update in Systemic Therapy of Urologic Malignancies. <i>Postgraduate Medicine</i> , 2014, 126, 44-54.	0.9	6
774	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	0.9	56
775	Towards personalised therapy for lymphangioliomyomatosis: lessons from cancer. <i>European Respiratory Review</i> , 2014, 23, 30-35.	3.0	18
776	Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. <i>Endocrine-Related Cancer</i> , 2014, 21, 487-493.	1.6	59
777	Molecular Mechanisms of Prostate Cancer Progression After Castration. <i>Current Clinical Urology</i> , 2014, , 31-41.	0.0	0

#	ARTICLE	IF	CITATIONS
778	Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxelâ€™an Indirect Comparison. <i>Clinical Medicine Insights: Oncology</i> , 2014, 8, CMO.S13671.	0.6	16
779	The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor. <i>Frontiers in Oncology</i> , 2014, 4, 295.	1.3	28
780	Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, T87-T103.	1.6	127
781	Unintended Consequences of Expensive Cancer Therapeuticsâ€™The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2014, 140, 1225.	1.2	263
782	GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer. <i>Endocrine-Related Cancer</i> , 2014, 21, R301-R317.	1.6	36
783	The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. <i>Asian Journal of Andrology</i> , 2014, 16, 331.	0.8	0
784	Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 401.	0.8	14
785	Intratatumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. <i>Prostate International</i> , 2014, 2, 105-113.	1.2	27
786	Novel agents in the management of castration resistant prostate cancer. <i>Journal of Carcinogenesis</i> , 2014, 13, 5.	2.5	20
787	The Oncological Outcomes and Risk Stratification in Docetaxel Chemotherapy for Castration-resistant Prostate Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 860-867.	0.6	15
788	Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy. <i>Urologia Internationalis</i> , 2014, 93, 49-54.	0.6	6
789	Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial. <i>Future Oncology</i> , 2014, 10, 351-362.	1.1	7
790	Pathologic fracture in patients with metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2014, 24, 595-600.	0.9	8
791	The transcriptional programme of the androgen receptor (<sc>AR</sc>) in prostate cancer. <i>BJU International</i> , 2014, 113, 358-366.	1.3	38
792	Dual PI3K/mTOR Inhibitor NVP-BEZ235 Sensitizes Docetaxel in Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2014, 191, 227-234.	0.2	60
793	The current role and limitations of surrogate endpoints in advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 28.e1-28.e9.	0.8	14
794	The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 66, 646-652.	0.9	126
795	Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Prostate Cancer Clinical Trials: Potential Roles and Possible Pitfalls. <i>Translational Oncology</i> , 2014, 7, 120-129.	1.7	20

#	ARTICLE	IF	CITATIONS
796	Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 27-32.	0.9	19
797	Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid. <i>European Urology</i> , 2014, 65, 146-153.	0.9	13
798	Serum testosterone levels after medical or surgical androgen deprivation: A comprehensive review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 38.e17-38.e28.	0.8	40
799	Toward a common therapeutic framework in castration-resistant prostate cancer: A model for urologic oncology and medical oncology interaction. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 380-382.	0.8	3
800	Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective "prospective observational study" a cohort from 4 European countries. <i>Journal of Bone Oncology</i> , 2014, 3, 40-48.	1.0	40
801	Sequencing Systemic Therapies in Advanced Prostate Cancer: Spoiled for Choice But Not for Evidence. <i>European Urology</i> , 2014, 66, 466-467.	0.9	5
802	Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model. <i>Molecular Oncology</i> , 2014, 8, 311-322.	2.1	28
803	Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. <i>Oncogene</i> , 2014, 33, 2815-2825.	2.6	289
804	Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment. <i>European Urology</i> , 2014, 65, 289-299.	0.9	113
805	AR function in promoting metastatic prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 399-411.	2.7	73
806	The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 441-468.	2.7	59
807	Novel drugs targeting the androgen receptor pathway in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 567-579.	2.7	29
808	Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2014, 19, 946-954.	1.0	19
809	Systemic Therapy of Bone Metastases. <i>Cancer Metastasis - Biology and Treatment</i> , 2014, , 247-273.	0.1	0
810	Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. <i>European Journal of Cancer</i> , 2014, 50, 78-84.	1.3	178
811	Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 732-741.	1.0	26
812	Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 197-209.	2.0	15
814	Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 219-222.	1.1	10

#	ARTICLE	IF	CITATIONS
815	Clinical characteristics and prognostic factors of prostate cancer with liver metastases. <i>Tumor Biology</i> , 2014, 35, 595-601.	0.8	34
816	Circulating tumor cells: Advances in isolation and analysis, and challenges for clinical applications. , 2014, 141, 209-221.		162
817	Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2014, 134, 2284-2293.	2.3	107
818	Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness. <i>Cell Metabolism</i> , 2014, 19, 393-406.	7.2	671
819	Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer. <i>Prostate</i> , 2014, 74, 959-969.	1.2	19
820	Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E1749-58.	3.3	41
821	New agents for prostate cancer. <i>Annals of Oncology</i> , 2014, 25, 1700-1709.	0.6	51
822	Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study. <i>European Urology</i> , 2014, 65, 1058-1066.	0.9	372
824	Circulating tumour cellsâ€™ monitoring treatment response in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 401-412.	12.5	110
825	Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 389-402.	1.6	51
826	High-risk prostate cancerâ€™ classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 308-323.	12.5	340
827	Managing bone metastases and reducing skeletal related events in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 335-345.	12.5	110
828	Response to Subsequent Docetaxel in a Patient Cohort With Metastatic Castration-Resistant Prostate Cancer After Abiraterone Acetate Treatment. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e167-e172.	0.9	32
829	Evolution of androgen receptor targeted therapy for advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 365-376.	12.5	172
830	Taxane Mechanisms of Action: Potential Implications for Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 1198-1204.	0.9	107
831	Metformin for Castrate-resistant Prostate Cancer: Learning More About an Old Dog's New Tricks. <i>European Urology</i> , 2014, 66, 475-477.	0.9	4
832	Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents. <i>Cancer Treatment Reviews</i> , 2014, 40, 170-177.	3.4	39
833	Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 76-82.	0.8	148

#	ARTICLE	IF	CITATIONS
834	Breast cancer: Current and future endocrine therapies. <i>Molecular and Cellular Endocrinology</i> , 2014, 382, 695-723.	1.6	81
835	Molecular alterations and emerging targets in castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 753-764.	1.3	44
836	p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis. <i>Cancer Research</i> , 2014, 74, 1870-1880.	0.4	80
837	Immunotherapy for prostate cancer: recent developments and future challenges. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 641-655.	2.7	53
838	Thérapies ciblées et biomarqueurs compagnons dans les cancers de la prostate métastatiques. <i>Medecine Nucleaire</i> , 2014, 38, 31-37.	0.2	0
839	EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 467-479.	0.9	1,304
840	New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 417-425.	0.5	22
841	CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents. <i>Nature Reviews Urology</i> , 2014, 11, 32-42.	1.9	132
842	Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 469-487.	1.9	19
843	Concept and viability of androgen annihilation for advanced prostate cancer. <i>Cancer</i> , 2014, 120, 2628-2637.	2.0	16
844	Multidisciplinary consensus: A practical guide for the integration of abiraterone into clinical practice. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 228-236.	0.7	3
845	P059 Efficacy and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: Data on Korean patients obtained by the cabazitaxel compassionate use program. <i>European Urology Supplements</i> , 2014, 13, 131.	0.1	0
846	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 73-80.	1.1	24
847	Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. <i>Prostate</i> , 2014, 74, 433-440.	1.2	13
848	Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors. <i>Prostate</i> , 2014, 74, 1400-1410.	1.2	19
849	Precision medicine for prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1305-1315.	1.1	11
850	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. <i>Lancet Oncology</i> , The, 2014, 15, 1397-1406.	5.1	351
851	Effect of docetaxel on safety and efficacy of radium-223. <i>Lancet Oncology</i> , The, 2014, 15, 1292-1293.	5.1	2

#	ARTICLE	IF	CITATIONS
852	Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1369-1378.	1.1	30
853	Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1590-1600.	3.2	165
854	Bone-Targeting Radiopharmaceuticals for the Treatment of Bone-Metastatic Castration-Resistant Prostate Cancer: Exploring the Implications of New Data. <i>Oncologist</i> , 2014, 19, 1012-1018.	1.9	14
855	FGF23: Mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia?. <i>Medical Hypotheses</i> , 2014, 83, 482-487.	0.8	19
856	KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. <i>Prostate</i> , 2014, 74, 1222-1230.	1.2	28
857	Muscle and bone effects of androgen deprivation therapy: current and emerging therapies. <i>Endocrine-Related Cancer</i> , 2014, 21, R371-R394.	1.6	50
858	A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1544-1550.	1.2	45
859	Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. <i>Oncogene</i> , 2014, 33, 5053-5064.	2.6	41
860	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1769-1781.	1.4	4
861	Structures of Human Steroidogenic Cytochrome P450 17A1 with Substrates. <i>Journal of Biological Chemistry</i> , 2014, 289, 32952-32964.	1.6	100
862	The promise of circulating tumor cell analysis in cancer management. <i>Genome Biology</i> , 2014, 15, 448.	3.8	47
863	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , 2014, 111, 2248-2253.	2.9	52
864	Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5547-5557.	3.2	43
865	Androgen Receptor Splice Variants in the Era of Enzalutamide and Abiraterone. <i>Hormones and Cancer</i> , 2014, 5, 265-273.	4.9	102
866	Nucleic acid-based tissue biomarkers of urologic malignancies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 173-199.	2.7	33
867	Emerging mechanisms of enzalutamide resistance in prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 712-716.	1.9	107
868	Synthesis and anticancer properties of RGD peptides conjugated to nitric oxide releasing functional groups and abiraterone. <i>Tetrahedron</i> , 2014, 70, 8343-8347.	1.0	7
870	Critical Evaluation of Disease Stabilization As a Measure of Activity of Systemic Therapy: Lessons From Trials With Arms in Which Patients Do Not Receive Active Treatment. <i>Journal of Clinical Oncology</i> , 2014, 32, 260-263.	0.8	19

#	ARTICLE	IF	CITATIONS
871	Salud Ásea en pacientes con cÁncer de prÁstata. Actas UrolÁgicas EspaÁolas, 2014, 38, 685-693.	0.3	1
872	Serum triÁand tetraÁantennary <i>N</i>Áglycan is a potential predictive biomarker for castrationÁresistant prostate cancer. Prostate, 2014, 74, 1521-1529.	1.2	48
873	Safety of antiandrogen therapy for treating prostate cancer. Expert Opinion on Drug Safety, 2014, 13, 1483-1499.	1.0	24
874	Steroidogenic Factor 1 Promotes Aggressive Growth of Castration-Resistant Prostate Cancer Cells by Stimulating Steroid Synthesis and Cell Proliferation. Endocrinology, 2014, 155, 358-369.	1.4	23
875	Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study. Journal of Clinical Oncology, 2014, 32, 3705-3715.	0.8	220
876	Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary. Clinical Cancer Research, 2014, 20, 9-14.	3.2	128
877	Real-world experience with abiraterone. Lancet Oncology, The, 2014, 15, 1188-1190.	5.1	0
878	Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). Journal of Clinical Oncology, 2014, 32, 1143-1150.	0.8	217
879	Discovery of Small-Molecule Inhibitors Selectively Targeting the DNA-Binding Domain of the Human Androgen Receptor. Journal of Medicinal Chemistry, 2014, 57, 6458-6467.	2.9	102
880	PIP5K1Á inhibition as a therapeutic strategy for prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 12578-12579.	3.3	11
881	Management of Castration Resistant Prostate Cancer. Current Clinical Urology, 2014, , .	0.0	2
882	Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 89, 1038-1046.	0.4	149
883	Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncology, The, 2014, 15, e404-e414.	5.1	196
884	Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 2014, 106, djt319-djt319.	3.0	279
885	Prostate cancer: Review in 2014. Diagnostic and Interventional Imaging, 2014, 95, 739-742.	1.8	8
886	Cancer de la prostateÁ: mise au point 2014. Diagnostic and Interventional Imaging, 2014, 95, 725-728.	0.0	0
887	Progression-free survival as an end-point in solid tumours Á€“ Perspectives from clinical trials and clinical practice. European Journal of Cancer, 2014, 50, 2303-2308.	1.3	32
888	Strategies for targeting the androgen receptor axis in prostate cancer. Drug Discovery Today, 2014, 19, 1493-1497.	3.2	18

#	ARTICLE	IF	CITATIONS
889	The role of transcription factors in prostate cancer and potential for future RNA interference therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 633-649.	1.5	44
890	Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. <i>Nature</i> , 2014, 510, 278-282.	13.7	811
891	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. <i>Cell</i> , 2014, 159, 176-187.	13.5	1,184
892	Molecular insights into the development of T cell-based immunotherapy for prostate cancer. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1547-1557.	1.3	7
894	Drug costs in the management of metastatic castration-resistant prostate cancer in Canada. <i>BMC Health Services Research</i> , 2014, 14, 252.	0.9	31
895	Molecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit. <i>Clinical Cancer Research</i> , 2014, 20, 791-798.	3.2	63
896	AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. <i>New England Journal of Medicine</i> , 2014, 371, 1028-1038.	13.9	2,233
897	Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 671-677.	0.8	410
898	Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2014, 74, 1560-1568.	1.2	36
899	Abiraterone Acetate to Lower Androgens in Women With Classic 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 2763-2770.	1.8	64
900	Targeting the Androgen Receptor in Prostate Cancer â€” A Resilient Foe. <i>New England Journal of Medicine</i> , 2014, 371, 1067-1069.	13.9	38
901	Radium-223 dichloride for the treatment of metastatic prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2105-2111.	0.9	4
902	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 227-235.	1.1	19
904	Docetaxel in Castration-Resistant Prostate Cancer: A Single-Centre Experience. <i>Cancer Investigation</i> , 2014, 32, 445-450.	0.6	0
905	Association of pretreatment neutrophil-to-lymphocyte ratio (<sc>NLR</sc>) and overall survival (<sc>OS</sc>) in patients with metastatic castration-resistant prostate cancer (<sc>mCRPC</sc>) treated with first-line docetaxel. <i>BJU International</i> , 2014, 114, E11-E17.	1.3	81
908	The hypothalamicâ€“pituitaryâ€“gonadal axis and prostate cancer: implications for androgen deprivation therapy. <i>World Journal of Urology</i> , 2014, 32, 669-676.	1.2	36
909	The effects of denosumab on calcium profiles in advanced cancer patients with bone metastases. <i>Supportive Care in Cancer</i> , 2014, 22, 1765-1771.	1.0	23
910	Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 555-566.	2.7	45

#	ARTICLE	IF	CITATIONS
911	Metastatic castration resistant prostate cancer: Current strategies of management in the Middle East. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 36-48.	2.0	3
912	Androgen Receptor Splice Variants Determine Taxane Sensitivity in Prostate Cancer. <i>Cancer Research</i> , 2014, 74, 2270-2282.	0.4	217
913	The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer. <i>Hormones and Cancer</i> , 2014, 5, 207-217.	4.9	64
914	Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling. <i>BMC Cancer</i> , 2014, 14, 325.	1.1	11
915	External validation of risk classification in patients with docetaxel-treated castration-resistant prostate cancer. <i>BMC Urology</i> , 2014, 14, 31.	0.6	13
916	Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report. <i>Journal of Medical Case Reports</i> , 2014, 8, 122.	0.4	3
917	Galeterone Prevents Androgen Receptor Binding to Chromatin and Enhances Degradation of Mutant Androgen Receptor. <i>Clinical Cancer Research</i> , 2014, 20, 4075-4085.	3.2	81
918	Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. <i>British Journal of Cancer</i> , 2014, 110, 2201-2208.	2.9	19
919	Prostate Cancer in the Elderly Patient. <i>Journal of Clinical Oncology</i> , 2014, 32, 2523-2530.	0.8	40
920	Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. <i>Lancet Oncology</i> , The, 2014, 15, 1263-1268.	5.1	46
921	New CYP17 Hydroxylase Inhibitors: Synthesis, Biological Evaluation, QSAR, and Molecular Docking Study of New Pregnenolone Analogs. <i>Archiv Der Pharmazie</i> , 2014, 347, 896-907.	2.1	13
922	Constitutive Activity of the Androgen Receptor. <i>Advances in Pharmacology</i> , 2014, 70, 327-366.	1.2	47
923	Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype. <i>Oncogene</i> , 2014, 33, 5666-5674.	2.6	74
924	Abiraterone acetate in metastatic castration-resistant prostate cancer: A retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole. <i>European Journal of Cancer</i> , 2014, 50, 2399-2407.	1.3	14
925	Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy. <i>European Urology</i> , 2014, 65, 875-883.	0.9	74
926	Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA. <i>Cancer Discovery</i> , 2014, 4, 650-661.	7.7	594
927	Correlating phosphoproteomic signaling with castration resistant prostate cancer survival through regression analysis. <i>Molecular BioSystems</i> , 2014, 10, 605-612.	2.9	1
928	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. <i>New England Journal of Medicine</i> , 2014, 371, 424-433.	13.9	2,456

#	ARTICLE	IF	CITATIONS
929	Maximal Testosterone Suppression in Prostate Cancer—Free vs Total Testosterone. <i>Urology</i> , 2014, 83, 1217-1222.	0.5	16
930	Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2014, 38, 327-333.	0.2	0
931	Next-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy. <i>European Urology</i> , 2014, 66, 32-39.	0.9	139
932	Inhibition of 17 β -hydroxylase/C17,20 lyase reduces gating deficits consequent to dopaminergic activation. <i>Psychoneuroendocrinology</i> , 2014, 39, 204-213.	1.3	19
933	Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2444-2447.	1.0	51
934	Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. <i>European Urology</i> , 2014, 66, 459-465.	0.9	128
935	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). <i>European Urology</i> , 2014, 66, 815-825.	0.9	221
936	Initial Results of a Prospective Clinical Trial Examining a Novel Rectal Obturator to Localise the Prostate and Spare the Rectum during Radical Prostate Radiotherapy. <i>Clinical Oncology</i> , 2014, 26, e3.	0.6	1
937	A C-14 labeled Pyrimidine polyamide localizes to a subcutaneous prostate cancer tumor. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4371-4375.	1.4	14
938	Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 31.e25-31.e33.	0.8	16
939	Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 253-261.	2.0	13
940	Prostate-specific antigen growth rate constant after first-line cytotoxic chemotherapy in metastatic castration-resistant prostate cancer: A monoinstitutional experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 42.e1-42.e5.	0.8	1
941	miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. <i>Biochemical Pharmacology</i> , 2014, 87, 579-597.	2.0	83
942	Taxanes in the management of metastatic castration-resistant prostate cancer: Efficacy and management of toxicity. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 248-256.	2.0	28
943	Acetato de abiraterona prequimioterapia. Propuesta de un algoritmo de tratamiento en el carcinoma de próstata resistente a castración. <i>Actas Urológicas Españolas</i> , 2014, 38, 327-333.	0.3	3
944	Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants. <i>Cell Reports</i> , 2014, 6, 657-669.	2.9	217
945	Role of Sorafenib in Overcoming Resistance of Chemotherapy-Failure Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 100-105.	0.9	13
946	Znaczenie terapii hormonalnej u pacjentów z przerzutowym opornym na kastrację rakiem stercza. <i>Zeszyty Naukowe WCO Letters in Oncology Science</i> , 2014, 11, 1-6.	0.2	0

#	ARTICLE	IF	CITATIONS
947	Metronomic Oral Cyclophosphamide Chemotherapy Possibly Contributes to Stabilization of Disease in Patients With Metastatic Castration-Resistant Prostate Cancer: A Prospective Analysis of Consecutive Cases. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e197-e203.	0.9	12
948	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014, 50, 1617-1627.	1.3	133
949	Human Cytochrome P450 17A1 Conformational Selection. <i>Journal of Biological Chemistry</i> , 2014, 289, 14310-14320.	1.6	63
950	Prostate cancer vaccines in combination with additional treatment modalities. <i>Immunologic Research</i> , 2014, 59, 236-242.	1.3	15
951	Cancer treatment and survivorship statistics, 2014. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 252-271.	157.7	2,474
952	Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3198-3210.	3.2	294
953	Challenges of managing elderly men with prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 354-364.	12.5	20
954	Activity of Cabazitaxel After Docetaxel and Abiraterone Acetate Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 428-432.	0.9	33
955	Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated With Shorter Time to Skeletal-Related Event. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 33-40.e4.	0.9	7
956	Role of Immunotherapy in Castration-Resistant Prostate Cancer (<scp>CRPC</scp>). <i>BJU International</i> , 2014, 113, 367-375.	1.3	7
957	Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 70-79.	0.8	30
958	Cost-Effectiveness Analysis of Abiraterone and Sipuleucel-T in Asymptomatic Metastatic Castration-Resistant Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1417-1425.	2.3	27
960	Challenges in overcoming hormonal resistance in prostate cancer. <i>Clinical Investigation</i> , 2014, 4, 153-162.	0.0	0
961	Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review). <i>International Journal of Oncology</i> , 2014, 45, 1337-1344.	1.4	14
963	Sequential Treatment with Taxanes and Novel Anti-Androgenic Compounds in Castration-Resistant Prostate Cancer. <i>Oncology Research and Treatment</i> , 2014, 37, 492-498.	0.8	9
964	Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer. <i>Clinical Investigation</i> , 2014, 4, 935-950.	0.0	25
965	Recommendations for Prostate Cancer Survivorship Care: An Update to the 2009 Michigan Cancer Consortium Guidelines for the Primary Care Management of Prostate Cancer Post-Treatment Sequelae. <i>Journal of Men's Health</i> , 2014, 11, 95-107.	0.1	7
966	Journal watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of clinical practice. <i>Clinical Practice (London, England)</i> , 2014, 11, 21-22.	0.1	0

#	ARTICLE	IF	CITATIONS
967	Orteronel for the treatment of prostate cancer. <i>Future Oncology</i> , 2014, 10, 803-811.	1.1	16
969	Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. <i>Asian Journal of Urology</i> , 2014, 1, 30-39.	0.5	1
970	Unusual small bowel metastatic localization in a castration-resistant prostate cancer patient. <i>Clinical Practice (London, England)</i> , 2014, 11, 559-562.	0.1	1
971	PSA Screening: A Discussion Based on the USPSTF Recommendations and the AUA and EAU Guidelines. <i>Journal of Men's Health</i> , 2014, 11, 10-17.	0.1	1
972	Effects of Abiraterone Acetate on Chronic Kidney Disease in 2 Patients With Metastatic Castration-resistant Prostate Cancer. <i>Medicine (United States)</i> , 2014, 93, e163.	0.4	4
973	Weekly low-dose docetaxel is an effective treatment with fewer adverse events for metastatic castration-resistant prostate cancer in Taiwanese patients. <i>Urological Science</i> , 2015, 26, 267-270.	0.2	2
974	Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4579-4587.	1.8	52
975	Prostate cancer multidisciplinary care: improving patient outcomes. <i>Trends in Urology & Men's Health</i> , 2015, 6, 18-20.	0.2	1
976	Prostate cancer: lessons to be learned from breast cancer. <i>Trends in Urology & Men's Health</i> , 2015, 6, 21-23.	0.2	1
977	Targeting the interleukin-11 receptor $\hat{\pm}$ in metastatic prostate cancer: A first-in-man study. <i>Cancer</i> , 2015, 121, 2411-2421.	2.0	44
978	Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. <i>BJU International</i> , 2015, 115, 764-771.	1.3	17
979	Renin-angiotensin system blockade: Its contribution and controversy. <i>International Journal of Urology</i> , 2015, 22, 721-730.	0.5	19
981	Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials. <i>American Economic Review</i> , 2015, 105, 2044-2085.	4.0	181
983	Nelfinavir and Nelfinavir Analogs Block Site-2 Protease Cleavage to Inhibit Castration-Resistant Prostate Cancer. <i>Scientific Reports</i> , 2015, 5, 9698.	1.6	45
984	Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy. <i>Experimental Hematology and Oncology</i> , 2015, 5, 15.	2.0	10
985	Abiraterone in Metastatic Salivary Duct Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 288-290.	2.3	18
986	Navigating Treatment of Metastatic Castration-Resistant Prostate Cancer: Nursing Perspectives. <i>Clinical Journal of Oncology Nursing</i> , 2015, 19, 723-732.	0.3	6
987	Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2015, 22, 109-120.	0.7	41

#	ARTICLE	IF	CITATIONS
990	Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics. <i>Computational and Structural Biotechnology Journal</i> , 2015, 13, 520-527.	1.9	14
993	Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2015, 75, 1329-1338.	1.2	24
995	Targeting molecular resistance in castration-resistant prostate cancer. <i>BMC Medicine</i> , 2015, 13, 206.	2.3	52
996	Persistent androgen receptor addiction in castration-resistant prostate cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 128.	6.9	59
997	Realities in cost-effectiveness analyses: a study of castration-resistant prostate cancer patients using a medical claims database. <i>SpringerPlus</i> , 2015, 4, 624.	1.2	8
998	Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1406-1414.	1.0	78
999	Interleukin-10 inhibits autonomous myelopoiesis in patients with myelofibrosis. <i>European Journal of Haematology</i> , 2015, 95, 239-243.	1.1	0
1000	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S23252.	0.6	27
1001	Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 479-482.	0.6	26
1002	Oncology service initiatives and research in regional Australia. <i>Australian Journal of Rural Health</i> , 2015, 23, 40-48.	0.7	17
1003	High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. <i>International Journal of Urology</i> , 2015, 22, 827-833.	0.5	23
1004	Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate. <i>Anti-Cancer Drugs</i> , 2015, 26, 884-887.	0.7	4
1005	Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 582-589.	2.3	57
1006	Targeting the relaxin hormonal pathway in prostate cancer. <i>International Journal of Cancer</i> , 2015, 137, 2287-2295.	2.3	18
1007	Development of enzalutamide for metastatic castration-resistant prostate cancer. <i>Annals of the New York Academy of Sciences</i> , 2015, 1358, 13-27.	1.8	9
1008	In Reply. <i>Oncologist</i> , 2015, 20, e14-e14.	1.9	0
1009	Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 63-73.	0.8	25
1010	Sequences and combinations of multifaceted therapy in advanced prostate cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 201-208.	1.1	7

#	ARTICLE	IF	CITATIONS
1011	Clinical Research in Metastatic Prostate Cancer: A Focus on Impact and Value. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 17-21.	1.8	4
1012	Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e263-e269.	1.8	1
1013	Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer. Journal of Multidisciplinary Healthcare, 2015, 8, 279.	1.1	15
1015	PACE4 regulates apoptosis in human prostate cancer cells via endoplasmic reticulum stress and mitochondrial signaling pathways. Drug Design, Development and Therapy, 2015, 9, 5911.	2.0	10
1016	Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis. Archivio Italiano Di Urologia Andrologia, 2015, 87, 121.	0.4	8
1017	Development of a preliminary nomogram to predict progression of bone scan for castration-resistant prostate cancer. OncoTargets and Therapy, 2015, 8, 713.	1.0	3
1018	Cancer treatment: at what cost?. Nursing and Residential Care, 2015, 17, 173-174.	0.1	1
1019	Immune Infiltration and Prostate Cancer. Frontiers in Oncology, 2015, 5, 128.	1.3	161

1020

#	ARTICLE	IF	CITATIONS
1031	New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones. <i>Asian Journal of Andrology</i> , 2015, 17, 925.	0.8	7
1032	<i>Cancer Therapeutics.</i> , 2015, , 635-650.e1.		0
1033	Prostate cancer: beware of disseminated intravascular coagulation. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014206814-bcr2014206814.	0.2	5
1034	Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. <i>Nature</i> , 2015, 523, 347-351.	13.7	221
1035	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	13.5	2,660
1036	A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 774-779.	0.6	8
1037	Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4749-4770.	2.9	27
1038	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 582.	3.4	552
1039	Targeted Therapies for Prostate Cancer. <i>Cancer Investigation</i> , 2015, 33, 276-285.	0.6	7
1040	MYC Drives <i>Pten/Trp53</i> -Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. <i>Cancer Discovery</i> , 2015, 5, 636-651.	7.7	65
1041	Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. <i>European Urology</i> , 2015, 68, 570-577.	0.9	50
1042	A new pregnenolone analogues as privileged scaffolds in inhibition of CYP17 hydroxylase enzyme. Synthesis and in silico molecular docking study. <i>Steroids</i> , 2015, 100, 52-59.	0.8	5
1043	New biaryl-chalcone derivatives of pregnenolone via Suzuki-Miyaura cross-coupling reaction. Synthesis, CYP17 hydroxylase inhibition activity, QSAR, and molecular docking study. <i>Steroids</i> , 2015, 101, 43-50.	0.8	19
1044	Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 338.e1-338.e7.	0.8	32
1045	Targeting the androgen receptor in prostate and breast cancer: several new agents in development. <i>Endocrine-Related Cancer</i> , 2015, 22, R87-R106.	1.6	76
1046	Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America. <i>Prostate</i> , 2015, 75, 836-844.	1.2	17
1047	The Hormonal Management of Metastatic Prostate Cancer. , 2015, , 817-833.		0
1048	AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies. <i>Investigational New Drugs</i> , 2015, 33, 679-690.	1.2	43

#	ARTICLE	IF	CITATIONS
1049	Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer. <i>Advances in Cancer Research</i> , 2015, 127, 123-158.	1.9	34
1051	Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels. <i>Basic and Clinical Andrology</i> , 2015, 25, 3.	0.8	9
1052	Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer. <i>BMC Cancer</i> , 2015, 15, 338.	1.1	35
1053	The development of abiraterone acetate for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 289-294.	0.8	14
1054	Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4133-4142.	3.2	57
1055	Corticosteroids and Prostate Cancer: Friend or Foe?. <i>European Urology</i> , 2015, 67, 874-875.	0.9	4
1056	Targeting bone metastases in prostate cancer: improving clinical outcome. <i>Nature Reviews Urology</i> , 2015, 12, 340-356.	1.9	87
1057	Exploration of new 3 β -pregnenolone ester analogues via Mitsunobu reaction, their anti-HIV activity and molecular modeling study. <i>European Journal of Chemistry</i> , 2015, 6, 1-7.	0.3	8
1058	Present and future of personalized medicine in adult genitourinary tumors. <i>Future Oncology</i> , 2015, 11, 1381-1388.	1.1	10
1059	Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 386-395.	1.3	14
1060	Disparities in Castration-Resistant Prostate Cancer Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 1101-1103.	0.8	43
1061	The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3221-3221.	0.8	3
1062	Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 150.	1.8	12
1063	Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine. <i>Oncology Research and Treatment</i> , 2015, 38, 654-668.	0.8	4
1064	Advances in the Treatment of Metastatic Prostate Cancer. <i>Mayo Clinic Proceedings</i> , 2015, 90, 1719-1733.	1.4	21
1065	Efficacy of degarelix in prostate cancer patients following failure on luteinizing hormone-releasing hormone agonist treatment: results from an open-label, multicentre, uncontrolled, phase II trial (CS27). <i>Therapeutic Advances in Urology</i> , 2015, 7, 105-115.	0.9	10
1066	Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study. <i>Urology</i> , 2015, 86, 1206-1211.	0.5	34
1067	Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 701-711.	12.8	1,044

#	ARTICLE	IF	CITATIONS
1068	Contemporary Systemic Therapy for Urologic Malignancies in Geriatric Patients. <i>Clinics in Geriatric Medicine</i> , 2015, 31, 645-665.	1.0	1
1069	The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 20865-20879.	1.6	28
1070	Docetaxel in very elderly men with metastatic castration-resistant prostate cancer. <i>Prostate International</i> , 2015, 3, 42-46.	1.2	18
1071	[18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. <i>Translational Oncology</i> , 2015, 8, 147-153.	1.7	6
1072	Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1971-1975.	3.3	17
1073	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015, 107, djv261.	3.0	53
1074	Drug design strategies for the treatment of prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 81-90.	2.5	9
1075	Inhibition of Stat5a/b Enhances Proteasomal Degradation of Androgen Receptor Liganded by Antiandrogens in Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 713-726.	1.9	16
1076	Screening baccharin analogs as selective inhibitors against type 5 17β -hydroxysteroid dehydrogenase (AKR1C3). <i>Chemico-Biological Interactions</i> , 2015, 234, 339-348.	1.7	24
1077	Switching and withdrawing hormonal agents for castration-resistant prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 37-47.	1.9	60
1078	Selective Estrogen Receptor Alpha Agonist GTx-758 Decreases Testosterone with Reduced Side Effects of Androgen Deprivation Therapy in Men with Advanced Prostate Cancer. <i>European Urology</i> , 2015, 67, 334-341.	0.9	15
1079	PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 39-43.	0.9	62
1080	Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 473-485.	0.9	24
1081	Targeted Prodrug Approaches for Hormone Refractory Prostate Cancer. <i>Medicinal Research Reviews</i> , 2015, 35, 554-585.	5.0	32
1082	Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e37-e49.	0.9	56
1083	Prognostic Utility of PET in Prostate Cancer. <i>PET Clinics</i> , 2015, 10, 255-263.	1.5	5
1084	Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 339-348.	1.1	8
1085	Update on systemic therapy for advance prostate cancer. <i>Current Problems in Cancer</i> , 2015, 39, 52-62.	1.0	1

#	ARTICLE	IF	CITATIONS
1086	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015, 68, 147-153.	0.9	73
1087	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043.	3.2	31
1088	The year chemotherapy finally gets some respect!. <i>Nature Reviews Urology</i> , 2015, 12, 71-72.	1.9	4
1089	Androgens regulate SMAD ubiquitination regulatory factor expression and prostate cancer cell invasion. <i>Prostate</i> , 2015, 75, 561-572.	1.2	17
1090	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. <i>Cancer Cell</i> , 2015, 27, 223-239.	7.7	128
1091	Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective. <i>Urology</i> , 2015, 85, 717-724.	0.5	40
1092	Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 1571-1576.	3.3	148
1093	Recent discoveries and developments of androgen receptor based therapy for prostate cancer. <i>MedChemComm</i> , 2015, 6, 746-768.	3.5	19
1094	Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study. <i>BJU International</i> , 2015, 115, 65-73.	1.3	9
1095	Enzalutamide in European and North American men participating in the AFFIRM trial. <i>BJU International</i> , 2015, 115, 41-49.	1.3	13
1096	A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2015, 67, 673-679.	0.9	80
1097	The Primary Local Stage at Diagnosis Predicts Regional Symptoms Caused by Local Progression in Patients With Castration-resistant Prostate Cancer. <i>Urology</i> , 2015, 85, 430-435.	0.5	7
1098	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	0.5	21
1099	Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?. <i>BJU International</i> , 2015, 115, 364-372.	1.3	8
1100	Metastatic castration-resistant prostate cancer: time for innovation. <i>Future Oncology</i> , 2015, 11, 91-106.	1.1	32
1101	Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 122-127.	2.0	78
1102	CYP17A1 inhibitors in castration-resistant prostate cancer. <i>Steroids</i> , 2015, 95, 80-87.	0.8	75
1103	Enzalutamide: A new prostate cancer targeted therapy against the androgen receptor. <i>Cancer Treatment Reviews</i> , 2015, 41, 247-253.	3.4	4

#	ARTICLE	IF	CITATIONS
1104	An update on enzalutamide in the treatment of prostate cancer. <i>Therapeutic Advances in Urology</i> , 2015, 7, 9-21.	0.9	41
1105	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015, 33, 723-731.	0.8	127
1106	Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 392-399.	0.9	36
1107	Î³â€œryzanol reduces caveolinâ€œ1 and PCGEM1 expression, markers of aggressiveness in prostate cancer cell lines. <i>Prostate</i> , 2015, 75, 783-797.	1.2	22
1108	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 152-160.	5.1	1,100
1109	New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 271-279.	0.9	34
1110	Analytical Challenges and Potential Applications of Sex Steroid Hormone Analysis in Breast and Prostate Cancer Patients. <i>Chromatographia</i> , 2015, 78, 359-365.	0.7	2
1111	Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. <i>Journal of Geriatric Oncology</i> , 2015, 6, 23-28.	0.5	24
1112	Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 143-145.	1.1	22
1113	Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. <i>British Journal of Cancer</i> , 2015, 112, 1166-1174.	2.9	59
1114	Failure of ELM-PC 5: An Ineffective Drug or an Unfit End Point?. <i>Journal of Clinical Oncology</i> , 2015, 33, 679-681.	0.8	6
1115	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2015, 10, 219-246.	1.0	11
1116	A phase 1 multiple-dose study of orteronel in Japanese patients with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 373-380.	1.1	3
1117	Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. <i>Scandinavian Journal of Urology</i> , 2015, 49, 211-217.	0.6	37
1118	Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 309-318.	0.9	43
1119	Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 749-754.	0.9	11
1120	Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.	0.8	120
1121	Nomogram Predicting Prostate Cancerâ€œspecific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2015, 67, 1160-1167.	0.9	192

#	ARTICLE	IF	CITATIONS
1122	Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience. <i>Medical Oncology</i> , 2015, 32, 52.	1.2	19
1123	Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 310-321.	0.8	27
1124	Corticosteroids in the Management of Prostate Cancer: A Critical Review. <i>Current Treatment Options in Oncology</i> , 2015, 16, 6.	1.3	27
1125	Transcription of <i>Nrdp1</i> by the androgen receptor is regulated by nuclear filamin A in prostate cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, 369-386.	1.6	16
1126	Sequencing current therapies in the treatment of metastatic prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 332-340.	3.4	38
1127	Evidence of epithelial-mesenchymal transition in canine prostate cancer metastasis. <i>Research in Veterinary Science</i> , 2015, 100, 176-181.	0.9	25
1128	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604.	0.6	279
1129	Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 439-445.	1.1	6
1130	Optimal sequence of bone target drugs in metastatic prostatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 923-929.	1.1	1
1131	American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options. <i>Journal of Clinical Oncology</i> , 2015, 33, 2563-2577.	0.8	783
1132	Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. <i>Journal of Urology</i> , 2015, 194, 1537-1547.	0.2	179
1133	Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 1946-1952.	1.3	63
1134	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 737-746.	13.9	2,112
1135	Fully-automated synthesis of ^{16}F -18 F-fluoro-5 α -dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer. <i>Applied Radiation and Isotopes</i> , 2015, 103, 9-14.	0.7	10
1136	Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301. <i>European Urology</i> , 2015, 67, 866-873.	0.9	49
1137	MicroRNA-19a regulates proliferation and apoptosis of castration-resistant prostate cancer cells by targeting BTG1. <i>FEBS Letters</i> , 2015, 589, 1485-1490.	1.3	43
1138	External Beam Radiation Therapy and Abiraterone in Men With Localized Prostate Cancer: Safety and Effect on Tissue Androgens. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 236-243.	0.4	34
1139	Should docetaxel be administered earlier in prostate cancer therapy?. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 977-979.	1.1	3

#	ARTICLE	IF	CITATIONS
1140	Prognostic Factors in Patients Treated with ²²³ Ra: The Role of Skeletal Tumor Burden on Baseline ¹⁸ F-Fluoride PET/CT in Predicting Overall Survival. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1177-1184.	2.8	111
1141	Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer. <i>Prostate International</i> , 2015, 3, 51-55.	1.2	23
1142	Molecular landscape of prostate cancer: Implications for current clinical trials. <i>Cancer Treatment Reviews</i> , 2015, 41, 761-766.	3.4	53
1143	Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v69-v77.	0.6	346
1144	The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics. <i>Biomaterials</i> , 2015, 66, 53-66.	5.7	90
1145	Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. <i>Cancer Letters</i> , 2015, 367, 12-17.	3.2	109
1146	Prostate-specific antigen kinetic profiles during androgen deprivation therapy as prognostic factors in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 203.e1-203.e9.	0.8	11
1147	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 265.e15-265.e21.	0.8	6
1148	Therapeutic Applications of the Prostate Cancer Epigenome. , 2015, , 233-268.		0
1150	"Natural course" of disease in patients with metastatic castrate-resistant prostate cancer: Survival and prognostic factors without life-prolonging treatment. <i>Scandinavian Journal of Urology</i> , 2015, 49, 440-445.	0.6	6
1151	Adherence to Abiraterone among the First 86 Recipients after Release in Saskatchewan. <i>Current Oncology</i> , 2015, 22, 64-67.	0.9	6
1152	Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 1277-1284.	0.2	65
1153	Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. <i>Annals of Oncology</i> , 2015, 26, 2044-2056.	0.6	89
1154	The third line of treatment for metastatic prostate cancer patients: Option or strategy?. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 265-271.	2.0	15
1155	Androgen pathway resistance in prostate cancer and therapeutic implications. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1521-1537.	0.9	50
1156	Using circulating tumor cells to inform on prostate cancer biology and clinical utility. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 191-210.	2.7	20
1158	Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , 2015, 67, 1028-1038.	0.9	340
1159	The androgen receptor for the radiation oncologist. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2015, 19, 220-227.	0.6	4

#	ARTICLE	IF	CITATIONS
1160	Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance. Reports of Practical Oncology and Radiotherapy, 2015, 20, 259-272.	0.3	16
1161	Interaction of novel oxazoline derivatives of 17(20)E-pregna-5,17(20)-diene with cytochrome P450 17A1. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2015, 9, 114-120.	0.2	6
1162	Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Critical Reviews in Oncology/Hematology, 2015, 96, 308-318.	2.0	17
1164	Emerging drugs for the treatment of bone metastasis. Expert Opinion on Emerging Drugs, 2015, 20, 637-651.	1.0	5
1165	A Perivesical Mass in a 79-Year-old With a Treated Adenocarcinoma of the Prostate. Urology, 2015, 85, 713-716.	0.5	0
1166	Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2015, 15, 151-156.	1.1	11
1167	New polycomb group protein enhancer of zeste homolog (EZH) 2-derived peptide with the potential to induce cancer-reactive cytotoxic T lymphocytes in prostate cancer patients with HLA-A3 supertype alleles. International Immunopharmacology, 2015, 26, 133-138.	1.7	3
1168	The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer. Chemico-Biological Interactions, 2015, 234, 332-338.	1.7	57
1169	Integrating Bone Targeting Radiopharmaceuticals Into the Management of Patients With Castrate-Resistant Prostate Cancer With Symptomatic Bone Metastases. Current Treatment Options in Oncology, 2015, 16, 325.	1.3	8
1170	Treatment of skeletal metastases with 223Ra-chloride. Clinical and Translational Imaging, 2015, 3, 159-165.	1.1	1
1172	Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer, 2015, 15, 222.	1.1	20
1173	Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Clinical Cancer Research, 2015, 21, 3170-3177.	3.2	57
1174	Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Molecular Medicine, 2015, 7, 878-894.	3.3	110
1175	Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy. Cancer Immunology Research, 2015, 3, 1063-1069.	1.6	17
1176	Efficacy and safety of docetaxel and prednisolone for castration-resistant prostate cancer: a multi-institutional retrospective study in Japan. Japanese Journal of Clinical Oncology, 2015, 45, 682-687.	0.6	4
1177	Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer. Urology, 2015, 85, 976-986.	0.5	13
1178	Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2015, 21, 2315-2324.	3.2	407
1179	Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncology, The, 2015, 16, 338-348.	5.1	106

#	ARTICLE	IF	CITATIONS
1180	Advances in the treatment of prostate cancer with radiotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 144-153.	2.0	14
1181	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	0.8	343
1182	CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel. <i>International Journal of Cancer</i> , 2015, 136, E760-72.	2.3	34
1183	ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells. <i>Clinical Cancer Research</i> , 2015, 21, 2569-2579.	3.2	60
1184	Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (^{mCRPC}). <i>BJU International</i> , 2015, 116, 17-29.	1.3	19
1185	The Evolving Role of Cytotoxic Chemotherapy in the Management of Patients with Metastatic Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 9.	1.3	2
1186	Radiotherapy for high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 145-154.	1.9	25
1187	Regulation of vascular endothelial growth factor in prostate cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R107-R123.	1.6	47
1188	Targeting extra-gonadal androgens in castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 157-163.	1.2	13
1189	Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 144-148.	2.0	11
1190	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>British Journal of Cancer</i> , 2015, 112, 1717-1724.	2.9	112
1191	Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. <i>Cancer Research</i> , 2015, 75, 1413-1422.	0.4	207
1192	Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 967-975.	1.5	16
1193	Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 795-807.	3.2	89
1194	CYP17A1 inhibitor failure—lessons for future drug development. <i>Nature Reviews Urology</i> , 2015, 12, 245-246.	1.9	5
1195	Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. <i>Science Translational Medicine</i> , 2015, 7, 269ra2.	5.8	205
1196	Targeting the MLL complex in castration-resistant prostate cancer. <i>Nature Medicine</i> , 2015, 21, 344-352.	15.2	165
1197	²²³Ra and other bone-targeting radiopharmaceuticals—the translation of radiation biology into clinical practice. <i>British Journal of Radiology</i> , 2015, 88, 20140752.	1.0	17

#	ARTICLE	IF	CITATIONS
1198	Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 161-166.	2.0	9
1199	Gene interference strategies as a new tool for the treatment of prostate cancer. <i>Endocrine</i> , 2015, 49, 588-605.	1.1	27
1200	Recent advances in allosteric androgen receptor inhibitors for the potential treatment of castration-resistant prostate cancer. <i>Pharmaceutical Patent Analyst</i> , 2015, 4, 387-402.	0.4	11
1201	Évaluation de la réponse métabolique en TEP/TDM à la F18-FCH après un mois de traitement par acétate d'abiraterone chez les patients présentant un cancer de la prostate métastatique résistant à la castration. <i>Medecine Nucleaire</i> , 2015, 39, 386-395.	0.2	0
1202	The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2015, 51, 2562-2569.	1.3	59
1203	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	5.8	366
1204	The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data. <i>Oncologist</i> , 2015, 20, 464-e20.	1.9	79
1205	Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809). <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2469-2474.	1.4	26
1206	Health-related quality of life in men with metastatic castration-resistant prostate cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 941-949.	0.7	3
1207	Regulation of tumor cell plasticity by the androgen receptor in prostate cancer. <i>Endocrine-Related Cancer</i> , 2015, 22, R165-R182.	1.6	52
1208	Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. <i>Expert Review of Vaccines</i> , 2015, 14, 1529-1541.	2.0	33
1209	Using routinely collected data to stratify prostate cancer patients into phases of care in the United Kingdom: implications for resource allocation and the cancer survivorship programme. <i>British Journal of Cancer</i> , 2015, 112, 1594-1602.	2.9	16
1210	Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. <i>Therapeutic Advances in Urology</i> , 2015, 7, 194-202.	0.9	29
1211	Targeting Transcription Factors in Cancer. <i>Trends in Cancer</i> , 2015, 1, 53-65.	3.8	247
1212	Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2015, 11, 2881-2891.	1.1	12
1213	Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Urology</i> , 2015, 194, 990-990.	0.2	2
1214	Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 441-446.	0.9	7
1215	2-weekly docetaxel: issues for clinical practice. <i>Cancer Biology and Therapy</i> , 2015, 16, 17-18.	1.5	0

#	ARTICLE	IF	CITATIONS
1217	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
1218	Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer going beyond PSA and imaging, a systematic literature review. <i>Annals of Oncology</i> , 2015, 26, 2221-2247.	0.6	10
1219	Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer. <i>Urology</i> , 2015, 86, 852-861.	0.5	42
1220	Novel xenografts in mice a new wave of preclinical models. <i>Nature Reviews Urology</i> , 2015, 12, 540-541.	1.9	3
1221	Treatment With Galeterone in an Elderly Man With Castration-Resistant Prostate Cancer: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e325-e328.	0.9	6
1222	ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1007-1017.	1.1	63
1223	Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 498-506.	2.0	54
1224	The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer. <i>Cancer Letters</i> , 2015, 367, 113-121.	3.2	46
1226	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 45.	1.8	3
1227	Drug therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2015, 11, 2395-2403.	1.1	1
1228	Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 884-892.	3.4	141
1229	Emerging agents for the therapy of advanced prostate cancer. <i>Future Oncology</i> , 2015, 11, 2775-2787.	1.1	10
1230	Gastrointestinal metastases from prostate cancer: a review of the literature. <i>Future Oncology</i> , 2015, 11, 691-702.	1.1	2
1231	Epithelial-mesenchymal transition in prostatic disease. <i>Future Oncology</i> , 2015, 11, 3197-3206.	1.1	26
1232	Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e361-e364.	0.9	1
1233	Reply to Kevin Lu's Letter to the Editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. <i>Eur Urol</i> 2015;67:441-7. <i>European Urology</i> , 2015, 68, e57-e58.	0.9	0
1234	Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. <i>Eur Urol</i> 2015;67:441-7. <i>European Urology</i> , 2015, 68, e55-e56.	0.9	0
1235	Palliative pelvic radiotherapy for symptomatic incurable prostate cancer A prospective multicenter study. <i>Radiotherapy and Oncology</i> , 2015, 115, 314-320.	0.3	25

#	ARTICLE	IF	CITATIONS
1236	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. <i>Cell Reports</i> , 2015, 12, 922-936.	2.9	216
1237	Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 57.	1.3	30
1238	Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy. <i>Prostate</i> , 2015, 75, 175-182.	1.2	11
1239	Efficacy of High-dose Palliative Radiotherapy for Localised, Castration-resistant Prostate Cancer. <i>Clinical Oncology</i> , 2015, 27, 16-21.	0.6	13
1240	Abiraterone Treatment in Castration-Resistant Prostate Cancer Selects for Progesterone Responsive Mutant Androgen Receptors. <i>Clinical Cancer Research</i> , 2015, 21, 1273-1280.	3.2	152
1241	Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2015, 32, 443.	1.2	16
1242	Radionuclide Therapy for Osseous Metastases in Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 66-80.	2.5	21
1243	Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study. <i>European Urology</i> , 2015, 67, 3-6.	0.9	136
1244	Treatment of castration-resistant prostate cancer and bone metastases with radium-223 dichloride. <i>International Journal of Urological Nursing</i> , 2015, 9, 3-13.	0.1	17
1245	Human Steroid Biosynthesis. , 2015, , 295-312.		3
1246	Steroid Sidestep: Evading Androgen Ablation by Abiraterone. <i>Clinical Cancer Research</i> , 2015, 21, 1240-1242.	3.2	4
1247	Effects of functional genetic polymorphisms in the <i>CYP19A1</i> gene on prostate cancer risk and survival. <i>International Journal of Cancer</i> , 2015, 136, 74-82.	2.3	39
1249	Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. <i>Oncogene</i> , 2015, 34, 1745-1757.	2.6	147
1250	Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. <i>European Urology</i> , 2015, 67, 441-447.	0.9	40
1251	Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies. <i>European Urology</i> , 2015, 68, 228-235.	0.9	144
1252	Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2015, 67, 53-60.	0.9	205
1253	A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 124-129.	0.9	14
1254	Combined blockade of testicular and locally made androgens in prostate cancer: A highly significant medical progress based upon intracrinology. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 144-156.	1.2	18

#	ARTICLE	IF	CITATIONS
1255	Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 59-69.	1.9	85
1256	Adverse effects of androgenâ€deprivation therapy in prostate cancer and their management. <i>BJU International</i> , 2015, 115, 3-13.	1.3	109
1257	Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. <i>Oncogene</i> , 2015, 34, 3700-3710.	2.6	80
1258	Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level. <i>European Urology</i> , 2015, 67, 470-479.	0.9	225
1259	Simultaneous Targeting of the Akt and Androgen Receptor Pathways. <i>European Urology</i> , 2015, 67, 991-992.	0.9	0
1260	Castration-Resistant Prostate Cancer: AUA Guideline Amendment. <i>Journal of Urology</i> , 2015, 193, 491-499.	0.2	134
1261	Quo vadis: Advanced prostate cancerâ€clinical care and clinical research in the era of multiple androgen receptorâ€directed therapies. <i>Cancer</i> , 2015, 121, 361-371.	2.0	9
1262	Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 49-58.	1.1	14
1263	Androgen receptor: structure, role in prostate cancer and drug discovery. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 3-23.	2.8	602
1264	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. <i>European Urology</i> , 2015, 68, 317-324.	0.9	96
1265	Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. <i>European Urology</i> , 2015, 68, 325-334.	0.9	239
1266	Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort. <i>World Journal of Urology</i> , 2015, 33, 833-839.	1.2	5
1267	Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 182-192.	0.8	26
1268	Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1520.	1.8	8
1269	Metastatic castration-resistant prostate cancer in very elderly patients: challenges and solutions. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 19-28.	1.3	8
1270	Polymeric Nanobiomaterials for Tumor Targeting. , 2016, , 541-564.		1
1271	Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. <i>International Journal of Biological Sciences</i> , 2016, 12, 409-426.	2.6	32
1272	Radium-223 and concomitant therapies: prospects and prudence. <i>Translational Andrology and Urology</i> , 2016, 5, 968-970.	0.6	2

#	ARTICLE	IF	CITATIONS
1273	Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>Yonsei Medical Journal</i> , 2016, 57, 1070.	0.9	9
1274	Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. <i>BioMed Research International</i> , 2016, 2016, 1-11.	0.9	43
1275	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.Ss34534.	0.6	14
1276	Galeterone for the treatment of advanced prostate cancer: the evidence to date. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2289-2297.	2.0	43
1277	CYP17A1 Polymorphisms and Clinical Outcome of Castration-Resistant Prostate Cancer Patients Treated with Abiraterone. <i>International Journal of Biological Markers</i> , 2016, 31, 264-269.	0.7	10
1278	Contemporary agents in the management of metastatic castration-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2016, 10, 414.	0.3	24
1279	Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. <i>Research and Reports in Urology</i> , 2016, Volume 8, 217-224.	0.6	4
1280	Abiraterone acetate. , 2016, , 13.		0
1281	Mechanistic Insights into Molecular Targeting and Combined Modality Therapy for Aggressive, Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2016, 6, 24.	1.3	20
1282	A Perspective of Immunotherapy for Prostate Cancer. <i>Cancers</i> , 2016, 8, 64.	1.7	28
1283	Common Genetic Variation in CYP17A1 and Response to Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1097.	1.8	22
1284	Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further. <i>Journal of UOEH</i> , 2016, 38, 129-138.	0.3	17
1285	Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?. <i>PLoS ONE</i> , 2016, 11, e0147191.	1.1	50
1286	Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease. <i>PLoS ONE</i> , 2016, 11, e0153840.	1.1	40
1287	Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer. <i>PLoS ONE</i> , 2016, 11, e0158952.	1.1	45
1288	11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored. <i>PLoS ONE</i> , 2016, 11, e0159867.	1.1	113
1289	Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival. <i>Frontiers in Pharmacology</i> , 2016, 7, 123.	1.6	35
1290	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016, 7, 376.	1.6	127

#	ARTICLE	IF	CITATIONS
1291	Linee guida Carcinoma della Prostata - AIRO, 2016. Tumori, 2016, 102, S1-S79.	0.6	4
1292	Conserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells. Molecular and Clinical Oncology, 2016, 4, 326-368.	0.4	4
1293	Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer. Oncotarget, 2016, 7, 32210-32220.	0.8	87
1294	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 279-290.	1.2	16
1295	Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. Prostate, 2016, 76, 325-334.	1.2	25
1296	Patient-Derived Prostate Cancer: from Basic Science to the Clinic. Hormones and Cancer, 2016, 7, 236-240.	4.9	8
1297	Use of androgen receptor signaling-targeted therapies in chemotherapy-naive metastatic castration-resistant prostate cancer: a call for patient-centered studies. Journal of Comparative Effectiveness Research, 2016, 5, 5-7.	0.6	2
1298	Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. International Journal of Urology, 2016, 23, 404-411.	0.5	26
1299	Androgen ablation elicits PP1-dependence for AR stabilization and transactivation in prostate cancer. Prostate, 2016, 76, 649-661.	1.2	8
1300	Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis. Cancer, 2016, 122, 1085-1096.	2.0	21
1301	Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer. International Journal of Cancer, 2016, 139, 1632-1647.	2.3	9
1302	Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer. Anti-Cancer Drugs, 2016, 27, 695-701.	0.7	3
1303	Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate, 2016, 76, 286-293.	1.2	30
1304	Abiraterone for the Treatment of mCRPC. , 2016, , 125-155.		0
1305	Patient-reported outcomes in metastatic castration-resistant prostate cancer. Nature Reviews Clinical Oncology, 2016, 13, 643-650.	12.5	27
1306	Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer, 2016, 16, 377.	1.1	28
1307	Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2 Cell Pharmacodynamics as a Determinant of Clinical Response. Prostate, 2016, 76, 1257-1270.	1.2	208
1308	Novel treatment strategies in congenital adrenal hyperplasia. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 225-232.	1.2	24

#	ARTICLE	IF	CITATIONS
1309	Precision medicine for advanced prostate cancer. <i>Current Opinion in Urology</i> , 2016, 26, 231-239.	0.9	23
1310	Immunotherapy for genitourinary cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 585-599.	0.7	4
1311	Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells. <i>Assay and Drug Development Technologies</i> , 2016, 14, 226-239.	0.6	26
1312	Cytochrome P450 17A1 Inhibitor Abiraterone Acetate Counteracts the Heat Shock Protein 27's Cell Survival Properties in Prostate Cancer Cells. <i>Urologia Internationalis</i> , 2016, 97, 112-117.	0.6	3
1313	The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 480-487.	1.6	15
1314	Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. <i>BMC Urology</i> , 2016, 16, 27.	0.6	10
1315	A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. <i>Oncologist</i> , 2016, 21, 1296-1297e.	1.9	23
1316	Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. <i>Oncologist</i> , 2016, 21, 1414-e9.	1.9	6
1317	The promise of circulating tumor cells for precision cancer therapy. <i>Biomarkers in Medicine</i> , 2016, 10, 1269-1285.	0.6	11
1319	Acute Aortic Dissection Following Treatment for Castration-Resistant Prostate Cancer. <i>Oncology Nursing Forum</i> , 2016, 43, 413-416.	0.5	3
1320	Estrogen receptors α and β and aromatase as independent predictors for prostate cancer outcome. <i>Scientific Reports</i> , 2016, 6, 33114.	1.6	30
1321	The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 330-333.	1.0	8
1322	Targeting the androgenic pathway in elderly patients with castration-resistant prostate cancer. <i>Medicine (United States)</i> , 2016, 95, e4636.	0.4	6
1323	Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 326-329.	1.0	11
1324	Immune Therapy for Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 334-341.	1.0	16
1325	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 488-498.	1.6	38
1326	The Molecular Evolution of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 506-513.	1.6	41
1327	Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. <i>European Urology Focus</i> , 2016, 2, 499-505.	1.6	55

#	ARTICLE	IF	CITATIONS
1328	Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer. <i>Translational Oncology</i> , 2016, 9, 600-605.	1.7	11
1329	Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis. <i>BMC Research Notes</i> , 2016, 9, 471.	0.6	16
1330	Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer. <i>Journal of Medical Economics</i> , 2016, 19, 777-784.	1.0	25
1331	Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 389-397.	0.9	5
1332	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 44.	1.2	40
1333	Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. <i>Oncolmmunology</i> , 2016, 5, e1107698.	2.1	28
1334	Volume of Bone Metastasis Assessed with Whole-Body Diffusion-weighted Imaging Is Associated with Overall Survival in Metastatic Castration-resistant Prostate Cancer. <i>Radiology</i> , 2016, 280, 151-160.	3.6	51
1335	Drug-induced hepatotoxicity in cancer patients - implication for treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1219-1238.	1.0	52
1336	Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel. <i>Lancet Oncology</i> , The, 2016, 17, 872-873.	5.1	2
1337	Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. <i>Nature</i> , 2016, 533, 547-551.	13.7	138
1338	Diagnostic Gleason score and castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2016, 27, 962-964.	0.6	4
1339	Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320a-Mediated Suppression of the Androgen Receptor. <i>Cancer Research</i> , 2016, 76, 4192-4204.	0.4	41
1340	A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone. <i>Journal of Geriatric Oncology</i> , 2016, 7, 81-89.	0.5	24
1341	Characterizations of Clinical and Therapeutic Histories for Men With Prostate Cancer-Specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 139-148.	0.9	2
1342	The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 163, 136-146.	1.2	24
1344	Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 231-241.	2.0	142
1345	What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence. <i>Therapeutic Advances in Urology</i> , 2016, 8, 272-278.	0.9	14
1346	The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 681-696.	1.1	7

#	ARTICLE	IF	CITATIONS
1347	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2731-2742.	0.4	79
1348	In touch with your feminine side: how oestrogen metabolism impacts prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R249-R266.	1.6	16
1349	Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. <i>Genome Biology</i> , 2016, 17, 10.	3.8	165
1350	Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?. <i>European Urology Focus</i> , 2016, 2, 426-440.	1.6	3
1351	Androgen-metabolizing enzymes: A structural perspective. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 161, 54-72.	1.2	7
1352	Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review. <i>Annals of Oncology</i> , 2016, 27, 975-984.	0.6	76
1353	Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. <i>BMC Cancer</i> , 2016, 16, 109.	1.1	29
1354	African American Participation in Oncology Clinical Trials—Focus on Prostate Cancer: Implications, Barriers, and Potential Solutions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 105-116.	0.9	32
1355	Prednisone Use in Conjunction with Abiraterone Acetate: Is Patient Safety a Concern with Long-term Steroid Exposure?. <i>European Urology</i> , 2016, 70, 445-446.	0.9	0
1356	The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 23-30.	1.1	10
1357	Is Gleason Grade 5 Prostate Cancer Resistant to Conventional Androgen Deprivation Therapy?. <i>European Urology</i> , 2016, 69, 761-763.	0.9	7
1358	Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy. <i>BMC Urology</i> , 2016, 16, 13.	0.6	13
1359	Defining and Targeting the Oncogenic Drivers of Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , 2016, 29, 431-432.	7.7	14
1360	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). <i>Annals of Oncology</i> , 2016, 27, 812-818.	0.6	234
1361	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1369-1380.	1.6	74
1362	Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 599-608.	0.9	111
1363	Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 1598.	3.4	290
1364	The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 381-388.	0.9	12

#	ARTICLE	IF	CITATIONS
1365	Predictors of Chemotherapy-Induced Toxicity and Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e559-e568.	0.9	14
1366	Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in Sweden. <i>Scandinavian Journal of Urology</i> , 2016, 50, 286-291.	0.6	13
1367	Suppression of rat and human androgen biosynthetic enzymes by apigenin: Possible use for the treatment of prostate cancer. <i>FÅ-toterapÅ-Åç</i> , 2016, 111, 66-72.	1.1	19
1368	Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 271-276.	2.0	3
1369	Linking the Price of Cancer Drug Treatments to Their Clinical Value. <i>Clinical Drug Investigation</i> , 2016, 36, 579-589.	1.1	5
1370	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , 2016, 61, 111-121.	1.3	51
1371	Treatment of Metastatic Prostate Cancer in Older Adults. <i>Current Oncology Reports</i> , 2016, 18, 63.	1.8	6
1372	In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1682-1691.	1.7	18
1373	Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 398-405.	2.0	12
1374	Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 185-194.	0.5	20
1375	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. <i>Asian Journal of Urology</i> , 2016, 3, 195-202.	0.5	12
1377	Non-invasive actionable biomarkers for metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 170-176.	0.5	8
1378	Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer. <i>Oncology</i> , 2016, 91, 267-273.	0.9	10
1379	PARP inhibitors and stratified treatment of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1213-1215.	1.1	6
1380	PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. <i>Journal of Nuclear Medicine</i> , 2016, 57, 97S-104S.	2.8	158
1381	Achieving resistance specificity in prostate cancer. <i>Chemico-Biological Interactions</i> , 2016, 260, 243-247.	1.7	4
1382	Impact of intense systemic therapy and improved survival on the use of palliative radiotherapy in patients with bone metastases from prostate cancer. <i>Oncology Letters</i> , 2016, 12, 2930-2935.	0.8	10
1383	Understanding the role of new systemic agents in the treatment of prostate cancer. <i>BJU International</i> , 2016, 118, 8-13.	1.3	15

#	ARTICLE	IF	CITATIONS
1384	Harmful effects behind the daily supplementation of a fixed vegetarian blend in the rat model. <i>Food and Chemical Toxicology</i> , 2016, 97, 367-374.	1.8	10
1385	Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 458-463.	0.8	4
1386	UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling. <i>Cancer Research</i> , 2016, 76, 6701-6711.	0.4	37
1387	Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7431-7444.	2.9	33
1388	Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. <i>Cell</i> , 2016, 166, 1041-1054.	13.5	206
1389	Cancer treatment and survivorship statistics, 2016. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 271-289.	157.7	4,123
1390	Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic. <i>International Journal of Urology</i> , 2016, 23, 654-665.	0.5	65
1391	Prolonged biochemical response after discontinuation of orteronel (TAK-700) in a patient with metastasized castration-resistant prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 656-658.	0.8	1
1392	Trends in scientific publications related to the field of onco-urology over the past 10 years. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1751-1755.	0.5	0
1393	Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. <i>Lancet Oncology</i> , The, 2016, 17, 1306-1316.	5.1	259
1394	Utility of novel androgen receptor therapies in the real world: A nuanced approach. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 340-347.	0.8	2
1395	The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 929-942.	1.1	5
1396	Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). <i>Prostate</i> , 2016, 76, 1519-1527.	1.2	16
1397	Systems Pharmacology Modeling of Prostate-Specific Antigen in Patients With Prostate Cancer Treated With an Androgen Receptor Antagonist and Down-Regulator. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 258-263.	1.3	3
1398	Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. <i>Prostate</i> , 2016, 76, 32-40.	1.2	13
1399	Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2016, 117, 215-225.	1.3	94
1400	Novel agents for castration-resistant prostate cancer: Early experience and beyond. <i>International Journal of Urology</i> , 2016, 23, 114-121.	0.5	31
1401	Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 360-369.	0.5	62

#	ARTICLE	IF	CITATIONS
1402	Uncontrolled diabetes predicts poor response to novel antiandrogens. <i>Endocrine-Related Cancer</i> , 2016, 23, 691-698.	1.6	14
1403	High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1391-1399.	0.8	18
1404	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. <i>Lancet Oncology</i> , The, 2016, 17, 1435-1444.	5.1	107
1405	Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis. <i>Clinical Therapeutics</i> , 2016, 38, 1817-1824.	1.1	14
1406	No manâ€™s land: information needs and resources of men with metastatic castrate resistant prostate cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 4471-4473.	1.0	5
1407	The safety and efficacy of radium-223 dichloride for the treatment of advanced prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 911-918.	1.1	16
1408	Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 14-24.	2.0	10
1409	Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. <i>Endocrine-Related Cancer</i> , 2016, 23, T179-T197.	1.6	132
1410	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. <i>Oncologist</i> , 2016, 21, 1427-1435.	1.9	60
1411	Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasisâ€™Free Survival and Prostate Cancerâ€™Specific Mortality. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 617-623.	0.4	12
1412	Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer. <i>ChemMedChem</i> , 2016, 11, 1983-1986.	1.6	10
1413	Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine. <i>Future Oncology</i> , 2016, 12, 2359-2361.	1.1	4
1414	Drug discovery in advanced prostate cancer: translating biology into therapy. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 699-718.	21.5	111
1415	Cytochrome b5 Activates the 17,20-Lyase Activity of Human Cytochrome P450 17A1 by Increasing the Coupling of NADPH Consumption to Androgen Production. <i>Biochemistry</i> , 2016, 55, 4356-4365.	1.2	37
1416	MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2155-2165.	1.9	58
1417	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	0.8	202
1418	Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide. <i>Prostate</i> , 2016, 76, 1484-1490.	1.2	29
1419	Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP). <i>ESMO Open</i> , 2016, 1, e000049.	2.0	2

#	ARTICLE	IF	CITATIONS
1420	Enhanced detection sensitivity of prostate-specific antigen via PSA-conjugated gold nanoparticles based on localized surface plasmon resonance: GNP-coated anti-PSA/LSPR as a novel approach for the identification of prostate anomalies. <i>Cancer Gene Therapy</i> , 2016, 23, 365-369.	2.2	80
1421	Emerging data on androgen receptor splice variants in prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, T199-T210.	1.6	47
1422	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
1423	Sequencing Treatment for Castration-Resistant Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 64.	1.3	29
1424	Cell-free and circulating tumor cell-based biomarkers in men with metastatic prostate cancer: Tools for real-time precision medicine?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 490-501.	0.8	11
1425	Androgen Receptor Tumor Suppressor Function Is Mediated by Recruitment of Retinoblastoma Protein. <i>Cell Reports</i> , 2016, 17, 966-976.	2.9	66
1426	Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer. <i>Scientific Reports</i> , 2016, 6, 35354.	1.6	33
1427	Advances in the management of castration resistant prostate cancer. <i>BMJ, The</i> , 2016, 355, i4405.	3.0	71
1428	New Drugs in the Treatment of Elderly Patients with Metastatic Castration-Resistance Prostate Cancer. <i>Tumori</i> , 2016, 102, 361-366.	0.6	1
1429	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34535.	0.6	34
1430	The evolving role of chemotherapy in prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 262-265.	0.5	1
1431	Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: "Game Over"?. <i>Targeted Oncology</i> , 2016, 11, 431-446.	1.7	7
1432	PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7124-7129.	3.3	627
1433	Androgen Receptor Signaling in Castration Resistant Prostate Cancer. , 2016, , 23-34.		0
1434	Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 93-95.	0.3	0
1435	Metabolic syndrome in prostate cancer: impact on risk and outcomes. <i>Future Oncology</i> , 2016, 12, 1947-1955.	1.1	6
1436	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 25-33.	3.4	22
1437	Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation. <i>Prostate International</i> , 2016, 4, 54-55.	1.2	0

#	ARTICLE	IF	CITATIONS
1438	Translational and clinical implications of the genetic landscape of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 597-610.	12.5	63
1439	(2 <i>S</i>)-2-(3-(1-Carboxy-5-(4 ²¹¹ At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted β -Particle Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1569-1575.	2.8	101
1440	Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53- deficiency-driven castration-resistant prostate cancer. <i>EBioMedicine</i> , 2016, 7, 50-61.	2.7	56
1441	Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2016, 15, 599-610.	2.9	101
1442	Implementation of the AUA Castration Resistant Prostate Cancer Guidelines into Practice: Establishing a Multidisciplinary Clinic. <i>Urology Practice</i> , 2016, 3, 203-209.	0.2	4
1443	CYP17 inhibitors in prostate cancer: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 267-275.	1.4	45
1444	Targeting intratumoral androgens: statins and beyond. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 388-395.	1.4	7
1445	Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. <i>BMC Cancer</i> , 2016, 16, 214.	1.1	35
1446	Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience. <i>BMC Urology</i> , 2016, 16, 12.	0.6	45
1447	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2636-2643.	0.8	77
1448	Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer. <i>European Urology</i> , 2016, 70, 985-992.	0.9	119
1449	β mediates prostate cancer cell death induced by combinatorial targeting of the androgen receptor. <i>BMC Cancer</i> , 2016, 16, 141.	1.1	10
1450	Association between the CYP11 family and six cancer types. <i>Oncology Letters</i> , 2016, 12, 35-40.	0.8	20
1451	Antineoplastic Isoflavonoids Derived from Intermediate <i>ortho</i> -Quinone Methides Generated from Mannich Bases. <i>ChemMedChem</i> , 2016, 11, 600-611.	1.6	19
1452	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. <i>Prostate</i> , 2016, 76, 512-520.	1.2	19
1453	Androgen-induced Long Noncoding RNA (lncRNA) SOCS2-AS1 Promotes Cell Growth and Inhibits Apoptosis in Prostate Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 17861-17880.	1.6	122
1455	Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients. <i>Chemotherapy</i> , 2016, 61, 127-133.	0.8	8
1456	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016, 12, 493-502.	1.1	8

#	ARTICLE	IF	CITATIONS
1457	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2098-2106.	0.8	264
1458	The efficacy of abiraterone acetate in treating Taiwanese chemo-refractory metastatic castration-resistant prostate cancer patients. <i>Urological Science</i> , 2016, 27, 218-222.	0.2	1
1459	The <i>MCT4</i> Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2721-2733.	3.2	84
1460	Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 254-262.	0.4	31
1461	Cytochrome P450 17A1 inhibitor abiraterone attenuates cellular growth of prostate cancer cells independently from androgen receptor signaling by modulation of oncogenic and apoptotic pathways. <i>International Journal of Oncology</i> , 2016, 48, 793-800.	1.4	36
1462	A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2016, 21, 773-782.	1.0	10
1463	BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer. <i>Molecular Cancer Research</i> , 2016, 14, 324-331.	1.5	137
1464	Role of corticosteroids in prostate cancer progression: implications for treatment strategy in metastatic castration-resistant patients. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 729-738.	1.8	7
1465	Synthesis and CYP17 α hydroxylase inhibition activity of new 3 α - and 3 β -ester derivatives of pregnenolone and related ether analogues. <i>Medicinal Chemistry Research</i> , 2016, 25, 310-321.	1.1	4
1466	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Oncolmmunology</i> , 2016, 5, e1105431.	2.1	11
1467	Immunotherapy in prostate cancer: challenges and opportunities. <i>Immunotherapy</i> , 2016, 8, 69-77.	1.0	14
1468	Association of <i>SLCO2B1</i> Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 352-359.	0.8	35
1469	Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. <i>Nature Reviews Urology</i> , 2016, 13, 47-60.	1.9	65
1470	HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. <i>Oncogene</i> , 2016, 35, 3781-3795.	2.6	128
1471	Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 12-20.	2.0	37
1472	Impaired 17,20-Lyase Activity in Male Mice Lacking Cytochrome b5 in Leydig Cells. <i>Molecular Endocrinology</i> , 2016, 30, 469-478.	3.7	13
1473	Chemotherapy for metastatic castrate-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 139-144.	2.0	16
1474	Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 438-444.	0.9	31

#	ARTICLE	IF	CITATIONS
1475	Multifaceted and personalized therapy of advanced prostate cancer. <i>Current Opinion in Oncology</i> , 2016, 28, 222-231.	1.1	5
1476	Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. <i>Cancer Medicine</i> , 2016, 5, 182-191.	1.3	55
1477	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 44, 61-73.	3.4	56
1478	Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. <i>Oncogene</i> , 2016, 35, 4807-4815.	2.6	32
1479	The evolving role of enzalutamide on the treatment of prostate cancer. <i>Future Oncology</i> , 2016, 12, 607-616.	1.1	7
1480	Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents. <i>Drugs</i> , 2016, 76, 421-430.	4.9	4
1481	Vitamin D in Prostate Cancer. <i>Vitamins and Hormones</i> , 2016, 100, 321-355.	0.7	21
1482	Low-Dose Docetaxel Combined with Dexamethasone Is Feasible for Patients with Castration-Resistant Prostate Cancer. <i>Chemotherapy</i> , 2016, 61, 23-31.	0.8	6
1483	Passing on the medicinal chemistry baton: training undergraduates to be industry-ready through research projects between the University of Nottingham and GlaxoSmithKline. <i>Drug Discovery Today</i> , 2016, 21, 880-887.	3.2	9
1484	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , 2016, 22, 298-305.	15.2	1,193
1485	Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Current Oncology Reports</i> , 2016, 18, 14.	1.8	39
1486	Isolation and analysis of discreet human prostate cellular populations. <i>Differentiation</i> , 2016, 91, 139-151.	1.0	16
1487	Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 111-121.	2.0	58
1488	Resisting resistance: Establishing new treatment options for CRPC patients. <i>Cancer Biology and Therapy</i> , 2016, 17, 337-338.	1.5	0
1489	Tasquinimod in the treatment of castrate-resistant prostate cancer – current status and future prospects. <i>Therapeutic Advances in Urology</i> , 2016, 8, 9-18.	0.9	24
1490	Serial ¹⁸ F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers. <i>Future Oncology</i> , 2016, 12, 333-342.	1.1	31
1491	Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial. <i>European Journal of Cancer</i> , 2016, 56, 93-100.	1.3	62
1492	Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 265-270.	0.9	18

#	ARTICLE	IF	CITATIONS
1493	The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer. <i>Hormones and Cancer</i> , 2016, 7, 149-164.	4.9	62
1494	The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 72-78.	2.0	20
1495	Imaging yield from 133 consecutive patients with prostate cancer and low trigger PSA from a single institution. <i>Clinical Radiology</i> , 2016, 71, e143-e149.	0.5	1
1496	Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.	0.8	1,089
1497	Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer. <i>Medicine (United States)</i> , 2016, 95, e2544.	0.4	63
1498	Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1546-1562.	3.3	37
1499	Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. <i>Nature Medicine</i> , 2016, 22, 369-378.	15.2	572
1500	Using CTCs for pharmacogenomic analysis. <i>Pharmacological Research</i> , 2016, 106, 92-100.	3.1	4
1501	CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (fAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. <i>Hormones and Cancer</i> , 2016, 7, 196-210.	4.9	20
1502	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 724-731.	0.9	59
1503	Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 356-367.	0.8	19
1504	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	6.3	1,570
1505	Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1356-1363.	3.2	71
1506	Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients. <i>Endocrine</i> , 2016, 54, 830-833.	1.1	3
1507	A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. <i>Annals of Oncology</i> , 2016, 27, 454-460.	0.6	142
1508	Opportunities and challenges in combination gene cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2016, 98, 35-40.	6.6	64
1509	Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials.. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 254-263.	2.0	2
1510	AR-V7 and prostate cancer: The watershed for treatment selection?. <i>Cancer Treatment Reviews</i> , 2016, 43, 27-35.	3.4	49

#	ARTICLE	IF	CITATIONS
1511	Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-285.	0.8	42
1512	Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis. <i>Targeted Oncology</i> , 2016, 11, 345-351.	1.7	56
1513	Management of Prostate Cancer in the Elderly. <i>Clinics in Geriatric Medicine</i> , 2016, 32, 113-132.	1.0	12
1514	Exercise for Men with Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 693-703.	0.9	207
1515	Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015. <i>Journal of Urology</i> , 2016, 195, 1444-1452.	0.2	56
1516	The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1969-1977.	3.2	170
1517	Cost-effectiveness of denosumab as a bone protective agent for patients with castration resistant prostate cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 5-10.	0.7	6
1518	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. <i>European Urology</i> , 2016, 69, 924-932.	0.9	22
1519	Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials. <i>Annals of Oncology</i> , 2016, 27, 699-705.	0.6	35
1520	What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?. <i>World Journal of Urology</i> , 2016, 34, 617-624.	1.2	15
1521	Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 48-55.	0.9	14
1522	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 563-573.	0.9	101
1524	Factors affecting 223Ra therapy: clinical experience after 532 cycles from a single institution. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 8-20.	3.3	48
1525	Novel functionalized 5-(phenoxyethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 139-147.	2.4	2
1526	CYP17A1 Enzyme Activity Is Linked to Ambulatory Blood Pressure in a Family-Based Population Study. <i>American Journal of Hypertension</i> , 2016, 29, 484-493.	1.0	13
1527	Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 35-45.	1.6	49
1528	Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 85-93.	1.2	32
1529	Incidence and Correlates of Fatigue in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 5-11.	0.9	12

#	ARTICLE	IF	CITATIONS
1530	The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. <i>European Urology</i> , 2016, 69, 601-609.	0.9	36
1531	“Hit the primary” A paradigm shift in the treatment of metastatic prostate cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 231-237.	2.0	18
1532	PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. <i>Oncogene</i> , 2016, 35, 2322-2332.	2.6	38
1533	Novel and next-generation androgen receptor“directed therapies for prostate cancer: Beyond abiraterone and enzalutamide. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 348-355.	0.8	30
1534	Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy. <i>World Journal of Urology</i> , 2016, 34, 261-267.	1.2	18
1535	Prostate cancer. <i>Lancet, The</i> , 2016, 387, 70-82.	6.3	801
1536	Recent progress in the development of protein“protein interaction inhibitors targeting androgen receptor“coactivator binding in prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 161, 36-44.	1.2	19
1537	Endocrinology of Benign Prostatic Hyperplasia and Prostate Cancer. , 2016, , 2467-2484.e5.		0
1538	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , 2017, 71, 81-92.	0.9	230
1539	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 319-327.	0.9	74
1540	Stem cells and the role of ETS transcription factors in the differentiation hierarchy of normal and malignant prostate epithelium. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 68-83.	1.2	13
1541	Epithelial-mesenchymal-transition regulators in prostate cancer: Androgens and beyond. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 84-90.	1.2	49
1542	Development and validation of a novel LC“MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 172, 231-239.	1.2	26
1543	Abiraterone-induced rhabdomyolysis: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 148-151.	0.5	12
1544	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017, 71, 656-664.	0.9	67
1545	Profiling adrenal 11“hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11“hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 54-67.	1.2	58
1546	Chromogranin A and neurone“specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration“resistant prostate cancer undergoing abiraterone therapy. <i>BJU International</i> , 2017, 119, 30-37.	1.3	42
1547	Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy. <i>JAMA Oncology</i> , 2017, 3, 652.	3.4	41

#	ARTICLE	IF	CITATIONS
1548	End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 203-209.	2.0	4
1549	CX4945 suppresses the growth of castration-resistant prostate cancer cells by reducing AR-V7 expression. <i>World Journal of Urology</i> , 2017, 35, 1213-1221.	1.2	6
1550	Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. <i>European Urology</i> , 2017, 72, 192-200.	0.9	106
1551	Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage. <i>Dalton Transactions</i> , 2017, 46, 2165-2173.	1.6	62
1552	The evolving role of chemotherapy in prostate cancer. <i>Future Oncology</i> , 2017, 13, 1091-1095.	1.1	14
1553	Cardiovascular toxicities of systemic treatments of prostate cancer. <i>Nature Reviews Urology</i> , 2017, 14, 230-243.	1.9	15
1554	Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. <i>Asian Journal of Urology</i> , 2017, 4, 37-43.	0.5	39
1555	Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 472-478.	0.9	13
1556	Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel. <i>Acta Oncologica</i> , 2017, 56, 555-562.	0.8	24
1557	Management of Prostate Cancer. , 2017, , .		5
1558	Chromogranin A and neuron-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2017, 120, 226-232.	1.3	27
1559	Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants. <i>Prostate</i> , 2017, 77, 584-596.	1.2	30
1560	The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 234-240.	2.0	4
1561	ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2017, 35, 599-607.	1.2	41
1563	Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155. <i>Molecular Cancer Research</i> , 2017, 15, 521-531.	1.5	17
1564	Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 551-560.	2.8	19
1565	Protein kinase C regulates Twist1 expression via NF- κ B in prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, 171-180.	1.6	10
1566	Mechanisms of Therapeutic Resistance in Prostate Cancer. <i>Current Oncology Reports</i> , 2017, 19, 13.	1.8	103

#	ARTICLE	IF	CITATIONS
1567	Simultaneous quantitation of abiraterone, enzalutamide, N -desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 197-205.	1.4	29
1568	Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e599-e602.	0.9	17
1569	Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 40957.	1.6	30
1570	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. <i>Scientific Reports</i> , 2017, 7, 42713.	1.6	85
1571	La quimioterapia no deber�a todav�a ser considerada en los pacientes con c�ncer de pr�stata metast�sico hormonosensible. <i>Actas Urol�gicas Espa�olas</i> , 2017, 41, 347-351.	0.3	0
1572	CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC. <i>Molecular Cancer Research</i> , 2017, 15, 660-669.	1.5	22
1573	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. <i>Lancet Oncology</i> , The, 2017, 18, 473-485.	5.1	67
1574	Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer. <i>Cancer Biology and Therapy</i> , 2017, 18, 203-204.	1.5	1
1575	Androgen dependent mechanisms of pro-angiogenic networks in placental and tumor development. <i>Placenta</i> , 2017, 56, 79-85.	0.7	8
1576	DNA vaccines for prostate cancer. , 2017, 174, 27-42.		36
1577	Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy. <i>Oncology Letters</i> , 2017, 13, 22-28.	0.8	15
1578	Illuminating cytochrome P450 binding: Ru(II)-caged inhibitors of CYP17A1. <i>Chemical Communications</i> , 2017, 53, 3673-3676.	2.2	61
1579	A potential panel of four-long noncoding RNA signature in prostate cancer predicts biochemical recurrence-free survival and disease-free survival. <i>International Urology and Nephrology</i> , 2017, 49, 825-835.	0.6	20
1580	Role of radical prostatectomy in metastatic prostate cancer: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 125-134.	0.8	26
1581	C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition. <i>Oncogene</i> , 2017, 36, 3718-3728.	2.6	35
1582	Aged patients with metastatic castration resistant prostate cancer: Should we treat with chemotherapy?. <i>Cancer Treatment Reviews</i> , 2017, 55, 173-180.	3.4	3
1583	Androgen deprivation therapy in the treatment of locally advanced, nonmetastatic prostate cancer: practical experience and a review of the clinical trial evidence. <i>Therapeutic Advances in Urology</i> , 2017, 9, 73-80.	0.9	11
1584	Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1051-1055.	1.1	14

#	ARTICLE	IF	CITATIONS
1585	Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study. <i>CMAJ Open</i> , 2017, 5, E265-E272.	1.1	12
1587	Management Options for Biochemically Recurrent Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 26.	1.3	27
1588	Amino-terminal enhancer of split gene <i>AES</i> encodes a tumor and metastasis suppressor of prostate cancer. <i>Cancer Science</i> , 2017, 108, 744-752.	1.7	15
1589	Darolutamide (ODM-201) for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 945-952.	0.9	52
1590	The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation. <i>BMC Cancer</i> , 2017, 17, 163.	1.1	14
1591	Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration. <i>International Journal of Urology</i> , 2017, 24, 441-448.	0.5	49
1592	Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4331-4340.	1.2	11
1593	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017, 77, 1012-1019.	1.2	6
1594	Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 352-360.	2.0	69
1595	Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 899-908.	0.9	5
1596	Neoadjuvant Enzalutamide Prior to Prostatectomy. <i>Clinical Cancer Research</i> , 2017, 23, 2169-2176.	3.2	80
1597	Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 463-471.	0.9	12
1598	Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 678-684.e1.	0.9	16
1599	Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet. <i>Targeted Oncology</i> , 2017, 12, 401-412.	1.7	6
1600	High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 733-741.e1.	0.9	16
1601	Abiraterone Acetate for Treatment of Metastatic Castration-resistant Prostate Cancer in Chemotherapy-naïve Patients: An Italian Analysis of Patients' Satisfaction. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 520-525.	0.9	11
1602	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Medicine (United States)</i> , 2017, 96, e6817.	0.4	4
1603	Characterization of a novel p110 ^β -specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells. <i>Prostate</i> , 2017, 77, 1187-1198.	1.2	17

#	ARTICLE	IF	CITATIONS
1604	Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities. <i>Cell Chemical Biology</i> , 2017, 24, 825-832.e6.	2.5	41
1605	Clinical development of immunotherapy for prostate cancer. <i>International Journal of Urology</i> , 2017, 24, 675-680.	0.5	6
1606	Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. <i>International Journal of Urology</i> , 2017, 24, 566-572.	0.5	22
1607	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	13.9	1,588
1608	Treatment strategies for DNA repair-deficient prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 889-898.	1.3	26
1609	Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer. <i>Endocrinology</i> , 2017, 158, 1533-1542.	1.4	58
1610	Bayesian kernel machine models for testing genetic pathway effects in prostate cancer prognosis. <i>Statistical Analysis and Data Mining</i> , 2017, 10, 378-392.	1.4	0
1611	Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 534-539.	0.9	3
1612	A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor. <i>Nature Chemical Biology</i> , 2017, 13, 771-778.	3.9	39
1613	Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 319-333.	1.4	18
1614	Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 625-633.	1.1	24
1615	Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. <i>Prostate</i> , 2017, 77, 1144-1150.	1.2	29
1616	Therapy assessment in prostate cancer using choline and PSMA PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 78-83.	3.3	31
1617	Exercise medicine for advanced prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 247-257.	0.5	52
1618	Circulating Tumor Cells as Cancer Biomarkers in the Clinic. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 1-41.	0.8	20
1619	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	13.9	1,315
1620	Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1345-1357.	2.0	22
1621	Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature. <i>Current Medical Research and Opinion</i> , 2017, 33, 1995-2008.	0.9	20

#	ARTICLE	IF	CITATIONS
1623	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. <i>Biomedical Chromatography</i> , 2017, 31, e3986.	0.8	20
1624	Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2017, 76, 36-44.	1.3	64
1625	Androgen Receptor in Health and Disease. , 2017, , 21-73.		2
1626	Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. <i>Cancer Cell</i> , 2017, 31, 532-548.e7.	7.7	85
1627	Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3- c]pyridine derivatives as potent and selective CYP17 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017, 132, 157-172.	2.6	8
1628	Association of Tissue Abiraterone Levels and <i>SLCO</i> Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4592-4601.	3.2	31
1629	Clinical significance of 11-oxygenated androgens. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 252-259.	1.2	60
1630	Androgen Signaling in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a030452.	2.9	278
1631	Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications. <i>Translational Oncology</i> , 2017, 10, 357-366.	1.7	31
1632	Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. <i>JAMA Oncology</i> , 2017, 3, e170231.	3.4	9
1633	ELF5-Mediated AR Activation Regulates Prostate Cancer Progression. <i>Scientific Reports</i> , 2017, 7, 42759.	1.6	11
1634	Management of metastatic castration-resistant prostate cancer: A focus on radium-223. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 43-51.	2.0	28
1635	Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017, 72, 10-13.	0.9	32
1636	Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 610-617.e3.	0.9	25
1637	Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. <i>Cancer Letters</i> , 2017, 397, 133-143.	3.2	33
1638	Targeting NF-kappa B Signaling by Artesunate Restores Sensitivity of Castrate-Resistant Prostate Cancer Cells to Antiandrogens. <i>Neoplasia</i> , 2017, 19, 333-345.	2.3	62
1639	Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 418-424.	0.8	24
1640	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 115-125.	1.2	41

#	ARTICLE	IF	CITATIONS
1641	Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. <i>European Journal of Cancer</i> , 2017, 72, 54-61.	1.3	54
1642	Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge. <i>BJU International</i> , 2017, 119, 3-4.	1.3	2
1643	The efficacy and safety of docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration: JMTO Pca 10-01 phase II trial. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 247-251.	0.6	12
1644	Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. <i>Prostate</i> , 2017, 77, 479-488.	1.2	39
1645	Clusterin as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 201-213.	1.5	102
1646	Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts. <i>Clinical Cancer Research</i> , 2017, 23, 2301-2312.	3.2	20
1647	The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside. <i>International Urology and Nephrology</i> , 2017, 49, 369-380.	0.6	22
1648	Predictive value of epithelial-mesenchymal transition (EMT) signature and PARP1 in prostate cancer radioresistance. <i>Prostate</i> , 2017, 77, 1583-1591.	1.2	36
1649	Abiraterone in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1694-1698.	13.9	36
1650	Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?. <i>Urologic Clinics of North America</i> , 2017, 44, 611-621.	0.8	46
1651	Cabazitaxel-conjugated nanoparticles for docetaxel-resistant and bone metastatic prostate cancer. <i>Cancer Letters</i> , 2017, 410, 169-179.	3.2	38
1652	Prostate Cancer: An Update on Molecular Pathology with Clinical Implications. <i>European Urology Supplements</i> , 2017, 16, 253-271.	0.1	2
1653	Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis. <i>Medical Oncology</i> , 2017, 34, 190.	1.2	13
1655	Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A preclinical study. <i>Prostate</i> , 2017, 77, 1550-1562.	1.2	25
1656	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. <i>Cancer Cell</i> , 2017, 32, 474-489.e6.	7.7	483
1657	Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1532-1542.	5.1	65
1658	BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1391-1397.	1.9	26
1659	Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2017, 77, 1565-1576.	4.9	30

#	ARTICLE	IF	CITATIONS
1660	AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. <i>European Urology</i> , 2017, 72, 828-834.	0.9	86
1661	Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , 2017, 14, 451-461.	0.7	59
1662	Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis. <i>Medical Oncology</i> , 2017, 34, 166.	1.2	4
1663	Castration-naïve metastatic prostate cancer: reshaping old paradigms. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 879-881.	1.1	3
1664	Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel. <i>Anti-Cancer Drugs</i> , 2017, 28, 1047-1052.	0.7	6
1665	LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. <i>Cancer Research</i> , 2017, 77, 5479-5490.	0.4	71
1666	A Novel Use of Olaparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Pharmacotherapy</i> , 2017, 37, 1406-1414.	1.2	21
1667	Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition. <i>Clinical Cancer Research</i> , 2017, 23, 6923-6933.	3.2	30
1668	Circulating steroid hormone variations throughout different stages of prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, R403-R420.	1.6	34
1669	Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017, 77, 1478-1488.	1.2	7
1670	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 76S-76S.	2.8	163
1672	Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. <i>Annals of Oncology</i> , 2017, 28, 2464-2471.	0.6	28
1673	Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 665-669.	0.8	0
1674	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 742-749.	0.9	21
1675	Inhibition of Androgen Receptor Function and Level in Castration-Resistant Prostate Cancer Cells by 2-[(isoxazol-4-ylmethyl)thio]-1-(4-phenylpiperazin-1-yl)ethanone. <i>Endocrinology</i> , 2017, 158, 3152-3161.	1.4	15
1676	The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility. <i>Current Urology Reports</i> , 2017, 18, 65.	1.0	5
1677	Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. <i>Cancer Science</i> , 2017, 108, 1452-1457.	1.7	37
1680	Evidence-based clinical practice guideline for prostate cancer (summary: Japanese Urological) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i>	0.5	111

#	ARTICLE	IF	CITATIONS
1681	Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies. <i>Cancer Treatment Reviews</i> , 2017, 59, 123-131.	3.4	49
1682	Prognostic nutritional index predicts initial response to treatment and prognosis in metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017, 77, 1233-1241.	1.2	33
1683	Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence. <i>Pharmacoeconomics</i> , 2017, 35, 1223-1236.	1.7	42
1684	The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer. <i>Prostate</i> , 2017, 77, 1303-1311.	1.2	19
1685	The biology of prostate cancer metastases. <i>Current Opinion in Urology</i> , 2017, 27, 542-546.	0.9	8
1686	Effect of food on abiraterone pharmacokinetics: a review. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 183-193.	0.5	8
1687	Targeting AR Variant Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. <i>Molecular Cancer Research</i> , 2017, 15, 1469-1480.	1.5	21
1688	Allosteric alterations in the androgen receptor and activity in prostate cancer. <i>Endocrine-Related Cancer</i> , 2017, 24, R335-R348.	1.6	10
1689	Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 559-565.	0.9	10
1690	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2017, 77, 5564-5575.	0.4	105
1691	Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity. <i>Pharmacology</i> , 2017, 100, 261-268.	0.9	14
1692	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 84, 88-101.	1.3	128
1693	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. <i>Urology</i> , 2017, 109, 6-18.	0.5	15
1694	Advancing Treatment Approach to the Older Patient with Cancer Through Clinical Trials Participation. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 719-728.	0.6	7
1695	Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2017, 28, 104-109.	0.7	24
1697	Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Current Urology</i> , 2017, 10, 169-173.	0.4	12
1698	Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer. <i>Scientific Reports</i> , 2017, 7, 16159.	1.6	53
1699	Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. <i>Nature Communications</i> , 2017, 8, 1816.	5.8	412

#	ARTICLE	IF	CITATIONS
1700	Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 15541.	1.6	11
1701	The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 227-233.	2.0	15
1702	Castration-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, 647-655.	0.8	2
1703	Second-line therapy in patients with metastatic castration-resistant prostate cancer with progression after or under docetaxel: A systematic review of nine randomized controlled trials. <i>Seminars in Oncology</i> , 2017, 44, 358-371.	0.8	13
1704	Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate. <i>Annals of Oncology</i> , 2017, 28, 668.	0.6	2
1705	The Diagnosis and Treatment of Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2532.	3.8	959
1706	Dose considerations for anti-cancer drugs in metastatic prostate cancer. <i>Prostate</i> , 2017, 77, 1199-1204.	1.2	5
1707	Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 479-486.	1.1	6
1708	Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. <i>Cancer Cell</i> , 2017, 32, 6-8.	7.7	12
1709	ABCB1 Mediates Cabazitaxel's Docetaxel Cross-Resistance in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2257-2266.	1.9	49
1710	Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate. <i>Anti-Cancer Drugs</i> , 2017, 28, 110-115.	0.7	6
1711	Inhibition of Androgen Receptor Nuclear Localization and Castration-Resistant Prostate Tumor Growth by Pyrroloimidazole-based Small Molecules. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2120-2129.	1.9	19
1713	Relevance of DNA damage repair in the management of prostate cancer. <i>Current Problems in Cancer</i> , 2017, 41, 287-301.	1.0	16
1714	Estradiol for the mitigation of adverse effects of androgen deprivation therapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R297-R313.	1.6	13
1715	New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer. <i>Targeted Oncology</i> , 2017, 12, 37-45.	1.7	10
1716	Prostate cancer: Developing novel approaches to castration-sensitive disease. <i>Cancer</i> , 2017, 123, 29-42.	2.0	8
1717	Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone. <i>Prostate</i> , 2017, 77, 114-120.	1.2	9
1718	Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer. <i>IEEE Transactions on Biomedical Engineering</i> , 2017, 64, 512-518.	2.5	23

#	ARTICLE	IF	CITATIONS
1719	Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 35-44.	1.9	100
1720	Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. <i>Oncogene</i> , 2017, 36, 1440-1450.	2.6	6
1721	The molecular underpinnings of prostate cancer: impacts on management and pathology practice. <i>Journal of Pathology</i> , 2017, 241, 173-182.	2.1	36
1722	Radium-223 Use in Clinical Practice and Variables Associated With Completion of Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e289-e298.	0.9	40
1723	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , 2017, 28, 90-95.	0.6	24
1725	Androgen synthesis in prostate cancer: do all roads lead to Rome?. <i>Nature Reviews Urology</i> , 2017, 14, 49-58.	1.9	34
1726	Comparing Sequencing of Abiraterone and Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer: A Retrospective Study. <i>Prostate</i> , 2017, 77, 33-40.	1.2	60
1727	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. <i>European Urology</i> , 2017, 71, 151-154.	0.9	306
1728	Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 166, 16-27.	1.2	35
1729	Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 726-734.	3.2	95
1730	Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e315-e323.	0.9	5
1731	Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 165, 342-355.	1.2	22
1732	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. <i>JAMA Oncology</i> , 2017, 3, 68.	3.4	33
1733	Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 191-202.	1.7	8
1734	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 630-642.	0.9	1,215
1735	Abiraterone for castration-resistant prostate cancer: adherence, survival and hospitalization. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 380-384.	1.0	7
1736	Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment. <i>International Journal of Cancer</i> , 2017, 140, 358-369.	2.3	21
1737	Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2017, 20, 67-71.	2.0	8

#	ARTICLE	IF	CITATIONS
1738	Prostate-Specific Antigen Flare Phenomenon Induced by Abiraterone Acetate in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 320-325.	0.9	28
1739	Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7â€“Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. <i>Eur Urol</i> 2017;71:4â€“6. <i>European Urology</i> , 2017, 71, 6-7.	0.9	5
1740	Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 32.e9-32.e16.	0.8	9
1741	Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins. <i>Future Oncology</i> , 2017, 13, 369-379.	1.1	9
1742	A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 935-945.	3.2	30
1743	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. <i>Clinical Cancer Research</i> , 2017, 23, 1967-1973.	3.2	46
1744	Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance. <i>Molecular Cancer Research</i> , 2017, 15, 59-68.	1.5	57
1745	Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?. <i>World Journal of Urology</i> , 2017, 35, 479-480.	1.2	0
1746	Germline genetic variation in <i>JAK2</i> as a prognostic marker in castration-resistant prostate cancer. <i>BJU International</i> , 2017, 119, 489-495.	1.3	8
1747	Branched Chain RNA <i>In Situ</i> Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 363-369.	3.2	23
1748	Tumor clone dynamics in lethal prostate cancer. <i>European Urology</i> , 2017, 71, 142-143.	0.9	2
1749	Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 269-283.	12.5	36
1750	The role of GATA2 in lethal prostate cancer aggressiveness. <i>Nature Reviews Urology</i> , 2017, 14, 38-48.	1.9	71
1752	Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. <i>Cancer Treatment Reviews</i> , 2017, 55, 211-217.	3.4	20
1753	Abiraterone acetate withdrawal syndrome: Speculations on the underlying mechanisms. <i>Oncology Letters</i> , 2018, 15, 2669-2672.	0.8	2
1755	Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer â€“ The urologists' perspective. <i>Urological Science</i> , 2017, 28, 190-196.	0.2	5
1756	Efficacy of androgen deprivation therapy and the role of oxidative stress. <i>Annals of Oncology</i> , 2017, 28, 451-453.	0.6	4
1757	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017, 7, 17978.	1.6	38

#	ARTICLE	IF	CITATIONS
1758	Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer. <i>Journal of Rural Medicine: JRM</i> , 2017, 12, 112-119.	0.2	6
1759	Oxibendazole inhibits prostate cancer cell growth. <i>Oncology Letters</i> , 2018, 15, 2218-2226.	0.8	9
1761	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 0, , .	1.5	3
1763	First Line Androgen Deprivation Therapy Duration Is Associated with the Efficacy of Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer after Docetaxel. <i>Frontiers in Pharmacology</i> , 2017, 8, 55.	1.6	7
1764	Prostate Cancer Stem Cells and Nanotechnology: A Focus on Wnt Signaling. <i>Frontiers in Pharmacology</i> , 2017, 8, 153.	1.6	23
1765	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. <i>Cancers</i> , 2017, 9, 13.	1.7	40
1767	Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study. <i>Cancer Management and Research</i> , 2017, Volume 9, 789-800.	0.9	16
1768	Natriuretic Peptides: The Case of Prostate Cancer. <i>Molecules</i> , 2017, 22, 1680.	1.7	9
1769	Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. <i>Cancers</i> , 2017, 9, 67.	1.7	83
1770	Androgen receptor splice variants and prostate cancer: From bench to bedside. <i>Oncotarget</i> , 2017, 8, 18550-18576.	0.8	100
1771	AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. <i>Cancers</i> , 2017, 9, 7.	1.7	49
1772	Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2017, 9, 22.	1.7	36
1773	AR Signaling and the PI3K Pathway in Prostate Cancer. <i>Cancers</i> , 2017, 9, 34.	1.7	118
1774	Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression. <i>Cancers</i> , 2017, 9, 102.	1.7	31
1775	MYC Deregulation in Primary Human Cancers. <i>Genes</i> , 2017, 8, 151.	1.0	281
1776	Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 473.	1.8	77
1777	Targeting Apoptotic Activity Against Prostate Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1648.	1.8	17
1778	Efficacy of Abiraterone and Enzalutamide in Pre- and Postdocetaxel Castration-Resistant Prostate Cancer: A Trial-Level Meta-Analysis. <i>Prostate Cancer</i> , 2017, 2017, 1-8.	0.4	15

#	ARTICLE	IF	CITATIONS
1779	Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. <i>ELife</i> , 2017, 6, .	2.8	154
1780	Neutrophil-to-Lymphocyte Ratio Predicts Prognosis in Castration-Resistant Prostate Cancer Patients Who Received Cabazitaxel Chemotherapy. <i>BioMed Research International</i> , 2017, 2017, 1-5.	0.9	27
1781	Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. <i>Cancer Management and Research</i> , 2017, Volume 9, 299-306.	0.9	3
1782	A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion. <i>Canadian Urological Association Journal</i> , 2017, 11, 350-5.	0.3	16
1783	A prognostic model for stratifying clinical outcomes in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <i>Canadian Urological Association Journal</i> , 2017, 12, E47-52.	0.3	13
1784	Serum Pre-Albumin Predicts the Clinical Outcome in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone. <i>Journal of Cancer</i> , 2017, 8, 3448-3455.	1.2	17
1785	LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression. <i>Oncotarget</i> , 2017, 8, 94358-94370.	0.8	78
1786	Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials. <i>PLoS ONE</i> , 2017, 12, e0183639.	1.1	2
1787	Mapping the STK4/Hippo signaling network in prostate cancer cell. <i>PLoS ONE</i> , 2017, 12, e0184590.	1.1	22
1788	An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. <i>PLoS ONE</i> , 2017, 12, e0177861.	1.1	12
1789	Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 457.	0.7	11
1790	The biological and clinical advances of androgen receptor function in age-related diseases and cancer [Review]. <i>Endocrine Journal</i> , 2017, 64, 933-946.	0.7	13
1791	Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians. <i>Canadian Urological Association Journal</i> , 2017, 11, 204.	0.3	7
1792	Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles. <i>Oncotarget</i> , 2017, 8, 3724-3745.	0.8	95
1793	Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 225-235.	0.5	13
1794	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017, 8, 2663-2668.	1.2	5
1795	Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, S34-S48.	0.5	15
1796	Degarelix treatment is compatible with diabetes and antithrombotic therapy in patients with prostate cancer. <i>Research and Reports in Urology</i> , 2017, Volume 9, 225-232.	0.6	1

#	ARTICLE	IF	CITATIONS
1797	Treatment Patterns and Trends in Patients Dying of Prostate Cancer in Quebec: A Population-Based Study. <i>Current Oncology</i> , 2017, 24, 240-248.	0.9	6
1798	Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. <i>Journal of Cancer</i> , 2017, 8, 507-512.	1.2	2
1799	Recent advances in the biology and therapy of medullary thyroid carcinoma. <i>F1000Research</i> , 2017, 6, 2184.	0.8	18
1800	Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. <i>Journal of Oncology Practice</i> , 2017, 13, e694-e702.	2.5	6
1801	Decipher Postprostatectomy: Is It Ready for Clinical Use?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1976-1977.	0.8	5
1802	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	0.8	251
1803	Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. <i>Journal of Clinical Oncology</i> , 2017, 35, 2149-2156.	0.8	371
1804	Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-11.	1.5	13
1805	Reversion of epithelial-mesenchymal transition by a novel agent DZ-50 via IGF binding protein-3 in prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 78507-78519.	0.8	21
1806	Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 59690-59697.	0.8	20
1807	Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. <i>Oncotarget</i> , 2017, 8, 84572-84578.	0.8	66
1808	Cellular plasticity and the neuroendocrine phenotype in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 271-286.	1.9	273
1810	Neuroendocrine Prostate Cancer. <i>Molecular Pathology Library</i> , 2018, , 323-341.	0.1	0
1811	Molecular Targeted Therapies of Prostate Cancer. <i>Molecular Pathology Library</i> , 2018, , 523-546.	0.1	1
1812	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e13-240.e20.	0.8	7
1813	Endocrinology of prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 1-2.	1.6	1
1814	TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways. <i>Cell Death and Disease</i> , 2018, 9, 155.	2.7	41
1815	AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 576-582.	1.2	46

#	ARTICLE	IF	CITATIONS
1816	Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases. <i>Medical Oncology</i> , 2018, 35, 46.	1.2	3
1817	Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 694.	3.4	46
1818	Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. <i>Annals of Oncology</i> , 2018, 29, 1235-1248.	0.6	196
1819	Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. <i>Current Medical Research and Opinion</i> , 2018, 34, 903-910.	0.9	18
1820	Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 507-509.	0.9	2
1821	Abiraterone acetate in the treatment of prostate cancer. <i>Biomedicine and Pharmacotherapy</i> , 2018, 101, 211-218.	2.5	51
1822	Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. <i>Clinical Cancer Research</i> , 2018, 24, 4319-4331.	3.2	36
1823	Pitfalls in bone density monitoring in prostate cancer during anti-resorptive treatment. <i>Osteoporosis International</i> , 2018, 29, 1665-1670.	1.3	1
1824	Medical Therapy for Cushing's Syndrome in the Twenty-first Century. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 427-440.	1.2	21
1825	Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells. <i>Molecular Carcinogenesis</i> , 2018, 57, 1055-1066.	1.3	13
1826	Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 3317-3324.	3.2	41
1827	Current and potential targets for drug design in the androgen receptor pathway for prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 489-496.	2.5	5
1828	Earlier use of androgen receptor-axis-targeted drugs may improve overall survival in patients with non-metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 766-772.	1.2	9
1829	Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 33-37.	0.3	0
1830	Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 1470-1486.	2.5	26
1831	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
1832	The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2018, 200, 344-352.	0.2	47
1834	Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer. <i>Cancer Science</i> , 2018, 109, 1230-1238.	1.7	38

#	ARTICLE	IF	CITATIONS
1835	Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 165-175.e2.	0.9	41
1836	Clinical and molecular features of treatment-related neuroendocrine prostate cancer. <i>International Journal of Urology</i> , 2018, 25, 345-351.	0.5	110
1837	Endocrine therapy for cancer. <i>Surgery</i> , 2018, 36, 128-133.	0.1	1
1838	Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 361-369.	1.5	5
1839	Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 262-267.	1.3	14
1840	A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1064-1067.	1.1	7
1841	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. <i>Endocrinology</i> , 2018, , 765-785.	0.1	0
1842	Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis. <i>Medical Oncology</i> , 2018, 35, 29.	1.2	7
1843	Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden. <i>Scandinavian Journal of Urology</i> , 2018, 52, 143-150.	0.6	11
1844	The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform. <i>Scientific Reports</i> , 2018, 8, 253.	1.6	71
1845	Concentration range of serum sex steroids in normal postmenopausal women and those with diagnosis of vulvovaginal atrophy. <i>Menopause</i> , 2018, 25, 293-300.	0.8	6
1846	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 645-657.	13.9	386
1847	An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer. <i>Clinical Therapeutics</i> , 2018, 40, 536-549.e3.	1.1	10
1848	When and how to use carboplatin in metastatic castration-resistant prostate cancer?. <i>European Journal of Cancer</i> , 2018, 92, 96-99.	1.3	2
1849	Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion. <i>Scientific Reports</i> , 2018, 8, 2090.	1.6	31
1850	Circulating tumor cells and survival in abiraterone and enzalutamide-treated patients with castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 435-445.	1.2	21
1851	Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. <i>Future Oncology</i> , 2018, 14, 431-442.	1.1	14
1852	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 425-438.	1.3	17

#	ARTICLE	IF	CITATIONS
1853	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 2065-2080.	0.4	60
1854	Current treatment strategies for advanced prostate cancer. <i>International Journal of Urology</i> , 2018, 25, 220-231.	0.5	164
1855	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 306-318.	2.0	21
1856	Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. <i>International Journal of Cancer</i> , 2018, 142, 2163-2174.	2.3	39
1857	Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 184-190.e2.	0.9	13
1858	Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e277-e287.	0.9	4
1859	Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 252-259.	2.0	71
1860	Systemic immune-inflammatory index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. <i>Prostate</i> , 2018, 78, 250-256.	1.2	43
1861	Prognostic and Therapeutic Implications of Circulating Androgen Receptor Gene Copy Number in Prostate Cancer Patients Using Droplet Digital Polymerase Chain Reaction. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 197-205.e5.	0.9	7
1862	Radium-223 international early access program: results from the Spanish subset. <i>Future Oncology</i> , 2018, 14, 41-50.	1.1	3
1863	Functional characterization of the G162R and D216H genetic variants of human CYP17A1. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 178, 159-166.	1.2	1
1864	Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 496-508.	3.3	152
1865	Toxicity profile characteristics of novel androgen-deprivation therapy agents in patients with prostate cancer: a meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 193-198.	1.1	24
1866	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	0.9	105
1867	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 155-163.	1.5	51
1868	Sex steroids in the tumor microenvironment and prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2018, 25, R179-R196.	1.6	24
1870	Abiraterone acetate: a potential source of interference in testosterone assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e138-e140.	1.4	5
1871	Ru(^{II}) polypyridyl complexes as photocages for bioactive compounds containing nitriles and aromatic heterocycles. <i>Chemical Communications</i> , 2018, 54, 1280-1290.	2.2	68

#	ARTICLE	IF	CITATIONS
1872	Neuroendocrine tumors of the prostate. <i>Modern Pathology</i> , 2018, 31, 122-132.	2.9	78
1873	Current approaches to incorporation of radium-223 in clinical practice. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 37-47.	2.0	55
1874	Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis. <i>BMC Cancer</i> , 2018, 18, 468.	1.1	12
1875	The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. <i>Cancer Treatment Reviews</i> , 2018, 68, 25-37.	3.4	37
1876	Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. , 2018, 6, 21.		33
1878	Bone Metastases in Prostate Cancer. , 2018, , 323-343.		0
1879	Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. , 2018, 189, 89-103.		101
1880	Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2018, 23, 791-797.	1.9	13
1881	PARP inhibitors for homologous recombination-deficient prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 123-133.	1.0	24
1882	Abiraterone: moving up in line?. <i>ESMO Open</i> , 2018, 3, e000318.	2.0	0
1883	A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone-and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2018, 23, 656-e64.	1.9	25
1884	LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E4179-E4188.	3.3	160
1885	Osimertinib in EGFR Mutation-Positive Advanced NSCLC. <i>New England Journal of Medicine</i> , 2018, 378, 1261-1263.	13.9	20
1886	Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. <i>Medical Oncology</i> , 2018, 35, 56.	1.2	4
1887	Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC). <i>Clinical Cancer Research</i> , 2018, 24, 3149-3162.	3.2	111
1888	New horizons in the management of castrate-resistant prostate cancer. <i>Journal of Clinical Urology</i> , 2018, 11, 258-265.	0.1	2
1889	Transcriptional Regulation in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030437.	2.9	57
1890	New Opportunities for Targeting the Androgen Receptor in Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030478.	2.9	19

#	ARTICLE	IF	CITATIONS
1891	Influence of prior oral ethinylestradiol use on the efficacy of enzalutamide for the treatment of castration-resistant prostate cancer in men. <i>International Journal of Urology</i> , 2018, 25, 464-470.	0.5	3
1892	Tumor Growth Kinetics Before and After First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 316-320.	0.6	0
1893	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , 2018, 4, 235-244.	1.6	14
1894	Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2018, 121, 203-208.	1.3	11
1895	Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2018, 4, 529-539.	1.6	30
1896	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials. <i>European Urology Focus</i> , 2018, 4, 547-553.	1.6	30
1897	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018, 4, 874-879.	1.6	30
1898	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	0.9	488
1899	Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 72-77.e1.	0.9	24
1900	Antitumor Activity and Safety of Enzalutamide After Abiraterone Acetate: Seeking the Optimal Treatment Sequence for Castration-resistant Prostate Cancer Patients. <i>European Urology</i> , 2018, 74, 46-47.	0.9	6
1901	Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e151-e159.	0.9	4
1902	Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naïve Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 142-148.	0.9	29
1903	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e233-e242.	0.9	8
1904	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 73, 834-844.	0.9	86
1905	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 168-182.	12.5	7
1906	The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e223-e231.	0.9	27
1907	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R1-R9.	1.6	13
1908	Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. <i>European Urology</i> , 2018, 74, 37-45.	0.9	86

#	ARTICLE	IF	CITATIONS
1909	Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease. <i>Investigative Radiology</i> , 2018, 53, 96-102.	3.5	36
1910	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 56-63.	1.6	12
1911	The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 734-740.	0.2	16
1912	Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030635.	2.9	128
1913	Transition from androgenic to neurosteroidal action of 5 α -androstane-3 β , 17 β -diol through the type A β -aminobutyric acid receptor in prostate cancer progression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 178, 89-98.	1.2	12
1914	Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach. <i>Value in Health</i> , 2018, 21, 416-422.	0.1	12
1915	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. <i>Endocrine-Related Cancer</i> , 2018, 25, R83-R113.	1.6	21
1916	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. <i>Cancer Biology and Therapy</i> , 2018, 19, 97-100.	1.5	1
1917	HSD3B1 status as a biomarker of androgen deprivation resistance and implications for prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 191-196.	1.9	34
1918	Platinum sensitivity in metastatic prostate cancer: does histology matter?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 92-99.	2.0	17
1919	Promising immunotherapy for prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 109-120.	1.4	5
1920	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018, 23, 193-202.	1.9	60
1921	Population-based Analysis of Treatment Toxicity Among Men With Castration-resistant Prostate Cancer: A Phase IV Study. <i>Urology</i> , 2018, 113, 138-145.	0.5	6
1922	Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 161.e19-161.e30.	0.8	26
1923	Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Urology. <i>BJU International</i> , 2018, 121, 703-715.	1.3	8
1924	Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 348-354.	3.3	22
1925	Randomized phase 2 therapeutic equivalence study of abiraterone acetate fine particle formulation vs. originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer: The STAAR study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 81.e9-81.e16.	0.8	15
1926	The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 927-938.	3.2	128

#	ARTICLE	IF	CITATIONS
1927	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 57-68.	1.2	17
1928	Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 217.	3.4	93
1929	Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223. <i>Clinical and Translational Oncology</i> , 2018, 20, 679-686.	1.2	5
1930	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. <i>International Urology and Nephrology</i> , 2018, 50, 71-78.	0.6	37
1931	Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. <i>European Urology</i> , 2018, 73, 845-846.	0.9	4
1932	Abiraterone-Associated Fulminant Liver Failure. <i>American Journal of Therapeutics</i> , 2018, 25, e505-e506.	0.5	6
1933	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-382.	0.8	75
1934	Low-Fat Abiraterone Food Effect Is of Great Consequence. <i>Journal of Clinical Oncology</i> , 2018, 36, 3058-3059.	0.8	6
1935	Recent trends in the management of advanced prostate cancer. <i>F1000Research</i> , 2018, 7, 1513.	0.8	69
1936	Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 2639-2646.	0.8	131
1937	Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 129, 192-208.	3.9	266
1938	Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 363-371.	1.8	27
1939	Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?. <i>Journal of Clinical Oncology</i> , 2018, 36, 525-527.	0.8	1
1940	Targeting DNA Repair in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1017-1019.	0.8	4
1941	Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1521-1539.	0.8	51
1942	Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1389-1395.	0.8	137
1943	Low-Dose Abiraterone With Food: Rebutting an Editorial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3060-3061.	0.8	7
1944	Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. <i>Journal of Clinical Oncology</i> , 2018, 36, 991-999.	0.8	169

#	ARTICLE	IF	CITATIONS
1946	The Winds of Change: Emerging Therapeutics in Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 382-390.	1.8	2
1947	Role of MicroRNAs in Treatment Response in Prostate Cancer. Current Cancer Drug Targets, 2018, 18, 929-944.	0.8	20
1948	Abiraterone survival benefit is independent of pain, prostate-specific antigen and Gleason sum in men with chemo-naïve metastatic castration-resistant prostate cancer (analysis of COU-AA-302). AME Medical Journal, 0, 3, 54-54.	0.4	0
1949	Expression of Androgen Receptor Variant 7 (AR-V7) in Circulated Tumor Cells and Correlation with Drug Resistance of Prostate Cancer Cells. Medical Science Monitor, 2018, 24, 7051-7056.	0.5	8
1950	The Biological Role of Androgen Receptor in Prostate Cancer Progression. , 2018, , .		1
1952	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine, 2018, 10, 85.	3.6	94
1953	Lutetium-PSMA therapyâ€”a new therapeutic option in metastatic castration-resistant prostate cancer?. Memo - Magazine of European Medical Oncology, 2018, 11, 301-304.	0.3	2
1954	Emerging cell cycle inhibitors for treating metastatic castration-resistant prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 271-282.	1.0	15
1955	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. OncoTargets and Therapy, 2018, Volume 11, 7353-7368.	1.0	58
1956	Getting to know each other: Integrating radiation and medical oncology training in urology (and) Tj ETQq1 1 0.784314 rgBT (Overlock 1 0,3 3		
1958	Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Therapeutic Advances in Urology, 2018, 10, 445-454.	0.9	10
1959	Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Canadian Urological Association Journal, 2018, 12, 328-336.	0.3	6
1960	Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations. Therapeutics and Clinical Risk Management, 2018, Volume 14, 2341-2347.	0.9	11
1961	Single-Cell Analysis Identifies LY6D as a Marker Linking Castration-Resistant Prostate Luminal Cells to Prostate Progenitors and Cancer. Cell Reports, 2018, 25, 3504-3518.e6.	2.9	70
1962	Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer. BMC Cancer, 2018, 18, 1257.	1.1	12
1963	Radium-223 for the treatment of metastatic castration-resistant prostate cancer: A window of opportunity. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2018, 42, 616-624.	0.2	0
1964	Human cytochrome P450 enzymes 5â€”51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition â€” toxic effects and benefits. Drug Metabolism Reviews, 2018, 50, 256-342.	1.5	36
1965	Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors. BMC Urology, 2018, 18, 110.	0.6	7

#	ARTICLE	IF	CITATIONS
1966	Vitamin D in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 244.	0.8	59
1967	Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review. <i>PLoS ONE</i> , 2018, 13, e0208063.	1.1	24
1968	Role of the Unconventional Prefoldin Proteins URI and UXT in Transcription Regulation. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1106, 85-94.	0.8	5
1969	Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. <i>Targeted Oncology</i> , 2018, 13, 679-689.	1.7	15
1970	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	1.3	20
1971	ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. <i>Molecular Cell</i> , 2018, 72, 341-354.e6.	4.5	64
1972	Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan. <i>American Journal of Men's Health</i> , 2018, 12, 1094-1101.	0.7	12
1973	Combining anticancer drugs with osteoprotective agents in prostate cancer—A contemporary update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 488-497.	0.8	0
1974	Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 71.	1.8	9
1975	PSA response following the "steroid switch"™ in patients with castration-resistant prostate cancer treated with abiraterone: A case report. <i>Oncology Letters</i> , 2018, 16, 5383-5388.	0.8	0
1976	Evaluating the Benefits of New Drugs in Health Technology Assessment Using Multiple Criteria Decision Analysis: A Case Study on Metastatic Prostate Cancer With the Dental and Pharmaceuticals Benefits Agency (TLV) in Sweden. <i>MDM Policy and Practice</i> , 2018, 3, 238146831879621.	0.5	5
1977	Serum DHEA-S Is a Predictive Parameter of Abiraterone Acetate in Patients with Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2018, 38, 5929-5935.	0.5	4
1978	Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. <i>Investigational New Drugs</i> , 2018, 36, 1110-1115.	1.2	9
1979	Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). <i>British Journal of Cancer</i> , 2018, 119, 1041-1043.	2.9	4
1980	Design of Peptoid-peptide Macrocycles to Inhibit the β -catenin TCF Interaction in Prostate Cancer. <i>Nature Communications</i> , 2018, 9, 4396.	5.8	66
1981	Advancing therapies in metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1797-1804.	0.9	23
1982	Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 659-664.	1.0	7
1983	Androgen Deprivation Therapy for Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 1-30.	0.8	13

#	ARTICLE	IF	CITATIONS
1984	Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 117-133.	0.8	58
1986	Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 1012-1021.	0.6	23
1987	Current therapeutic options in metastatic castration-resistant prostate cancer. <i>Seminars in Oncology</i> , 2018, 45, 303-315.	0.8	63
1988	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 15442.	1.6	21
1989	Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4043-4088.	1.8	667
1990	Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. <i>Cancer Treatment and Research Communications</i> , 2018, 17, 37-42.	0.7	6
1991	ADT with antiandrogens in prostate cancer induces adverse effect of increasing resistance, neuroendocrine differentiation and tumor metastasis. <i>Cancer Letters</i> , 2018, 439, 47-55.	3.2	35
1992	Outcome of Patients with Metastatic Castration-resistant Prostate Cancer After PSA Progression with Abiraterone Acetate. <i>Anticancer Research</i> , 2018, 38, 5429-5436.	0.5	3
1993	Genome-Based Classification and Therapy of Prostate Cancer. <i>Diagnostics</i> , 2018, 8, 62.	1.3	16
1994	Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer. <i>Cancer Letters</i> , 2018, 438, 86-96.	3.2	1
1995	Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 429-436.	0.9	8
1996	Long-term Survival and Excellent Response to Repeated ¹⁷⁷ Lu-PSMA Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, 755-756.	0.7	5
1997	Genetics and biology of prostate cancer. <i>Genes and Development</i> , 2018, 32, 1105-1140.	2.7	434
1998	Preferences for Toxicity Monitoring of Patients on Abiraterone Acetate Plus Prednisone. <i>Clinical Oncology</i> , 2018, 30, 674-675.	0.6	0
1999	Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2341-2352.	1.9	32
2000	Attempt to predict early recurrence of prostate cancer following prostatectomy through machine learning. <i>AME Medical Journal</i> , 2018, 3, 96-96.	0.4	3
2001	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. <i>Nature Genetics</i> , 2018, 50, 814-824.	9.4	196
2002	Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. <i>British Journal of Radiology</i> , 2018, 91, 20180308.	1.0	50

#	ARTICLE	IF	CITATIONS
2003	Adrenal Androgen in Prostate Cancer. , 2018, , 51-58.		0
2004	Generation of Prostate Cancer Patient-Derived Xenografts to Investigate Mechanisms of Novel Treatments and Treatment Resistance. <i>Methods in Molecular Biology</i> , 2018, 1786, 1-27.	0.4	7
2005	Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4946-4960.	2.9	24
2006	Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 807-819.	1.6	16
2007	Genetic Polymorphism Analysis in Predicting Prognosis of Advanced Prostate Cancer. , 2018, , 175-187.		0
2008	Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 553-559.	1.9	18
2009	Metabolic alterations in urine extracellular vesicles are associated to prostate cancer pathogenesis and progression. <i>Journal of Extracellular Vesicles</i> , 2018, 7, 1470442.	5.5	103
2010	Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses. <i>Clinical and Translational Imaging</i> , 2018, 6, 223-237.	1.1	5
2011	Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen. <i>PLoS ONE</i> , 2018, 13, e0195790.	1.1	4
2012	Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. <i>Acta Pharmaceutica Sinica B</i> , 2018, 8, 518-529.	5.7	53
2013	Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 727-734.	2.3	2
2014	Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. <i>Canadian Urological Association Journal</i> , 2018, 12, E365-E372.	0.3	7
2015	Mathematical modeling of intracrine androgen metabolism in prostate cancer: Methodological aspects. <i>Prostate</i> , 2018, 78, 1069-1076.	1.2	2
2016	Rhabdomyolysis With Abiraterone Exposure: A Brief Review of the Food and Drug Administration Adverse Event Reporting System (FAERS). <i>Annals of Pharmacotherapy</i> , 2018, 52, 1160-1161.	0.9	3
2017	Local Therapy in Combination with Androgen Deprivation Therapy for Metastatic Prostate Cancer. , 2018, , 189-199.		0
2019	Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker. <i>Future Oncology</i> , 2018, 14, 2543-2556.	1.1	48
2020	11-Oxygenated androgen precursors are the preferred substrates for aldo-keto reductase 1C3 (AKR1C3): Implications for castration resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2018, 183, 192-201.	1.2	51
2021	Prostate Disease Overview. , 2018, , 334-340.		0

#	ARTICLE	IF	CITATIONS
2022	Landmarks in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 627-642.	1.9	78
2023	Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. <i>Communications Biology</i> , 2018, 1, 100.	2.0	249
2024	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 572-580.	0.8	187
2025	The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer. <i>Cancer Medicine</i> , 2018, 7, 4379-4386.	1.3	29
2026	A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer. <i>Molecular Carcinogenesis</i> , 2018, 57, 1332-1341.	1.3	22
2027	Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2018. <i>Journal of Urology</i> , 2018, 200, 1264-1272.	0.2	91
2028	Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer. <i>Oncology Letters</i> , 2018, 15, 6806-6814.	0.8	1
2029	Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials. <i>Journal of Cancer</i> , 2018, 9, 690-701.	1.2	5
2030	Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2079-2090.	1.9	19
2031	Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network. <i>Frontiers in Oncology</i> , 2018, 8, 93.	1.3	16
2032	Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?. <i>Frontiers in Oncology</i> , 2018, 8, 246.	1.3	18
2033	A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer. <i>PLoS ONE</i> , 2018, 13, e0198389.	1.1	86
2035	Precision medicine applications in prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	12
2036	Molecular underpinnings of enzalutamide resistance. <i>Endocrine-Related Cancer</i> , 2018, 25, R545-R557.	1.6	28
2037	Radio-223 en el tratamiento del c�ncer de pr�stata resistente a la castraci�n metast�sico: una ventana de oportunidad. <i>Actas Urol�gicas Espa�olas</i> , 2018, 42, 616-624.	0.3	0
2038	PARP Inhibitor Drugs in the Treatment of Breast, Ovarian, Prostate and Pancreatic Cancers: An Update of Clinical Trials. <i>Current Drug Targets</i> , 2018, 19, 21-37.	1.0	100
2039	Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency. <i>Pharmaceuticals</i> , 2018, 11, 37.	1.7	30
2040	Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5225-5232.	3.2	16

#	ARTICLE	IF	CITATIONS
2041	Abiraterone or Enzalutamide in CRPC After Chemotherapy. , 2018, , 139-143.		0
2042	Radiopharmaceutical Therapy in Metastatic CRPC. , 2018, , 175-179.		0
2043	Treatment in the STAMPEDE era for castrate resistant prostate cancer in the UK: ongoing challenges and underappreciated clinical problems. BMC Cancer, 2018, 18, 667.	1.1	4
2044	Cheminformatics Driven Development of Novel Therapies for Drug Resistant Prostate Cancer. Molecular Informatics, 2018, 37, e1800043.	1.4	8
2045	Novel Approaches of Treatment with Radium-223 Targeted Therapy. , 2018, , 379-391.		0
2046	Temporal and geographic variation in the systemic treatment of advanced prostate cancer. BMC Cancer, 2018, 18, 258.	1.1	22
2048	Eukaryotic Translation Initiation Factor 4 Gamma 1 (eIF4G1) is upregulated during Prostate cancer progression and modulates cell growth and metastasis. Scientific Reports, 2018, 8, 7459.	1.6	31
2049	Personalization of prostate cancer therapy through phosphoproteomics. Nature Reviews Urology, 2018, 15, 483-497.	1.9	25
2050	LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models. Cancer Cell International, 2018, 18, 71.	1.8	19
2051	Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. Annals of Oncology, 2018, 29, 1554-1560.	0.6	65
2052	Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer – recent developments and future directions. Expert Opinion on Investigational Drugs, 2018, 27, 811-822.	1.9	5
2053	Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation. Neoplasia, 2018, 20, 917-929.	2.3	12
2054	Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation. Current Urology Reports, 2018, 19, 79.	1.0	6
2055	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. Cancer Treatment Reviews, 2018, 70, 67-74.	3.4	41
2056	A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. Pharmacological Research, 2018, 136, 56-61.	3.1	11
2057	Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer. Future Oncology, 2018, 14, 2383-2401.	1.1	6
2058	The role of ketoconazole in current prostate cancer care. Nature Reviews Urology, 2018, 15, 643-651.	1.9	48
2059	Apalutamide for the treatment of prostate cancer. Expert Review of Anticancer Therapy, 2018, 18, 823-836.	1.1	29

#	ARTICLE	IF	CITATIONS
2060	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , 2018, 174, 1200-1215.e20.	13.5	96
2061	PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 27698-27707.	0.8	12
2062	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq0 0 0zBT /Overlock 10 Tf		
2063	Alternative splicing in prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 663-675.	12.5	142
2064	High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer. <i>Assay and Drug Development Technologies</i> , 2018, 16, 297-319.	0.6	7
2065	Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2018, 78, 5731-5740.	0.4	40
2066	Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 411-418.	2.0	32
2067	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 419-430.	2.0	3
2068	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 975-986.	5.1	296
2069	Options After Chemotherapy for Patients with Metastatic, Castration-Resistant Prostate Cancer. , 2018, , 121-134.		0
2070	The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis. <i>International Journal of Surgery</i> , 2018, 56, 133-140.	1.1	9
2071	Changes in the Epigenetic Landscape of Prostate Cancer. , 2018, , 59-85.		0
2072	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2018, 78, 1053-1062.	1.2	4
2073	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018, 78, 1035-1041.	1.2	11
2074	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 318-324.	0.9	4
2075	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. <i>European Urology</i> , 2018, 74, 376-386.	0.9	58
2076	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. <i>Clinical Cancer Research</i> , 2019, 25, 928-936.	3.2	232
2077	Bone-Modifying Agents and Anticancer Agents with Bone Effects. , 2019, , 13-25.		1

#	ARTICLE	IF	CITATIONS
2078	Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 249-258.	1.2	4
2079	Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men. <i>Journal of the National Cancer Institute</i> , 2019, 111, 34-41.	3.0	42
2080	Hormone-Responsive Cancers. , 2019, , 717-741.e8.		2
2081	Money back guarantee? A cost-benefit framework of performance-based agreements (PBAs) for the reimbursement of pharmaceuticals. <i>Eurasian Business Review</i> , 2019, 9, 89-101.	2.5	2
2082	Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1293-1300.	0.5	3
2083	Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 351-358.	1.2	18
2084	Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 24-38.	2.0	215
2085	Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression. <i>Prostate</i> , 2019, 79, 54-61.	1.2	20
2086	An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (<scp>CAPRISTANA</scp>). <i>BJU International</i> , 2019, 123, 456-464.	1.3	15
2087	Potential role of rituximab in metastatic castrate-resistant prostate cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1509-1511.	0.5	8
2088	Prostate cancer sheds the $\alpha 3 \beta 1$ integrin in vivo through exosomes. <i>Matrix Biology</i> , 2019, 77, 41-57.	1.5	73
2089	Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 16-23.	2.0	22
2090	Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2019, 123, 300-306.	1.3	17
2091	Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 457-467.	1.2	19
2092	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. <i>Health Information and Libraries Journal</i> , 2019, 36, 318-340.	1.3	3
2093	Androgen Receptor Signaling in Castration-Resistant Prostate Cancer Alters Hyperpolarized Pyruvate to Lactate Conversion and Lactate Levels In Vivo. <i>Molecular Imaging and Biology</i> , 2019, 21, 86-94.	1.3	20
2094	Sequencing strategies in the new treatment landscape of prostate cancer. <i>Future Oncology</i> , 2019, 15, 2967-2982.	1.1	6
2095	Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort. <i>Journal of Clinical Medicine</i> , 2019, 8, 1251.	1.0	12

#	ARTICLE	IF	CITATIONS
2096	Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. <i>Cancer</i> , 2019, 125, 4003-4010.	2.0	15
2097	Recognition and Treatment of Adrenal Insufficiency Secondary to Abiraterone: A Case Report and Literature Review. <i>Oncology</i> , 2019, 97, 301-305.	0.9	7
2098	The small molecule WNT/ β -catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 342.	3.5	46
2099	Rooibos suppresses proliferation of castration-resistant prostate cancer cells via inhibition of Akt signaling. <i>Phytomedicine</i> , 2019, 64, 153068.	2.3	15
2100	Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale. <i>Translational Andrology and Urology</i> , 2019, 8, S341-S345.	0.6	7
2101	Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAACT). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 457-463.e6.	0.9	34
2102	SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression. <i>Cancer Research</i> , 2019, 79, 5204-5217.	0.4	51
2103	A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 759-770.	1.1	4
2104	No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1604-1610.	1.2	1
2105	Bone Target Therapy in Urologic Malignancies. , 2019, , 77-93.		0
2106	The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	47
2107	Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 449-458.	0.7	6
2108	Sex Steroids, Cognate Receptors, and Aging. , 2019, , 265-296.		0
2109	AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1875-1886.	1.9	51
2111	Prostate Cancer: Quo Vadis?. <i>European Urology</i> , 2019, 76, 709-711.	0.9	3
2112	Predictive factors for abiraterone withdrawal syndrome. <i>Actas Urológicas Españolas (English)</i> Tj ETQq1 1 0.784314rgBT /Overlock 10	0.2	0
2113	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2974-2986.	0.8	643
2114	An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression. <i>Prostate</i> , 2019, 79, 1457-1465.	1.2	21

#	ARTICLE	IF	CITATIONS
2115	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e1-813.e9.	0.8	16
2116	Could Circulating Tumor Cells and ARV7 Detection Improve Clinical Decisions in Metastatic Castration-Resistant Prostate Cancer? The Istituto Nazionale dei Tumori (INT) Experience. <i>Cancers</i> , 2019, 11, 980.	1.7	18
2117	Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?. <i>Annals of Oncology</i> , 2019, 30, 1591-1600.	0.6	16
2118	Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. <i>Translational Research</i> , 2019, 212, 89-103.	2.2	47
2119	Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2615-2621.	1.2	26
2120	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2019, 13, 307-314.	0.3	21
2121	Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e893-e896.	0.9	0
2122	Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 14573-14582.	3.3	69
2123	DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. <i>Clinical Cancer Research</i> , 2019, 25, 5608-5622.	3.2	17
2124	Apalutamide for Metastatic, Hormone-Responsive Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 84-86.	13.9	1
2125	Flutamide as an Alternative Anti-androgen Agent and Predictor of the Efficacy of Novel Androgen Receptor-targeted Agents. <i>Anticancer Research</i> , 2019, 39, 3879-3885.	0.5	4
2126	Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience. <i>Anticancer Research</i> , 2019, 39, 3901-3908.	0.5	14
2127	Clonal Evolution and Epithelial Plasticity in the Emergence of AR-Independent Prostate Carcinoma. <i>Trends in Cancer</i> , 2019, 5, 440-455.	3.8	29
2128	Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer. <i>Neoplasia</i> , 2019, 21, 802-809.	2.3	32
2129	Low-dose Docetaxel Enhanced the Anticancer Effect of Tamsulosin by Overcoming Autophagy in Prostate Cancer Cells. <i>Anticancer Research</i> , 2019, 39, 5417-5425.	0.5	13
2130	Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1493-1495.	13.9	4
2131	Androgen Receptor Modulation Optimized for Response to Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 843-851.	0.9	36
2132	Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor- β /matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer. <i>Cancer Letters</i> , 2019, 467, 72-84.	3.2	17

#	ARTICLE	IF	CITATIONS
2133	Plasma Androgen Receptor in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1719.	1.7	13
2134	Design and synthesis of a phenyl C-glycoside derivative of Spliceostatin A and its biological evaluation toward prostate cancer treatment. <i>Tetrahedron Letters</i> , 2019, 60, 151313.	0.7	8
2135	<p>Darolutamide For Castration-Resistant Prostate Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8769-8777.	1.0	24
2136	Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients. <i>European Urology Oncology</i> , 2021, 4, 609-617.	2.6	16
2137	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019, 16, 745-756.	1.9	71
2138	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Oncology</i> , 2021, 4, 618-627.	2.6	6
2139	Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 3518-3527.	0.8	47
2140	Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 2031-2034.	0.5	2
2141	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
2142	TheraP: a randomized phase 2 trial of ¹⁷⁷Luâ€<sc>PSMA</sc>â€617 theranostic treatment vs cabazitaxel in progressive metastatic castrationâ€resistant prostate cancer (Clinical Trial Protocol) Tj ETQq1 1 0.784314 rgBT10		10
2143	Metronomic Oral Cyclophosphamide in 2 Heavilyâ€Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 157-160.	0.9	3
2144	Current management of Cushing's disease. <i>Journal of Internal Medicine</i> , 2019, 286, 526-541.	2.7	32
2145	Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel. <i>Cancers</i> , 2019, 11, 1212.	1.7	21
2146	CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. <i>Cancer Discovery</i> , 2019, 9, 1538-1555.	7.7	88
2147	PARP Inhibition Suppresses GRâ€MYCNâ€CDK5â€RB1â€E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6839-6851.	3.2	50
2148	Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 70.	1.1	10
2149	Quality of Lifeâ€Focused Decision-Making for Prostate Cancer. <i>Current Urology Reports</i> , 2019, 20, 57.	1.0	15
2150	The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <i>Future Oncology</i> , 2019, 15, 1469-1479.	1.1	8

#	ARTICLE	IF	CITATIONS
2151	Role of Androgen Receptor in Prostate Cancer: A Review. <i>World Journal of Men's Health</i> , 2019, 37, 288.	1.7	270
2152	Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. <i>Journal of Medical Economics</i> , 2019, 22, 1202-1209.	1.0	22
2153	Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 858.	1.3	125
2154	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2961-2967.	0.8	13
2155	HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond. <i>Endocrinology</i> , 2019, 160, 2180-2188.	1.4	33
2156	Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4606.	1.8	31
2157	Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor. <i>Assay and Drug Development Technologies</i> , 2019, 17, 364-386.	0.6	4
2158	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.. <i>Cancers</i> , 2019, 11, 1355.	1.7	54
2159	ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 5260-5271.	0.4	19
2160	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2506-2518.	13.9	403
2161	CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions. <i>Cells</i> , 2019, 8, 1115.	1.8	23
2162	Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 801.	1.3	205
2163	Past, Current, and Future of Immunotherapies for Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 884.	1.3	89
2164	Orally Bioavailable Androgen Receptor Degradar, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6764-6780.	3.2	46
2165	The Potential for Chemotherapy-Free Strategies in Advanced Prostate Cancer. <i>Current Urology</i> , 2019, 13, 57-63.	0.4	4
2166	Towards precision oncology in advanced prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 645-654.	1.9	156
2167	Moving upstream in anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 159-160.	21.5	7
2168	Treatment of Advanced Prostate Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 479-499.	5.0	417

#	ARTICLE	IF	CITATIONS
2169	Cardiac arrhythmia considerations of hormone cancer therapies. <i>Cardiovascular Research</i> , 2019, 115, 878-894.	1.8	42
2170	Outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 872-881.	1.0	9
2171	Design, synthesis, and biological evaluation of 2-(5-methyl-1H-pyrazol-1-yl) acetamide derivatives as androgen receptor antagonists. <i>Medicinal Chemistry Research</i> , 2019, 28, 380-386.	1.1	0
2172	Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882080.	0.9	2
2173	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. <i>BMC Cancer</i> , 2019, 19, 12.	1.1	36
2174	Clinical Outcomes of ¹⁷⁷ Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 955-962.	2.8	93
2175	Mechanistic Investigation of the Androgen Receptor DNA-Binding Domain Inhibitor Pyrvinium. <i>ACS Omega</i> , 2019, 4, 2472-2481.	1.6	16
2176	Urine-based liquid biopsy: non-invasive and sensitive AR-V7 detection in urinary EVs from patients with prostate cancer. <i>Lab on A Chip</i> , 2019, 19, 87-97.	3.1	56
2177	Adoption of Abiraterone and Enzalutamide by Urologists. <i>Urology</i> , 2019, 131, 176-183.	0.5	18
2178	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4624-4633.	3.2	21
2179	Prognostic significance of antihypertensive agents in men with castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 813.e21-813.e26.	0.8	0
2180	FAM84B promotes prostate tumorigenesis through a network alteration. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984637.	1.4	17
2181	Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e946-e956.	0.9	5
2182	Dacomitinib, but not lapatinib, suppressed progression in castration-resistant prostate cancer models by preventing HER2 increase. <i>British Journal of Cancer</i> , 2019, 121, 237-248.	2.9	15
2183	Biomarkers of Prostate Cancer. , 2019, , 125-132.		0
2184	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1159.	3.4	50
2185	Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. <i>Clinical Hypertension</i> , 2019, 25, 12.	0.7	21
2186	The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively?. <i>Clinical Oncology</i> , 2019, 31, 824-833.	0.6	66

#	ARTICLE	IF	CITATIONS
2187	Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies. <i>Drugs and Aging</i> , 2019, 36, 701-717.	1.3	14
2188	Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database. <i>Clinical Oncology</i> , 2019, 31, 630-636.	0.6	19
2189	Safety of Abiraterone Acetate Administration in Elderly Patients Receiving Peritoneal Dialysis with Castration-Resistant Prostate Cancer: Two Case Reports. <i>Journal of Nippon Medical School</i> , 2019, 86, 135-138.	0.3	2
2190	The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. <i>BMC Cancer</i> , 2019, 19, 487.	1.1	8
2191	Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2626.	1.8	80
2192	6 Years of experience with abiraterone acetate at SAMS day care hospital. <i>Annals of Medicine</i> , 2024, 51, 82-82.	1.5	0
2193	Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality?. <i>AME Medical Journal</i> , 2019, 4, 24-24.	0.4	0
2194	Radiometabolic Therapy of Bone Metastases. , 2019, , 85-99.		0
2195	Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer. <i>BMC Cancer</i> , 2019, 19, 524.	1.1	12
2196	Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	1.3	29
2197	Nuclear Medicine Therapy. , 2019, , .		5
2198	Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. <i>Anticancer Research</i> , 2019, 39, 2467-2473.	0.5	10
2199	Value-Added Decisions in Oncology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 122-131.	1.8	5
2200	Docetaxel-based chemotherapy combined with dexamethasone 1Âmg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. <i>International Journal of Urology</i> , 2019, 26, 797-803.	0.5	8
2201	Risk of development of visceral metastases subsequent to abiraterone vs placebo: An analysis of mode of radiographic progression in COU-AA-302. <i>Prostate</i> , 2019, 79, 929-933.	1.2	3
2202	Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 139-146.	1.1	10
2203	Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death. <i>PLoS ONE</i> , 2019, 14, e0211090.	1.1	10
2204	Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapy. <i>Prostate</i> , 2019, 79, 1147-1155.	1.2	8

#	ARTICLE	IF	CITATIONS
2205	Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 510-522.	0.5	7
2206	Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. <i>BJU International</i> , 2019, 124, 373-382.	1.3	11
2207	Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1436-1447.	2.8	30
2208	Disseminated Intravascular Coagulation as an Initial Manifestation of Metastatic Prostate Cancer Emergently Treated with Docetaxel-Based Chemotherapy. <i>Case Reports in Oncological Medicine</i> , 2019, 1-6.	0.2	5
2209	Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy. <i>Anticancer Research</i> , 2019, 39, 2553-2559.	0.5	11
2210	Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 241-247.e1.	0.9	11
2211	Red Cell Distribution Width Predicts Prostate-Specific Antigen Response and Survival of Patients With Castration-Resistant Prostate Cancer Treated With Androgen Receptor Axis-Targeted Agents. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 223-230.	0.9	13
2212	Radioligand Therapy With ¹⁷⁷ Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>American Journal of Roentgenology</i> , 2019, 213, 275-285.	1.0	134
2213	Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. <i>JAMA Network Open</i> , 2019, 2, e192589.	2.8	44
2214	Remarkable response to abiraterone acetate in castration-resistant prostate cancer patient with aggressive liver metastasis. <i>IJU Case Reports</i> , 2019, 2, 12-14.	0.1	0
2215	Neoadjuvant chemotherapy for high-risk prostatic adenocarcinoma. <i>IJU Case Reports</i> , 2019, 2, 61-64.	0.1	1
2216	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	8
2217	Management algorithms for metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 50-60.	0.3	6
2218	Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 676-685.	0.9	62
2219	A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling. <i>Prostate</i> , 2019, 79, 937-948.	1.2	14
2220	¹⁷⁷ Lu-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 538-545.	0.9	25
2221	Loss of Notch1 Activity Inhibits Prostate Cancer Growth and Metastasis and Sensitizes Prostate Cancer Cells to Antiandrogen Therapies. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1230-1242.	1.9	36
2222	Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer. <i>Medicine (United States)</i> , 2019, 98, e14254.	0.4	1

#	ARTICLE	IF	CITATIONS
2223	Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, S1-S11.	0.5	14
2224	<i>In situ</i> hydrogelation of bicalutamide-peptide conjugates at prostate tissue for smart drug release based on pH and enzymatic activity. <i>Nanoscale</i> , 2019, 11, 5030-5037.	2.8	22
2226	Emerging therapeutic targets for patients with advanced prostate cancer. <i>Cancer Treatment Reviews</i> , 2019, 76, 1-9.	3.4	26
2227	Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer. <i>European Journal of Medicinal Chemistry</i> , 2019, 171, 265-281.	2.6	12
2228	Clinical characteristics, treatment pattern, and medical costs associated with metastatic castration-resistant prostate cancer in Chinese tertiary care hospital settings. <i>Journal of Medical Economics</i> , 2019, 22, 728-735.	1.0	4
2229	Combining abiraterone and radiotherapy in metastatic castration-resistant prostate cancer: a review of current evidence. <i>Tumori</i> , 2019, 105, 277-281.	0.6	6
2230	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. <i>World Journal of Urology</i> , 2019, 37, 2631-2637.	1.2	69
2231	Cardiovascular and Metabolic Toxicity of Abiraterone in Castration-resistant Prostate Cancer: Post-marketing Experience. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e592-e601.	0.9	9
2232	Systemic treatment for metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 162-168.	0.5	31
2233	Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis. <i>Clinical Hypertension</i> , 2019, 25, 5.	0.7	11
2234	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	23
2235	Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 199-209.	1.7	8
2236	Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable ROR β Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 4716-4730.	2.9	34
2237	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. <i>Endocrine-Related Cancer</i> , 2019, 26, R31-R52.	1.6	49
2238	Effectiveness of Platinum-Based Chemotherapy in Patients With Metastatic Prostate Cancer: Systematic Review and Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e627-e644.	0.9	17
2239	Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or enzalutamide. <i>Cancer</i> , 2019, 125, 1777-1788.	2.0	50
2240	The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis. <i>Cancers</i> , 2019, 11, 434.	1.7	74
2241	NCL1, A Highly Selective Lysine-Specific Demethylase 1 Inhibitor, Suppresses Castration-Resistant Prostate Cancer Growth via Regulation of Apoptosis and Autophagy. <i>Journal of Clinical Medicine</i> , 2019, 8, 442.	1.0	19

#	ARTICLE	IF	CITATIONS
2242	Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. <i>Journal of Clinical Oncology</i> , 2019, 37, 923-931.	0.8	78
2243	Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers. <i>Endocrine Connections</i> , 2019, 8, R10-R26.	0.8	33
2244	Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. <i>BMC Cancer</i> , 2019, 19, 291.	1.1	17
2245	DHX15 is upregulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations. <i>Prostate</i> , 2019, 79, 657-666.	1.2	10
2246	Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. <i>Oncogene</i> , 2019, 38, 4875-4884.	2.6	27
2247	Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio. <i>World Journal of Urology</i> , 2019, 37, 2375-2384.	1.2	10
2248	Zoledronic acid for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 657-666.	0.9	23
2249	The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. <i>Drugs</i> , 2019, 79, 381-400.	4.9	23
2250	Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naïve prostate cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 2019, 15, 1167-1179.	1.1	8
2252	Safety and outcomes of new generation hormone-therapy in elderly chemotherapy-naïve metastatic castration-resistant prostate cancer patients in the real world. <i>Archives of Gerontology and Geriatrics</i> , 2019, 82, 179-185.	1.4	15
2253	Increased Serine and One-Carbon Pathway Metabolism by PKC δ Deficiency Promotes Neuroendocrine Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 385-400.e9.	7.7	128
2254	A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer. <i>Oncogene</i> , 2019, 38, 4977-4989.	2.6	80
2255	ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. <i>Cancer Cell</i> , 2019, 35, 401-413.e6.	7.7	127
2257	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, 17-23.	0.3	17
2258	The importance of antiandrogen in prostate cancer treatment. <i>Annals of Translational Medicine</i> , 2019, 7, S362-S362.	0.7	6
2259	A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 371, 703-712.	1.3	13
2260	Synthesis, Characterization and biological Study of some new derivatives from Pregnenolone via McMurry reaction. <i>Journal of Physics: Conference Series</i> , 2019, 1294, 052023.	0.3	0
2261	Novel approaches targeting mitochondrial fission to deplete stem-like tumor cells in prostate cancer and improve treatment outcomes. <i>Annals of Translational Medicine</i> , 2019, 7, S335-S335.	0.7	3

#	ARTICLE	IF	CITATIONS
2262	Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S26-S30.	0.2	2
2263	Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer. <i>BMC Medical Imaging</i> , 2019, 19, 90.	1.4	9
2264	Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2019, . .	1.5	1
2265	A novel approach to assess real-world efficacy of cancer therapy in metastatic prostate cancer. Analysis of national data on Veterans treated with abiraterone and enzalutamide. <i>Seminars in Oncology</i> , 2019, 46, 351-361.	0.8	15
2266	Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. <i>European Urology Oncology</i> , 2019, 2, 152-162.	2.6	29
2268	Expression pattern of androgen receptors, <i>AR-V7</i> and <i>AR-567es</i> , in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer. <i>Analyst, The</i> , 2019, 144, 6671-6680.	1.7	21
2269	Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer. <i>Cancers</i> , 2019, 11, 1852.	1.7	31
2270	CV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF- κ B/VEGF pathway. <i>Journal of Cancer</i> , 2019, 10, 6269-6277.	1.2	10
2271	Characterization of a Prostate- and Prostate Cancer-Specific Circular RNA Encoded by the Androgen Receptor Gene. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 18, 916-926.	2.3	30
2272	Downregulation of class II phosphoinositide 3-kinase PI3K-C2 β delays cell division and potentiates the effect of docetaxel on cancer cell growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 472.	3.5	14
2273	Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells. <i>Genes</i> , 2019, 10, 964.	1.0	17
2274	Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	63
2275	The Evolving Landscape of Cancer Therapeutics. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 43-79.	0.9	10
2276	Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases. <i>Anti-Cancer Drugs</i> , 2019, 30, 179-185.	0.7	14
2277	CYP17A1 and Androgen-Receptor Expression in Prostate Carcinoma Tissues and Cancer Cell Lines. <i>Current Urology</i> , 2019, 13, 157-165.	0.4	22
2279	Patient and Provider Variables Associated with Systemic Treatment of Advanced Prostate Cancer. <i>Urology Practice</i> , 2019, 6, 234-242.	0.2	12
2280	Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 917-927.	0.6	3
2281	Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer. <i>Medicine (United States)</i> , 2019, 98, e17748.	0.4	11

#	ARTICLE	IF	CITATIONS
2282	GABARAPL1 Promotes AR+ Prostate Cancer Growth by Increasing FL-AR/AR-V Transcription Activity and Nuclear Translocation. <i>Frontiers in Oncology</i> , 2019, 9, 1254.	1.3	10
2283	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. <i>Cancers</i> , 2019, 11, 1908.	1.7	1
2284	Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, e510-e519.	2.5	1
2285	Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 52-63.	3.2	44
2286	Functional Silencing of <i>HSD17B2</i> in Prostate Cancer Promotes Disease Progression. <i>Clinical Cancer Research</i> , 2019, 25, 1291-1301.	3.2	40
2287	Urologic Malignancies. , 2019, , 115-133.		0
2288	Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 631-640.	3.3	198
2289	Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study. <i>Prostate</i> , 2019, 79, 506-514.	1.2	25
2290	An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5 β -abiraterone, and their inactive glucuronide derivatives. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1104, 249-255.	1.2	13
2291	French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. <i>Joint Bone Spine</i> , 2019, 86, 21-28.	0.8	28
2292	Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 335-340.	0.5	3
2293	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223. <i>Cancer Treatment and Research Communications</i> , 2019, 18, 100114.	0.7	9
2294	Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2019, 37, 331-337.	1.2	18
2295	Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. <i>Nature Reviews Urology</i> , 2019, 16, 7-22.	1.9	39
2296	Treatment Experiences, Information Needs, Pain and Quality of Life in Men with Metastatic Castrate-resistant Prostate Cancer: Results from the EXTREQOL Study. <i>Clinical Oncology</i> , 2019, 31, 99-107.	0.6	12
2297	Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy. <i>European Journal of Oncology Nursing</i> , 2019, 38, 8-12.	0.9	12
2298	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	0.9	14
2299	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 524-532.	2.0	8

#	ARTICLE	IF	CITATIONS
2300	Metastatic bone disease: Pathogenesis and therapeutic options. <i>Journal of Bone Oncology</i> , 2019, 15, 100205.	1.0	153
2301	Selective Castration-resistant Prostate Cancer Photothermal Ablation With Copper Sulfide Nanoplates. <i>Urology</i> , 2019, 125, 248-255.	0.5	4
2302	Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 163-172.	0.9	24
2303	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 420-427.	2.0	49
2304	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 1459-1469.	2.0	38
2305	Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 567-573.	1.2	11
2306	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	1.8	38
2307	Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. <i>Cancer Treatment Reviews</i> , 2019, 74, 35-42. Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. BoevÅ©, Maarten C.C.M. Hulshof, AndrÅ© N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. <i>Eur Urol</i> 2019;75:410â€8. <i>European Urology</i> , 2019, 75, e131-e132.	3.4	30
2308	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 127, 25-33.	0.9	1
2309	Cell-based evidence regarding the role of FSH in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 290.e1-290.e8.	0.9	13
2310	Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 141-146.	0.8	8
2311	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9â€10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	0.7	2
2312	Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes. <i>Endocrine Reviews</i> , 2019, 40, 447-475.	0.9	18
2313	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 1-14.	8.9	73
2314	Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis. <i>Prostate</i> , 2019, 79, 281-287.	0	0
2315	Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 509-517.	1.2	15
2316	Permanent 125 I prostate brachytherapy for castration-resistant prostate cancer. <i>International Journal of Urology</i> , 2019, 26, 278-283.	1.1	9
2317		0.5	4

#	ARTICLE	IF	CITATIONS
2318	Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 535-542.	0.8	2
2319	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. <i>Annual Review of Cancer Biology</i> , 2019, 3, 385-408.	2.3	17
2320	Abiraterone and spironolactone in prostate cancer: a combination to avoid. <i>Acta Clinica Belgica</i> , 2019, 74, 439-444.	0.5	14
2321	Metastatic prostate cancer remains incurable, why?. <i>Asian Journal of Urology</i> , 2019, 6, 26-41.	0.5	103
2322	Recommandations françaises de stratégies thérapeutiques pour la prévention et le traitement de l'ostéoporose induite par la castration dans le cancer de la prostate. <i>Revue Du Rhumatisme (Edition) Tj ETQq</i> , 2019, 45, 10-17.	0.0	0
2323	AKR1C3 (type 5 17 β -hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders. <i>Molecular and Cellular Endocrinology</i> , 2019, 489, 82-91.	1.6	72
2324	Hsp70 Binds to the Androgen Receptor N-terminal Domain and Modulates the Receptor Function in Prostate Cancer Cells. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 39-50.	1.9	25
2325	Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology. <i>Clinical and Translational Oncology</i> , 2019, 21, 420-432.	1.2	6
2326	Potential impact of combined inhibition of 3 β -oxidoreductases and 5 α -reductases on prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 50-56.	0.5	9
2327	Impact of age on exposure to oral antiandrogen therapies in clinical practice. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 168-175.	2.0	4
2328	Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 192, 105115.	1.2	17
2329	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019, 75, 88-99.	0.9	333
2330	Liver induced transgene tolerance with AAV vectors. <i>Cellular Immunology</i> , 2019, 342, 103728.	1.4	45
2331	ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2020, 6, 63-70.	1.6	7
2332	Role of androgen receptor splice variants, their clinical relevance and treatment options. <i>World Journal of Urology</i> , 2020, 38, 647-656.	1.2	21
2333	Cardiovascular toxicities of therapy for genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 121-128.	0.8	1
2334	Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 77, 14-21.	0.9	51
2335	Drug-Drug Interactions in Prostate Cancer Treatment. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e71-e82.	0.9	13

#	ARTICLE	IF	CITATIONS
2336	Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 293-305.	0.5	3
2337	Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer.. <i>Seminars in Cancer Biology</i> , 2020, 60, 132-137.	4.3	38
2338	Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review. <i>World Journal of Urology</i> , 2020, 38, 601-611.	1.2	6
2339	Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients. <i>European Urology Oncology</i> , 2020, 3, 119-127.	2.6	20
2340	Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?. <i>Cancer Biology and Therapy</i> , 2020, 21, 1-3.	1.5	8
2341	Clinical utility of emerging biomarkers in prostate cancer liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 219-230.	1.5	36
2342	Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 1-10.	0.9	52
2343	Exposure-response analyses of abiraterone and its metabolites in real-world patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 244-251.	2.0	19
2344	Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. <i>Social Science and Medicine</i> , 2020, 246, 112595.	1.8	23
2345	Sex Hormones and Prostate Cancer. <i>Annual Review of Medicine</i> , 2020, 71, 33-45.	5.0	58
2346	Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e46-e54.	0.9	9
2347	Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 104-111.	2.6	11
2348	Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. <i>European Urology</i> , 2020, 77, 158-166.	0.9	36
2350	Clinicopathologic Diagnostic Approach to Aggressive Variant Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 18-23.	1.2	13
2351	Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives. <i>Briefings in Bioinformatics</i> , 2020, 21, 936-945.	3.2	35
2352	Values of alkaline phosphatase at the diagnosis of castration resistance and response to primary androgen deprivation therapy as predictors of subsequent metastasis in non-metastatic castration-resistant prostate cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 479-485.	1.0	1
2353	Corticosteroid switch after progression on abiraterone acetate plus prednisone. <i>International Journal of Clinical Oncology</i> , 2020, 25, 240-246.	1.0	7
2354	Disparities in prostate cancer incidence and mortality rates: Solvable or not?. <i>Prostate</i> , 2020, 80, 3-16.	1.2	30

#	ARTICLE	IF	CITATIONS
2355	Anti-androgen hormonal therapy for cancer and other diseases. <i>European Journal of Pharmacology</i> , 2020, 866, 172783.	1.7	38
2356	Hormone Effects on Tumors. , 2020, , 667-693.		2
2357	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 9-21.	0.7	27
2358	Ultra-effective near-infrared Photothermal therapy for the prostate cancer Nursing care through novel intended and surface tailored photo-responsive Ga-Au@MPS nanovesicles. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2020, 202, 111685.	1.7	14
2359	The role of adrenal derived androgens in castration resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 197, 105506.	1.2	37
2360	The Use of Transdermal Estrogen in Castrate-resistant, Steroid-refractory Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e217-e223.	0.9	3
2361	Management of bone complications in patients with genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 94-104.	0.8	1
2362	Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 69-76.e4.	0.9	11
2363	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 284-294.	0.9	91
2364	Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 146, 102864.	2.0	18
2365	A castrate-resistant metastatic prostate cancer patient with severe pancytopenia, successfully treated with docetaxel chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1254-1258.	0.5	4
2366	A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population. <i>International Journal of Cancer</i> , 2020, 147, 1143-1151.	2.3	16
2367	Multiparametric MRI as a Biomarker of Response to Neoadjuvant Therapy for Localized Prostate Cancer—A Pilot Study. <i>Academic Radiology</i> , 2020, 27, 1432-1439.	1.3	9
2368	Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis. <i>Biochemical Pharmacology</i> , 2020, 172, 113781.	2.0	10
2369	Conceptual review of key themes in treating prostate cancer in older adults. <i>Journal of Geriatric Oncology</i> , 2020, 11, 893-898.	0.5	1
2370	Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review. <i>Andrology</i> , 2020, 8, 559-574.	1.9	14
2371	Noncanonical Wnt as a prognostic marker in prostate cancer: “you can’t always get what you Wnt.” Expert Review of Molecular Diagnostics, 2020, 20, 245-254.	1.5	4
2372	Pain, opioid therapy, and survival: a needed discussion. <i>Pain</i> , 2020, 161, 496-501.	2.0	33

#	ARTICLE	IF	CITATIONS
2373	A review of prostate cancer treatment impact on the CNS and cognitive function. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 207-219.	2.0	59
2374	Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes. <i>JAMA Oncology</i> , 2020, 6, 206.	3.4	22
2375	Prostate cancer research: The next generation; report from the 2019 Coffeyâ€Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2020, 80, 113-132.	1.2	25
2376	Recruitment of miR-8080 by luteolin inhibits androgen receptor splice variant 7 expression in castration-resistant prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 1145-1157.	1.3	37
2377	Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by antiâ€androgens. <i>Prostate</i> , 2020, 80, 214-224.	1.2	10
2378	Prospective computational design and in vitro bio-analytical tests of new chemical entities as potential selective CYP17A1 lyase inhibitors. <i>Bioorganic Chemistry</i> , 2020, 94, 103462.	2.0	5
2380	Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 316-323.	2.0	6
2381	Comparison of Oncologic Outcomes between Two Alternative Sequences with Abiraterone Acetate and Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 8.	1.7	18
2382	Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide. <i>Frontiers in Oncology</i> , 2020, 10, 567809.	1.3	5
2383	Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 2855.	1.7	16
2384	A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer. <i>Advances in Therapy</i> , 2020, 37, 4910-4929.	1.3	9
2385	MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer. <i>Oncogene</i> , 2020, 39, 7209-7223.	2.6	28
2386	Impact of antiandrogen withdrawal syndrome in castrationâ€resistant prostate cancer patients treated with abiraterone or enzalutamide. <i>International Journal of Urology</i> , 2020, 27, 1109-1115.	0.5	3
2387	Development and prevalence of castration-resistant prostate cancer subtypes. <i>Neoplasia</i> , 2020, 22, 566-575.	2.3	65
2388	Genetic biomarkers to guide poly(ADPâ€ribose) polymeraseâ€inhibitor precision treatment of prostate cancer. <i>Pharmacogenomics</i> , 2020, 21, 1101-1115.	0.6	0
2389	Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100193.	0.7	2
2390	Synthesis and Biological Evaluation of Analogs of Didehydroepiandrosterone as Potential New Anticancer Agents. <i>Molecules</i> , 2020, 25, 3052.	1.7	2
2392	Identification of key genes and pathways in castrate-resistant prostate cancer by integrated bioinformatics analysis. <i>Pathology Research and Practice</i> , 2020, 216, 153109.	1.0	10

#	ARTICLE	IF	CITATIONS
2393	Predictors of resistance to abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer in post-docetaxel setting: a single-center cohort study. <i>Anti-Cancer Drugs</i> , 2020, 31, 742-746.	0.7	0
2394	Phenotypic plasticity and lineage switching in prostate cancer. , 2020, , 591-615.		3
2395	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	1.3	4
2396	Cardiovascular Complications of Prostate Cancer Therapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	6
2397	Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.	5.7	45
2398	Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 594023.	1.3	7
2399	<p>Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5667-5676.	0.9	15
2400	Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092006.	1.4	1
2401	The Movember Prostate Cancer Landscape Analysis: an assessment of unmet research needs. <i>Nature Reviews Urology</i> , 2020, 17, 499-512.	1.9	15
2402	Combination therapy with androgen receptor Nâ€terminal domain antagonist EPIâ€7170 and enzalutamide yields synergistic activity in ARâ€V7â€positive prostate cancer. <i>Molecular Oncology</i> , 2020, 14, 2455-2470.	2.1	31
2403	Adding carboplatin to chemotherapy regimens for metastatic castrateâ€resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes. <i>Prostate</i> , 2020, 80, 1216-1222.	1.2	2
2404	Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5484.	1.8	36
2405	Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151047.	0.7	3
2406	Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 930.	2.0	17
2407	Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 581515.	1.3	27
2408	<p>PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 10251-10260.	0.9	5
2409	Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 580617.	1.3	44
2410	Synthesis, In Vitro Anti-HIV Activity, Cytotoxicity, and Computational Studies of Some New Steroids and Their Pyrazoline and Oxime Analogues. <i>Russian Journal of Bioorganic Chemistry</i> , 2020, 46, 822-836.	0.3	4

#	ARTICLE	IF	CITATIONS
2411	Clinical Impact of Tumor-Infiltrating Lymphocytes and PD-L1-Positive Cells as Prognostic and Predictive Biomarkers in Urological Malignancies and Retroperitoneal Sarcoma. <i>Cancers</i> , 2020, 12, 3153.	1.7	15
2412	Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients. <i>PLoS ONE</i> , 2020, 15, e0238814.	1.1	4
2413	The efficacy and safety of abiraterone acetate in patients with high-risk prostate cancer: a meta-analysis based on six randomized control trials. <i>Translational Andrology and Urology</i> , 2020, 9, 1691-1699.	0.6	0
2414	Bone Tumors: Types and Treatments. , 2020, , .		0
2415	Prescribing practices for tumour aggressiveness and castration resistance in risk-stratified prostate cancer patients. <i>Journal of Prescribing Practice</i> , 2020, 2, 392-397.	0.1	0
2416	Interventional Pharmacoeconomics. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 330-334.	1.0	8
2417	p62 promotes proliferation, apoptosis resistance and invasion of prostate cancer cells through the Keap1/Nrf2/ARE axis. <i>Oncology Reports</i> , 2020, 43, 1547-1557.	1.2	18
2418	Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer. <i>Nature Genetics</i> , 2020, 52, 1011-1017.	9.4	78
2419	Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1892-1900.	1.0	45
2420	Evaluation of Cognitive Function in Trials Testing New-Generation Hormonal Therapy in Patients with Prostate Cancer: A Systematic Review. <i>Cancers</i> , 2020, 12, 2568.	1.7	8
2421	Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6064-6074.	3.2	16
2422	Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. <i>Cancers</i> , 2020, 12, 2313.	1.7	33
2423	Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. <i>Epigenomics</i> , 2020, 12, 1317-1332.	1.0	15
2424	Efficacy of abiraterone acetate in castration-resistant metastatic prostate cancer: A real-world data analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 17, e201-e207.	0.7	5
2425	Adherence Measures for Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate plus Prednisone: Results of a Prospective, Cluster-Randomized Trial. <i>Cancers</i> , 2020, 12, 2550.	1.7	7
2426	YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. <i>Pharmacogenomics</i> , 2020, 21, 919-928.	0.6	3
2428	Interleukin-10 Induces Expression of Neuroendocrine Markers and PDL1 in Prostate Cancer Cells. <i>Prostate Cancer</i> , 2020, 2020, 1-12.	0.4	10
2429	A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?. <i>Cancer Investigation</i> , 2020, 38, 486-492.	0.6	5

#	ARTICLE	IF	CITATIONS
2430	Neuroendocrine and Aggressive-Variant Prostate Cancer. <i>Cancers</i> , 2020, 12, 3792.	1.7	42
2431	Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 606133.	1.3	1
2432	Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2020, 12, CD013245.	1.5	3
2433	Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. <i>European Urology Open Science</i> , 2020, 22, 34-44.	0.2	7
2434	Duration of Androgen Deprivation Therapy and Cardiovascular Fitness. <i>JACC: CardioOncology</i> , 2020, 2, 564-566.	1.7	0
2435	Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel â€” A Final Analysis of the Prostly II Trial. <i>Anticancer Research</i> , 2020, 40, 6915-6921.	0.5	2
2436	Clinical implications of genomic evaluations for prostate cancer risk stratification, screening, and treatment: a narrative review. <i>Prostate International</i> , 2020, 8, 99-106.	1.2	16
2437	Pharmacokinetic drugâ€”drug interactions: an insight into recent US FDA-approved drugs for prostate cancer. <i>Bioanalysis</i> , 2020, 12, 1647-1664.	0.6	7
2438	Therapeutic targeting of the androgen receptor (AR) and AR variants in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 271-283.	0.5	17
2439	Old drug, new clinical use, no manâ€™s land for the indication: an awareness call from European experts. <i>ESMO Open</i> , 2020, 5, e000615.	2.0	10
2440	Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 3517-3524.	3.2	11
2441	Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 483-490.	1.1	3
2442	A Novel Small Molecule Targets Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 75-88.	1.9	14
2443	Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 12315-12323.	3.3	87
2444	New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 837-839.	0.6	2
2445	Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review. <i>Oncology Research and Treatment</i> , 2020, 43, 299-306.	0.8	17
2446	Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion. <i>ESMO Open</i> , 2020, 5, e000652.	2.0	23
2447	Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 682.e1-682.e9.	0.8	8

#	ARTICLE	IF	CITATIONS
2448	Tumor-infiltrating Leukocytes Suppress Local Inflammation Via Interleukin-1 Receptor Antagonist in a Syngeneic Prostate Cancer Model. <i>Biology</i> , 2020, 9, 67.	1.3	2
2449	A critical update on the strategies towards modulators targeting androgen receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115554.	1.4	7
2450	Synthesis of some steroidal mitocans of nanomolar cytotoxicity acting by apoptosis. <i>European Journal of Medicinal Chemistry</i> , 2020, 199, 112425.	2.6	11
2451	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 680-688.	2.0	20
2452	Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype. <i>Annals of Oncology</i> , 2020, 31, 1178-1185.	0.6	27
2453	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	1.5	25
2454	Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e241-e252.	1.8	16
2455	Pharmacotherapeutic strategies for castrate-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1431-1448.	0.9	23
2456	Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 258-267.e1.	0.9	11
2457	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020, 6, 702-715.	3.8	122
2458	Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES). <i>BJUI Compass</i> , 2020, 1, 21-31.	0.7	1
2459	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α -particle therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15172-15181.	3.3	16
2460	Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer. <i>Prostate</i> , 2020, 80, 926-937.	1.2	3
2461	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020, 88, 102057.	3.4	28
2462	Cell-Free DNA Alterations in the <i>AR</i> Enhancer and Locus Predict Resistance to AR-Directed Therapy in Patients With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 680-713.	1.5	20
2463	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 714-729.	1.5	18
2464	Emerging promising biomarkers for treatment decision in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 801-815.	0.8	7
2465	Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 629-638.	1.1	4

#	ARTICLE	IF	CITATIONS
2466	Hormonal prostate cancer therapies and cardiovascular disease: a systematic review. <i>Heart Failure Reviews</i> , 2022, 27, 119-134.	1.7	13
2467	PAWI-2: A novel inhibitor for eradication of cancer. <i>Medicinal Chemistry Research</i> , 2020, 29, 1147-1159.	1.1	1
2468	Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand-binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5162-5171.	3.2	29
2469	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. <i>Nature Reviews Urology</i> , 2020, 17, 292-307.	1.9	59
2470	Influence of short-term dexamethasone on the efficacy of ¹⁷⁷ Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 619-631.	1.2	20
2471	Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 810-820.	0.6	25
2472	“The same old story”™: thoughts on authorized doses of anticancer drugs. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592090541.	1.4	5
2473	Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 381-397.	2.0	34
2474	Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 539-548.	2.0	27
2475	Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. <i>PLoS ONE</i> , 2020, 15, e0229754.	1.1	6
2477	Palladium-Catalyzed Synthesis and Anticancer Activity of Paclitaxel-Dehydroepiandrosterone Hybrids. <i>ACS Omega</i> , 2020, 5, 5589-5600.	1.6	5
2478	Second-line Hormonal Therapy for the Management of Metastatic Castration-resistant Prostate Cancer: a Real-World Data Study Using a Claims Database. <i>Scientific Reports</i> , 2020, 10, 4240.	1.6	9
2479	Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer. <i>Theranostics</i> , 2020, 10, 2888-2896.	4.6	28
2480	Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials. <i>Clinical and Translational Oncology</i> , 2020, 22, 2126-2129.	1.2	6
2481	Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. <i>European Journal of Cancer</i> , 2020, 129, 117-122.	1.3	12
2482	11-Oxygenated androgens in health and disease. <i>Nature Reviews Endocrinology</i> , 2020, 16, 284-296.	4.3	99
2483	Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report. <i>Case Reports in Oncology</i> , 2020, 13, 55-61.	0.3	3
2484	Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. <i>JCO Global Oncology</i> , 2020, 6, 382-386.	0.8	21

#	ARTICLE	IF	CITATIONS
2485	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. <i>Oncology and Therapy</i> , 2020, 8, 209-230.	1.0	37
2486	Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. <i>Future Oncology</i> , 2020, 16, 1889-1901.	1.1	3
2487	Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC. <i>Canadian Urological Association Journal</i> , 2020, 14, E616-E620.	0.3	8
2488	Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1950.	1.0	3
2489	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485
2490	Androgen receptor variants: RNA-based mechanisms and therapeutic targets. <i>Human Molecular Genetics</i> , 2020, 29, R19-R26.	1.4	14
2491	Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer. <i>Cancers</i> , 2020, 12, 1750.	1.7	10
2492	Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer. <i>Cells</i> , 2020, 9, 1495.	1.8	8
2493	Orphan nuclear receptor ROR γ 3 confers doxorubicin resistance in prostate cancer. <i>Cell Biology International</i> , 2020, 44, 2170-2176.	1.4	10
2494	New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?. <i>Cells</i> , 2020, 9, 1522.	1.8	6
2495	Dynamics of Cellular Plasticity in Prostate Cancer Progression. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 130.	1.6	22
2496	Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone. <i>Actas Urológicas Españolas (English Edition)</i> , 2020, 44, 164-171.	0.2	0
2497	Advances in the Medical Treatment of Cushing Disease. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 401-412.	1.2	20
2498	Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 767-768.	0.9	2
2499	A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone. , 2020, 8, e000642.		77
2500	Engineering Prostate Cancer from Induced Pluripotent Stem Cells—New Opportunities to Develop Preclinical Tools in Prostate and Prostate Cancer Studies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 905.	1.8	15
2501	Methiothepin mesylate causes apoptosis of human prostate cancer cells by mediating oxidative stress and mitochondrial dysfunction. <i>Free Radical Biology and Medicine</i> , 2020, 150, 12-22.	1.3	9
2502	Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 709-718.	0.5	2

#	ARTICLE	IF	CITATIONS
2503	The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 753-760.	1.1	5
2504	Regulation of androgen receptor variants in prostate cancer. <i>Asian Journal of Urology</i> , 2020, 7, 251-257.	0.5	19
2505	The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 147-150.	1.1	3
2506	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 619-625.	0.6	54
2507	Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. <i>European Urology Focus</i> , 2021, 7, 742-751.	1.6	19
2508	Overall survival and second primary malignancies in men with metastatic prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0227552.	1.1	24
2509	Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 64-75.	1.0	26
2510	Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 21-28.	1.0	1
2511	Treatment of Primary in Metastatic Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 83-86.	1.0	1
2512	Neoadjuvant Approaches Prior To Radical Prostatectomy. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 2-12.	1.0	5
2513	Roles of Splicing Factors in Hormone-Related Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1551.	1.8	16
2514	Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 847-857.	2.0	15
2515	Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone. <i>Advances in Therapy</i> , 2020, 37, 2083-2097.	1.3	12
2516	Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. <i>British Journal of Cancer</i> , 2020, 122, 1068-1076.	2.9	13
2517	<i>HSD3B1</i> Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, e196496.	3.4	50
2518	A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 171-178.e2.	0.9	25
2519	Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2020, 9, 203.	1.8	15
2520	Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. <i>Nature Communications</i> , 2020, 11, 384.	5.8	56

#	ARTICLE	IF	CITATIONS
2521	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100837.	2.7	6
2522	Systemic treatment for metastatic castrate resistant prostate cancer: Does sequence matter?. <i>Prostate</i> , 2020, 80, 399-406.	1.2	12
2523	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
2524	Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis. <i>Cell Communication and Signaling</i> , 2020, 18, 11.	2.7	54
2525	A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 127, 67-75.	1.3	6
2526	Biomarkers of response to advanced prostate cancer therapy. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 195-205.	1.5	12
2527	Pregnenolonyl- β -glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activities. <i>Chemical Communications</i> , 2020, 56, 1733-1736.	2.2	0
2528	Amrubicin for Patients With Platinum-refractory Small-cell Prostate Cancer: Two Case Reports. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e324-e329.	0.9	4
2529	Pharmacological cancer treatment and venous thromboembolism risk. <i>European Heart Journal Supplements</i> , 2020, 22, C2-C14.	0.0	11
2530	Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer. <i>Biochemical Pharmacology</i> , 2020, 177, 113946.	2.0	5
2531	Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127148.	1.0	12
2532	Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids. <i>International Journal of Pharmaceutics</i> , 2020, 582, 119264.	2.6	16
2533	Aspalathin-rich green <i>Aspalathus linearis</i> extract suppresses migration and invasion of human castration-resistant prostate cancer cells via inhibition of YAP signaling. <i>Phytomedicine</i> , 2020, 69, 153210.	2.3	12
2534	Multistep Binding of the Non-Steroidal Inhibitors Orteronel and Seviteronel to Human Cytochrome P450 17A1 and Relevance to Inhibition of Enzyme Activity. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 6513-6522.	2.9	7
2535	Survival in patients diagnosed with castration-resistant prostate cancer: a population-based observational study in Sweden. <i>Scandinavian Journal of Urology</i> , 2020, 54, 115-121.	0.6	36
2537	Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 436-443.	0.9	1
2538	Initial treatment outcome and feasibility of low-dose cabazitaxel against docetaxel- and castration-resistant prostate cancer in a Japanese hospital. <i>Journal of Rural Medicine: JRM</i> , 2020, 15, 25-28.	0.2	0
2539	Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer. <i>Cancers</i> , 2020, 12, 989.	1.7	7

#	ARTICLE	IF	CITATIONS
2540	Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 198-207.	1.8	5
2541	Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer. Anticancer Research, 2020, 40, 2291-2296.	0.5	8
2542	Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland. Pharmacoepidemiology and Drug Safety, 2020, 29, 653-663.	0.9	9
2543	Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model. Nature Communications, 2020, 11, 1884.	5.8	62
2544	Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8584-8592.	3.3	35
2545	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. Medicine (United States), 2020, 99, e19760.	0.4	34
2546	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk,). Tj ETQq0 0 0 rgBT/Overlap 10 Tf 50		
2547	The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?. Prostate Cancer, 2020, 2020, 1-16.	0.4	10
2548	Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 1965-1976.	3.2	55
2549	One-Year, Open-Label Extension Study on the Safety and Efficacy of Abiraterone Acetate Fine Particle Formulation in Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights Urology, 2020, 13, 117956112091012.	0.4	0
2550	Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation. Cancers, 2020, 12, 831.	1.7	11
2551	Nuclear receptor ERR1± contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis. Theranostics, 2020, 10, 4201-4216.	4.6	20
2552	The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study. Journal of Nuclear Medicine, 2021, 62, 81-87.	2.8	25
2553	Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature. Journal of Oncology Pharmacy Practice, 2021, 27, 216-219.	0.5	5
2554	Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study. PharmacoEconomics - Open, 2021, 5, 299-310.	0.9	11
2555	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. European Urology Oncology, 2021, 4, 447-455.	2.6	52
2556	A novel pregnane analogs: synthesis, cytotoxicity on prostate cancer of PC-3 and LNCaP-AI cells and in silico molecular docking study. Molecular Diversity, 2021, 25, 661-671.	2.1	5
2557	Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. Hormones, 2021, 20, 73-84.	0.9	4

#	ARTICLE	IF	CITATIONS
2558	Treatment outcomes for patients with metastatic castrate-resistant prostate cancer following docetaxel for hormone-sensitive disease. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 36-42.	0.7	6
2559	Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. <i>British Journal of Pharmacology</i> , 2021, 178, 239-261.	2.7	53
2560	An up-to-date evaluation of darolutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 397-402.	0.9	2
2561	Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in Japan. <i>BJU International</i> , 2021, 127, 212-221.	1.3	2
2562	Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Value in Health</i> , 2021, 24, 121-128.	0.1	6
2563	Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 448-456.	2.0	0
2564	The development of apalutamide for the treatment of prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 217-226.	2.5	5
2565	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II: 2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	0.9	633
2566	Promotional Payments Made to Urologists by the Pharmaceutical Industry and Prescribing Patterns for Targeted Therapies. <i>Urology</i> , 2021, 148, 134-140.	0.5	1
2567	Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 170-172.	0.9	3
2568	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 389-400.	1.1	2
2569	Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 490-499.	1.9	55
2570	Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 301-309.	2.0	19
2571	TP53 alterations of hormone-naïve prostate cancer in the Chinese population. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 482-491.	2.0	21
2572	Plectin is a regulator of prostate cancer growth and metastasis. <i>Oncogene</i> , 2021, 40, 663-676.	2.6	26
2573	The Role of Theranostics in Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 71-82.	1.0	20
2574	Impact of prostate cancer stem cell niches on prostate cancer tumorigenesis and progression. <i>Advances in Stem Cells and Their Niches</i> , 2021, 5, 177-204.	0.1	0
2575	Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188481.	3.3	24

#	ARTICLE	IF	CITATIONS
2576	Cognition and depression effects of androgen receptor axis-targeted drugs in men with prostate cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2021, 12, 687-695.	0.5	17
2577	The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103199.	2.0	16
2578	Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1271-1278.	0.4	10
2579	Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 149-163.	1.1	4
2580	Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. <i>British Journal of Cancer</i> , 2021, 124, 552-563.	2.9	63
2581	Prognostic significance of complete blood count parameters in castration-resistant prostate cancer patients treated with androgen receptor pathway inhibitors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 365.e1-365.e7.	0.8	3
2582	Prognosis and safety of radium-223 with concurrent abiraterone acetate or enzalutamide use for metastatic castration-resistant prostate cancer: Real-world data of Japanese patients. <i>BJUI Compass</i> , 2021, 2, 31-38.	0.7	4
2583	Nanomedicine for the Treatment of Advanced Prostate Cancer. <i>Advanced Therapeutics</i> , 2021, 4, 2000136.	1.6	3
2584	Clinical indicators for predicting prognosis after radium-223 administration in castration-resistant prostate cancer with bone metastases. <i>International Journal of Clinical Oncology</i> , 2021, 26, 192-198.	1.0	21
2585	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 341-348.	2.0	8
2586	MOCRPC overview of management options. <i>World Journal of Urology</i> , 2021, 39, 349-356.	1.2	6
2587	New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer. <i>Cells</i> , 2021, 10, 193.	1.8	26
2588	Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 1583-1594.	0.4	140
2589	A comparison of parametric propensity score-based methods for causal inference with multiple treatments and a binary outcome. <i>Statistics in Medicine</i> , 2021, 40, 1653-1677.	0.8	6
2590	Targeting the p300/CBP Axis in Lethal Prostate Cancer. <i>Cancer Discovery</i> , 2021, 11, 1118-1137.	7.7	124
2591	Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 524-531.	2.0	32
2592	Clinical and Biological Features of Neuroendocrine Prostate Cancer. <i>Current Oncology Reports</i> , 2021, 23, 15.	1.8	99
2593	Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 526.	1.7	5

#	ARTICLE	IF	CITATIONS
2594	Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer. , 2021, , 23-46.		0
2595	Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer. <i>Oncotarget</i> , 2021, 12, 15-21.	0.8	5
2596	Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098765.	1.4	19
2597	Response of prostate cancer to addition of dutasteride after progression on abiraterone. <i>Asian Journal of Andrology</i> , 2021, 23, 222.	0.8	6
2598	Precision Medicine in Cancer. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 433-466.	0.1	0
2599	CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 2.	3.5	28
2600	A novel long non-coding RNA PCLN16 facilitates androgen receptor signaling in prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2021, 537, 78-84.	1.0	11
2601	Effective Prediction of Prostate Cancer Recurrence through the IQGAP1 Network. <i>Cancers</i> , 2021, 13, 430.	1.7	7
2602	Androgen metabolism in castration-resistant prostate cancer. , 2021, , 339-368.		0
2603	Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3931-3945.	0.6	3
2604	Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 725-732.	2.0	5
2605	Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer. <i>Journal of Biological Chemistry</i> , 2021, 296, 100240.	1.6	17
2606	Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. <i>Journal of Urology</i> , 2021, 205, 14-21.	0.2	167
2607	Malignant Evaluation and Clinical Prognostic Values of M6A RNA Methylation Regulators in Prostate Cancer. <i>Journal of Cancer</i> , 2021, 12, 3575-3586.	1.2	7
2608	Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. <i>BMC Cancer</i> , 2021, 21, 35.	1.1	7
2609	Onco-hypertension: Overview of hypertension with anti-cancer agents. <i>Journal of Onco-Nephrology</i> , 2021, 5, 57-69.	0.3	8
2610	SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 969-979.	1.2	18
2611	JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer. <i>Cancer Research</i> , 2022, 81, 1087-1100.	0.4	23

#	ARTICLE	IF	CITATIONS
2612	Androgen Receptor Signaling and the Emergence of Lethal Neuroendocrine Prostate Cancer With the Treatment-Induced Suppression of the Androgen Receptor: A Literature Review. <i>Cureus</i> , 2021, 13, e13402.	0.2	4
2613	Medicinal Use of Testosterone and Related Steroids Revisited. <i>Molecules</i> , 2021, 26, 1032.	1.7	21
2614	Prognostic impact of prior local therapy in castration-resistant prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1142-1148.	0.6	6
2615	Căncer de prĂstata. <i>Medicine</i> , 2021, 13, 1454-1466.	0.0	0
2616	Nomogram predicting survival to assist decision-making of radical prostatectomy in patients with metastatic prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 879-887.	0.6	3
2617	LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level. <i>Frontiers in Oncology</i> , 2020, 10, 616185.	1.3	13
2618	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 345.	1.3	14
2619	Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. <i>Current Medical Research and Opinion</i> , 2021, 37, 609-622.	0.9	12
2620	Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE. <i>Journal of Bone Oncology</i> , 2021, 26, 100341.	1.0	4
2621	Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer. <i>Current Medical Research and Opinion</i> , 2021, 37, 635-642.	0.9	5
2622	Treating Prostate Cancer by Antibody-Drug Conjugates. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1551.	1.8	38
2623	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 743-749.	2.0	4
2624	Differential Expression of a Panel of Ten CNTN1-Associated Genes during Prostate Cancer Progression and the Predictive Properties of the Panel towards Prostate Cancer Relapse. <i>Genes</i> , 2021, 12, 257.	1.0	2
2625	EDITORIAL COMMENT. <i>Urology</i> , 2021, 148, 140.	0.5	0
2626	Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. <i>Acta Oncologica</i> , 2021, 60, 459-465.	0.8	7
2627	Circulating tumor cell profiling for precision oncology. <i>Molecular Oncology</i> , 2021, 15, 1622-1646.	2.1	33
2628	MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	31
2629	[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet</i> , 2021, 397, 797-804.	6.3	552

#	ARTICLE	IF	CITATIONS
2630	The Real-World Experience of Single-Center, Retrospective Study of the Prognostic Effect of Secondary Hormone Agent on Survival in Patients With Hormone-Refractory Metastatic Prostate Cancer. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 48-59.	0.1	0
2631	Design, Synthesis and Biological Evaluation of Steroidal Glycoconjugates as Potential Antiproliferative Agents. <i>ChemMedChem</i> , 2021, 16, 1488-1498.	1.6	3
2632	Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients. <i>Drugs and Aging</i> , 2021, 38, 111-123.	1.3	8
2633	Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	30
2634	Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. <i>Cancer Reports</i> , 2021, 4, e1340.	0.6	13
2635	Prostate cancer. <i>Nature Reviews Disease Primers</i> , 2021, 7, 9.	18.1	434
2636	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). <i>Canadian Urological Association Journal</i> , 2020, 15, E81-9.	0.3	10
2637	Patient-derived xenografts and organoids model therapy response in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1117.	5.8	76
2638	Cyproterone acetate acts as a disruptor of the aryl hydrocarbon receptor. <i>Scientific Reports</i> , 2021, 11, 5457.	1.6	3
2639	Distinct DNA methylation patterns associated with treatment resistance in metastatic castration resistant prostate cancer. <i>Scientific Reports</i> , 2021, 11, 6630.	1.6	8
2640	Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 25-37.	1.1	19
2641	Cross-Resistance to Abiraterone and Enzalutamide in Castration Resistance Prostate Cancer Cellular Models Is Mediated by AR Transcriptional Reactivation. <i>Cancers</i> , 2021, 13, 1483.	1.7	18
2642	A noncanonical AR addiction drives enzalutamide resistance in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1521.	5.8	43
2643	Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients. <i>Diagnostics</i> , 2021, 11, 515.	1.3	8
2644	Influence of prostate cancer status on the prevalence of medication-related osteonecrosis of the jaw. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 131, 312-318.	0.2	2
2645	Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. <i>Journal of Clinical Oncology</i> , 2021, 39, 950-955.	0.8	28
2646	Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 1979.	5.8	70
2647	Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective. <i>Current Cancer Drug Targets</i> , 2021, 21, 107-116.	0.8	0

#	ARTICLE	IF	CITATIONS
2648	How I Treat Metastatic Hormone-Sensitive Prostate Cancer?. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 100-107.	0.1	0
2649	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. Cells, 2021, 10, 659.	1.8	77
2650	Effects of Medical Treatment of Prostate Cancer on Bone Health. Trends in Endocrinology and Metabolism, 2021, 32, 135-158.	3.1	21
2651	Y06014 is a selective BET inhibitor for the treatment of prostate cancer. Acta Pharmacologica Sinica, 2021, 42, 2120-2131.	2.8	3
2652	Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer. Oncogene, 2021, 40, 2625-2634.	2.6	19
2653	Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2021, 20, 763-774.	1.9	2
2654	YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer. Oncogene, 2021, 40, 2407-2421.	2.6	37
2655	Factors influencing treatment of veterans with advanced prostate cancer. Cancer, 2021, 127, 2311-2318.	2.0	6
2656	Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Targeted Oncology, 2021, 16, 369-380.	1.7	21
2657	Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer. Scientific Reports, 2021, 11, 6377.	1.6	38
2658	Prostate Cancer: Community Education and Disparities in Diagnosis and Treatment. Oncologist, 2021, 26, 537-548.	1.9	8
2659	Abiraterone and D4, 3-keto Abiraterone binding to CYP17A1, a structural comparison study by molecular dynamic simulation. Steroids, 2021, 167, 108799.	0.8	1
2660	Validation of circulating steroid hormone measurements across different matrices by liquid chromatography-tandem mass spectrometry. Steroids, 2021, 167, 108800.	0.8	5
2661	Mutated SPOP E3 Ligase Promotes 17 β HSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. Cancer Research, 2021, 81, 3593-3606.	0.4	18
2662	A New Insight for the Identification of Oncogenic Variants in Breast and Prostate Cancers in Diverse Human Populations, With a Focus on Latinos. Frontiers in Pharmacology, 2021, 12, 630658.	1.6	3
2663	The Deadly Duo of COVID-19 and Cancer!. Frontiers in Molecular Biosciences, 2021, 8, 643004.	1.6	23
2664	A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide. ESMO Open, 2021, 6, 100082.	2.0	2
2665	Endocrine therapy for cancer. Surgery, 2021, 39, 208-214.	0.1	0

#	ARTICLE	IF	CITATIONS
2666	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4712.	1.8	14
2667	Pulmonary metastasectomy in germ cell tumors and prostate cancer. <i>Journal of Thoracic Disease</i> , 2021, 13, 2661-2668.	0.6	3
2668	Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer. <i>Oncogene</i> , 2021, 40, 3087-3100.	2.6	18
2669	Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. <i>Cancer</i> , 2021, 127, 2623-2630.	2.0	2
2670	Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCDC). <i>JCO Global Oncology</i> , 2021, 7, 559-571.	0.8	10
2671	Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells. <i>Experimental and Molecular Pathology</i> , 2021, 119, 104607.	0.9	6
2672	Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry. <i>Targeted Oncology</i> , 2021, 16, 357-367.	1.7	13
2673	Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment. <i>Prostate</i> , 2021, 81, 543-552.	1.2	20
2676	²²⁵ Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis. <i>Prostate</i> , 2021, 81, 580-591.	1.2	18
2677	Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. <i>Clinical Cancer Research</i> , 2021, 27, 4077-4088.	3.2	21
2679	An up-to-date evaluation of abiraterone for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1227-1234.	0.9	3
2680	Interim and end-treatment 18F-Fluorocholine PET/CT and bone scan in prostate cancer patients treated with Radium 223 dichloride. <i>Scientific Reports</i> , 2021, 11, 7389.	1.6	7
2681	Healthcare Funding Decisions and Real-World Benefits: Reducing Bias by Matching Untreated Patients. <i>Pharmacoeconomics</i> , 2021, 39, 741-756.	1.7	0
2682	Resistance to the Androgen Receptor Centred Therapies: Biology and Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1593-1609.	0.3	0
2683	Digital Medicine in Men with Advanced Prostate Cancer – A Feasibility Study of Electronic Patient-reported Outcomes in Patients on Systemic Treatment. <i>Clinical Oncology</i> , 2021, 33, 751-760.	0.6	7
2684	Recent Advances in the Treatment of Metastatic Prostate Cancer. <i>Advances in Oncology</i> , 2021, 1, 263-272.	0.1	1
2685	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021, 15, 2453-2465.	2.1	9
2686	Steroidogenic cytochrome P450 17A1 structure and function. <i>Molecular and Cellular Endocrinology</i> , 2021, 528, 111261.	1.6	22

#	ARTICLE	IF	CITATIONS
2687	11-Ketotestosterone: the resilience of a potent androgen in prostate cancer patients after castration. JCI Insight, 2021, 6, .	2.3	5
2688	Post Hoc Health-Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies. Oncologist, 2021, 26, e1179-e1188.	1.9	2
2689	Hexose-6-phosphate dehydrogenase blockade reverses prostate cancer drug resistance in xenograft models by glucocorticoid inactivation. Science Translational Medicine, 2021, 13, .	5.8	20
2691	Transperineal Parallel Biopsy of the Prostate: A New Approach of Tissue Sampling for Precision Medicine. International Journal of General Medicine, 2021, Volume 14, 1631-1640.	0.8	1
2692	Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth. Journal of Clinical Investigation, 2021, 131, .	3.9	23
2693	2020 Korean guidelines for the management of metastatic prostate cancer. Korean Journal of Internal Medicine, 2021, 36, 491-514.	0.7	5
2695	Coronary artery disease in patients with cancer: challenges and opportunities for improvement. Current Opinion in Cardiology, 2021, 36, 597-608.	0.8	5
2696	Heart Failure With Targeted Cancer Therapies. Circulation Research, 2021, 128, 1576-1593.	2.0	33
2697	AR-V7 in Metastatic Prostate Cancer: A Strategy beyond Redemption. International Journal of Molecular Sciences, 2021, 22, 5515.	1.8	20
2698	Large-cell neuroendocrine tumor of the prostate: a case report and review of the literature. Journal of Medical Case Reports, 2021, 15, 254.	0.4	7
2699	Combination Treatment Options for Castration-Resistant Prostate Cancer. , 0, , 59-80.		5
2700	Therapeutic efficacy of ²²⁵ Ac-PSMA-617 targeted alpha therapy in patients of metastatic castrate resistant prostate cancer after taxane-based chemotherapy. Annals of Nuclear Medicine, 2021, 35, 794-810.	1.2	12
2701	Efficacy and Safety of [²²⁵ Ac]Ac-PSMA-617 Augmented [¹⁷⁷ Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis. Pharmaceuticals, 2021, 13, 722.	2.0	25
2702	Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study. Japanese Journal of Clinical Oncology, 2021, 51, 1452-1461.	0.6	3
2703	Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. Frontiers in Oncology, 2021, 11, 595285.	1.3	6
2704	Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. Cells, 2021, 10, 1133.	1.8	13
2705	In vitro Anticancer Effects of JI017 on Two Prostate Cancer Cell Lines Involve Endoplasmic Reticulum Stress Mediated by Elevated Levels of Reactive Oxygen Species. Frontiers in Pharmacology, 2021, 12, 683575.	1.6	5
2706	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. Nuclear Medicine and Biology, 2021, 96-97, 101-111.	0.3	10

#	ARTICLE	IF	CITATIONS
2707	MUCIN 1 in Prostate Cancer. , 0, , 125-138.		1
2708	MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. <i>Cancers</i> , 2021, 13, 2380.	1.7	12
2709	Pharmacoeconomics. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 218-220.	0.1	1
2710	Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival. <i>Nuclear Medicine Communications</i> , 2021, 42, 1217-1226.	0.5	7
2711	Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer. <i>Current Molecular Pharmacology</i> , 2021, 14, .	0.7	3
2712	Cardiovascular toxicities associated with abiraterone compared to enzalutamideâ€A pharmacovigilance study. <i>EClinicalMedicine</i> , 2021, 36, 100887.	3.2	16
2714	Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2021, 150, 83-94.	1.3	25
2715	Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e190-e202.	1.8	9
2716	Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells. <i>Nature Communications</i> , 2021, 12, 3862.	5.8	42
2717	Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience. <i>Frontiers in Oncology</i> , 2021, 11, 656146.	1.3	7
2718	Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 210, 105859.	1.2	6
2719	A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer. <i>Research and Reports in Urology</i> , 2021, Volume 13, 457-472.	0.6	21
2720	Renal Safety of [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function. <i>Cancers</i> , 2021, 13, 3095.	1.7	27
2721	Global experience with PSMA-based alpha therapy in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 30-46.	3.3	27
2722	Epigenetic Editing in Prostate Cancer: Challenges and Opportunities. <i>Epigenetics</i> , 2022, 17, 564-588.	1.3	4
2723	Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1245-1252.	1.3	3
2724	Real world treatment utilization patterns in patients with castration-resistant prostate cancer. <i>Scandinavian Journal of Urology</i> , 2021, 55, 299-306.	0.6	4
2725	A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0253021.	1.1	6

#	ARTICLE	IF	CITATIONS
2726	Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. <i>European Urology</i> , 2021, 79, 710-712.	0.9	9
2727	The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2. <i>Scientific Reports</i> , 2021, 11, 11478.	1.6	10
2728	Pretreatment neutrophil-to-lymphocyte ratio as a potential prognostic biomarker for newly diagnosed patients with metastatic castration-sensitive prostate cancer. <i>Cancer Reports</i> , 2021, 4, e1392.	0.6	2
2729	Olaparib for the treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2021, 17, 2413-2429.	1.1	2
2730	Extracellular Vesicles in Advanced Prostate Cancer: Tools to Predict and Thwart Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 3791.	1.7	5
2731	ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. <i>Oncogene</i> , 2021, 40, 5379-5392.	2.6	16
2732	The Prostate Cancer Therapy Enzalutamide Compared with Abiraterone Acetate/Prednisone Impacts Motivation for Exploration, Spatial Learning and Alters Dopaminergic Transmission in Aged Castrated Mice. <i>Cancers</i> , 2021, 13, 3518.	1.7	5
2733	Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 754-763.	0.8	2
2734	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 131-142.	6.3	167
2735	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021, 10, 5775-5782.	1.3	7
2736	Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. <i>Pharmaceuticals</i> , 2021, 14, 670.	1.7	11
2737	Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors. <i>Advances in Therapy</i> , 2021, 38, 4520-4540.	1.3	32
2738	Clinical outcomes and prognosis of metastatic prostate cancer patients ≥60-year-old. <i>World Journal of Urology</i> , 2021, 39, 4319-4325.	1.2	3
2739	A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide. <i>Urology</i> , 2021, 153, 147-155.	0.5	5
2740	Molecular events in neuroendocrine prostate cancer development. <i>Nature Reviews Urology</i> , 2021, 18, 581-596.	1.9	65
2741	¹⁷⁷ Lu-PSMA-617 and Idronexil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 560-566.	2.8	22
2742	Synthesis and biological evaluation of 17-cyanopyridine derivatives of pregnenolone as potential anti-prostate cancer agents. <i>Steroids</i> , 2021, 171, 108841.	0.8	7
2743	A Narrative Review of Implementing Precision Oncology in Metastatic Castration-Resistant Prostate Cancer in Emerging Countries. <i>Oncology and Therapy</i> , 2021, 9, 311-327.	1.0	1

#	ARTICLE	IF	CITATIONS
2744	Response Assessment and Prediction of Progression-Free Survival by 68Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy. <i>Biomolecules</i> , 2021, 11, 1099.	1.8	14
2745	rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression. <i>Gene Therapy</i> , 2022, 29, 418-424.	2.3	2
2746	A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer. <i>European Urology Open Science</i> , 2021, 29, 59-67.	0.2	4
2747	Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis. <i>Prostate</i> , 2021, 81, 1091-1096.	1.2	1
2748	Safety and preliminary immunogenicity of JNJ-64041809, a live-attenuated, double-deleted <i>Listeria monocytogenes</i> -based immunotherapy, in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 219-228.	2.0	12
2749	Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer. <i>Scientific Reports</i> , 2021, 11, 14131.	1.6	4
2750	Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients. <i>Prostate International</i> , 2021, 9, 208-214.	1.2	5
2751	Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2021, 11, 61.	1.1	16
2752	Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. <i>Journal of Urology</i> , 2021, 206, 80-87.	0.2	35
2753	Application of the <i>in silico</i> approach in the study of critical genes predicting chemotherapeutic response to oxaliplatin in treatment of prostate cancer (literature review). <i>Onkourologiya</i> , 2021, 17, 139-144.	0.1	0
2754	Value of Combined PET Imaging with [18F]FDG and [68Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [177Lu]Lu-PSMA-617 RLT. <i>Cancers</i> , 2021, 13, 4134.	1.7	15
2755	Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention. <i>Pharmaceutics</i> , 2021, 13, 1195.	2.0	32
2756	Prognostic Score and Benefit from Abiraterone in First-line Metastatic, Castration-resistant Prostate Cancer. <i>European Urology</i> , 2021, 80, 641-649.	0.9	4
2757	Salvage Radioligand Therapy with Repeated Cycles of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Marrow Involvement. <i>Cancers</i> , 2021, 13, 4017.	1.7	5
2758	Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, T19-T38.	1.6	20
2759	A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 491-500.	0.9	2
2760	Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	5
2761	Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer. <i>Life</i> , 2021, 11, 884.	1.1	5

#	ARTICLE	IF	CITATIONS
2762	Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016. <i>JAMA Network Open</i> , 2021, 4, e2119568.	2.8	50
2764	Manejo actual de las metástasis vertebrales: un trabajo en equipo. <i>Revista Chilena De Ortopedia Y Traumatología</i> , 2021, 62, e136-e142.	0.0	0
2765	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). <i>European Urology Oncology</i> , 2021, 4, 543-552.	2.6	11
2766	Telomerase-based GX301 cancer vaccine in patients with metastatic castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3679-3692.	2.0	15
2767	Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer. <i>Nature Cancer</i> , 2021, 2, 978-993.	5.7	52
2768	KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021, 17, 3017-3026.	1.1	19
2769	Outcome of 177Lu-PSMA-617 Radioligand Therapy in Chemo-Refractory Patients with Metastatic Castration-Resistant Early-Onset Prostate Cancer. <i>Cancers</i> , 2021, 13, 4193.	1.7	5
2770	The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1170-1178.	1.1	5
2771	The heterogeneity of prostate cancers lacking AR activity will require diverse treatment approaches. <i>Endocrine-Related Cancer</i> , 2021, 28, T51-T66.	1.6	28
2772	MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer. <i>Nature Communications</i> , 2021, 12, 5066.	5.8	34
2773	Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 905-914.	2.3	21
2775	Increasing prevalence of metastatic castration-resistant prostate cancer in a managed care population in the United States. <i>Cancer Causes and Control</i> , 2021, 32, 1365-1374.	0.8	10
2776	Stereotactic body radiotherapy for osseous low alpha-beta resistant metastases for pain relief—SOLAR-P. <i>Radiation Oncology</i> , 2021, 16, 170.	1.2	0
2777	Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 17-24.	0.9	15
2778	Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Biomedicines</i> , 2021, 9, 1247.	1.4	22
2779	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	1.7	19
2780	Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 53-58.	2.0	7
2781	Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. <i>Cancer Letters</i> , 2021, 523, 162-169.	3.2	24

#	ARTICLE	IF	CITATIONS
2782	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 739-762.	1.9	38
2783	Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer. <i>International Journal of Urology</i> , 2022, 29, 26-32.	0.5	5
2784	Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 4.e19-4.e28.	0.8	7
2785	Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 1541-1559.	5.1	60
2786	A Systematic Review of Artificial Intelligence Techniques in Cancer Prediction and Diagnosis. <i>Archives of Computational Methods in Engineering</i> , 2022, 29, 2043-2070.	6.0	68
2787	Clinical Relevance of Circulating Tumor Cells in Prostate Cancer Management. <i>Biomedicines</i> , 2021, 9, 1179.	1.4	17
2788	Androgens in prostate cancer: A tale that never ends. <i>Cancer Letters</i> , 2021, 516, 1-12.	3.2	23
2789	Predicting cancer drug TARGETS - Treatment Response Generalized Elastic-net Signatures. <i>Npj Genomic Medicine</i> , 2021, 6, 76.	1.7	10
2790	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. <i>European Journal of Cancer</i> , 2021, 155, 56-63.	1.3	8
2791	Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. <i>Cancers</i> , 2021, 13, 4522.	1.7	22
2792	A Case Report of Metastatic Castration-Resistant Prostate Cancer Harboring a PTEN Loss. <i>Frontiers in Oncology</i> , 2021, 11, 731002.	1.3	3
2793	The tumor suppressor miR-642a-5p targets Wilms Tumor 1 gene and cell-cycle progression in prostate cancer. <i>Scientific Reports</i> , 2021, 11, 18003.	1.6	10
2794	25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 521-527.	0.8	3
2795	PD05-06 PROMOTIONAL PAYMENTS TO MEDICAL ONCOLOGISTS AND UROLOGISTS AND PRESCRIPTIONS FOR ABIRATERONE AND ENZALUTAMIDE. <i>Journal of Urology</i> , 2021, 206, .	0.2	1
2796	Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics. <i>Neoplasia</i> , 2021, 23, 851-858.	2.3	31
2797	Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2021, 14, 101145.	1.7	8
2798	Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55.	1.4	75
2799	Prostate cancer. <i>Lancet</i> , The, 2021, 398, 1075-1090.	6.3	240

#	ARTICLE	IF	CITATIONS
2800	Use of clinical selection for intensification of therapy in metastatic castrate-resistant prostate cancer. <i>Annals of Oncology</i> , 2021, 32, 1192-1193.	0.6	0
2801	Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. <i>Cell Reports</i> , 2021, 36, 109665.	2.9	24
2802	Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 695136.	1.3	6
2803	Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. <i>ESMO Open</i> , 2021, 6, 100261.	2.0	14
2804	Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e299-e305.	0.9	6
2805	Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 728.e13-728.e24.	0.8	8
2806	The treatment landscape of metastatic prostate cancer. <i>Cancer Letters</i> , 2021, 519, 20-29.	3.2	50
2807	Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans. <i>Life Sciences</i> , 2021, 284, 119896.	2.0	12
2808	miRNAs and androgen deprivation therapy for prostate cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188625.	3.3	19
2809	Prostate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics. , 2021, 228, 107932.		44
2810	Early Evaluation of PSA Response in Metastatic Prostate Cancer Treated with Abiraterone. <i>Open Journal of Urology</i> , 2021, 11, 251-263.	0.0	1
2811	Tight binding of cytochrome b5 to cytochrome P450 17A1 is a critical feature of stimulation of C21 steroid lyase activity and androgen synthesis. <i>Journal of Biological Chemistry</i> , 2021, 296, 100571.	1.6	18
2812	Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel. <i>Frontiers in Pharmacology</i> , 2020, 11, 601513.	1.6	12
2813	Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 909-924.	2.9	16
2814	Clinical-Pathological Conference Series from the Medical University of Graz. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 515-522.	1.0	0
2815	Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study. <i>Prostate</i> , 2021, 81, 194-201.	1.2	6
2816	Immunotherapy as a Precision Medicine Tool for the Treatment of Prostate Cancer. <i>Cancers</i> , 2021, 13, 173.	1.7	14
2817	Hormonal Therapy for Prostate Cancer. <i>Endocrine Reviews</i> , 2021, 42, 354-373.	8.9	136

#	ARTICLE	IF	CITATIONS
2819	The Impact of Epigenetic Alterations on Diagnosis, Prediction, and Therapy of Prostate Cancer. , 2012, , 123-157.		1
2820	The Expression Signature of Androgen Receptor Splice Variants and Their Distinctive Transcriptional Activities in Castration-Resistant Prostate Cancer. , 2013, , 201-213.		2
2821	Androgen Receptor Dependence. Advances in Experimental Medicine and Biology, 2019, 1210, 333-350.	0.8	19
2822	Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance. Advances in Experimental Medicine and Biology, 2019, 1210, 351-378.	0.8	55
2823	The Tumor Microenvironments of Lethal Prostate Cancer. Advances in Experimental Medicine and Biology, 2019, 1210, 149-170.	0.8	7
2824	P450 Enzymes in Steroid Processing. , 2015, , 851-879.		23
2825	Neue Arzneimittel 2011. , 2012, , 43-126.		1
2826	Uroonkologie beim Älteren Patienten. , 2014, , 317-326.		1
2827	Relevance of Network Hierarchy in Cancer Drug-Target Selection. , 2012, , 339-362.		3
2828	Oxidative Stress and Castration-Resistant Prostate Cancer. , 2018, , 201-214.		2
2829	Treatment of Castration-Resistant Prostate Cancer. , 2012, , 2954-2971.e4.		3
2831	GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Letters, 2020, 485, 45-55.	3.2	42
2832	COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. Critical Reviews in Oncology/Hematology, 2020, 152, 102991.	2.0	41
2833	Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. Critical Reviews in Oncology/Hematology, 2020, 152, 102994.	2.0	13
2834	Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 25, 100256.	0.7	10
2835	Intracrine androgen biosynthesis, metabolism and action revisited. Molecular and Cellular Endocrinology, 2018, 465, 4-26.	1.6	144
2836	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. Urologic Clinics of North America, 2020, 47, e17-e54.	0.8	39
2837	Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 91.e7-91.e15.	0.8	11

#	ARTICLE	IF	CITATIONS
2839	Abiraterone acetate for prostate cancer: a new era of hormonal therapies. <i>Asian Journal of Andrology</i> , 2011, 13, 663-664.	0.8	3
2840	Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. <i>Oncogene</i> , 2018, 37, 710-721.	2.6	69
2841	Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. <i>Journal of Urology</i> , 2020, 204, 71-78.	0.2	8
2847	Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1708-1718.	1.9	42
2848	Tumor fraction in cell-free DNA as a biomarker in prostate cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	94
2849	Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy. <i>JCI Insight</i> , 2019, 4, .	2.3	26
2850	Molecular determinants of response to high-dose androgen therapy in prostate cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	17
2851	An imaging agent to detect androgen receptor and its active splice variants in prostate cancer. <i>JCI Insight</i> , 2016, 1, .	2.3	16
2852	Targeting FOXA1-mediated repression of TGF- β 2 signaling suppresses castration-resistant prostate cancer progression. <i>Journal of Clinical Investigation</i> , 2018, 129, 569-582.	3.9	116
2853	Obesity-induced excess of 17-hydroxyprogesterone promotes hyperglycemia through activation of glucocorticoid receptor. <i>Journal of Clinical Investigation</i> , 2020, 130, 3791-3804.	3.9	28
2854	Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. <i>Journal of Clinical Investigation</i> , 2017, 127, 2326-2338.	3.9	40
2855	Role of steroid receptor and coregulator mutations in hormone-dependent cancers. <i>Journal of Clinical Investigation</i> , 2017, 127, 1126-1135.	3.9	42
2856	HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 3333-3340.	3.9	43
2857	Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase III Cancer of the Ovary Abiraterone (CORAL) trial (CRUK A16037). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097535.	1.4	2
2858	Nonhormone Therapy for Metastatic Castration-Resistant Prostate Cancer: Chemotherapy, Bone-Targeted Treatments, and Others. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e161-e165.	1.8	2
2859	Emerging medical therapies for congenital adrenal hyperplasia. <i>F1000Research</i> , 2019, 8, 363.	0.8	12
2860	Treatment patterns and clinical effectiveness in metastatic castrate resistant prostate cancer after first-line docetaxel. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 321-328.	0.1	3
2861	Docetaxel chemotherapy for Chinese patients with castrate-resistant prostate cancer. <i>Hong Kong Medical Journal</i> , 2013, 19, 237-41.	0.1	2

#	ARTICLE	IF	CITATIONS
2862	Impact of skeletal-related events on survival in patients with metastatic prostate cancer prescribed androgen deprivation therapy. <i>Hong Kong Medical Journal</i> , 2016, 22, 106-15.	0.1	9
2863	Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy. <i>PLoS Biology</i> , 2018, 16, e2002930.	2.6	47
2864	Risk of Hormone Escape in a Human Prostate Cancer Model Depends on Therapy Modalities and Can Be Reduced by Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2012, 7, e42252.	1.1	12
2865	Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways. <i>PLoS ONE</i> , 2012, 7, e51189.	1.1	32
2866	In Vivo Targeting of ADAM9 Gene Expression Using Lentivirus-Delivered shRNA Suppresses Prostate Cancer Growth by Regulating REG4 Dependent Cell Cycle Progression. <i>PLoS ONE</i> , 2013, 8, e53795.	1.1	28
2867	Circulating Endothelial Progenitor Cells in Castration Resistant Prostate Cancer: A Randomized, Controlled, Biomarker Study. <i>PLoS ONE</i> , 2014, 9, e95310.	1.1	4
2868	Prostate Cancer Characteristics Associated with Response to Pre-Receptor Targeting of the Androgen Axis. <i>PLoS ONE</i> , 2014, 9, e111545.	1.1	6
2869	Mutation of Androgen Receptor N-Terminal Phosphorylation Site Tyr-267 Leads to Inhibition of Nuclear Translocation and DNA Binding. <i>PLoS ONE</i> , 2015, 10, e0126270.	1.1	12
2870	Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0141589.	1.1	38
2871	Arg-Gly-Asp (RGD)-Modified E1A/E1B Double Mutant Adenovirus Enhances Antitumor Activity in Prostate Cancer Cells In Vitro and in Mice. <i>PLoS ONE</i> , 2016, 11, e0147173.	1.1	15
2872	Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate. <i>PLoS ONE</i> , 2016, 11, e0161959.	1.1	15
2873	Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer. <i>PLoS ONE</i> , 2017, 12, e0174134.	1.1	10
2874	Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0243386.	1.1	39
2875	Progress in the Treatment of Advanced Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 117-131.	1.8	31
2876	MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. <i>European Journal of Endocrinology</i> , 2017, 177, R231-R248.	1.9	58
2877	Abiraterone acetate treatment lowers 11-oxygenated androgens. <i>European Journal of Endocrinology</i> , 2020, 182, 413-421.	1.9	43
2878	Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 131-140.	1.6	28
2879	Roles of the HOXA10 gene during castrate-resistant prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2019, 26, 279-292.	1.6	8

#	ARTICLE	IF	CITATIONS
2880	Applying mass spectrometric methods to study androgen biosynthesis and metabolism in prostate cancer. <i>Journal of Molecular Endocrinology</i> , 2019, 62, R255-R267.	1.1	9
2881	Clinical and surgical assistance in prostate cancer during the COVID-19 Pandemic: implementation of assistance protocols. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 50-61.	0.7	10
2882	Steroidal Inhibitors of CYP17A1 as a Template For Novel Anti-Cancer Agents Development. <i>Biomedical Chemistry Research and Methods</i> , 2018, 1, e00020.	0.1	2
2884	Lysophosphatidic acid receptor isoforms expression in prostate cancer cells is differentially regulated by the CYP17A1 inhibitor abiraterone and depends on the androgen receptor. <i>Advances in Modern Oncology Research</i> , 2016, 2, 57.	0.1	3
2885	MYSM1-AR complex-mediated repression of Akt/c-Raf/GSK-3 β signaling impedes castration-resistant prostate cancer growth. <i>Aging</i> , 2019, 11, 10644-10663.	1.4	8
2886	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. <i>Oncotarget</i> , 2016, 7, 64447-64470.	0.8	130
2887	Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression. <i>Oncotarget</i> , 2016, 7, 61955-61969.	0.8	18
2888	Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer. <i>Oncotarget</i> , 2016, 7, 62240-62254.	0.8	23
2889	Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells. <i>Oncotarget</i> , 2016, 7, 74724-74733.	0.8	4
2890	Amplification of MUC1 in prostate cancer metastasis and CRPC development. <i>Oncotarget</i> , 2016, 7, 83115-83133.	0.8	27
2891	Combinatorial antitumor effect of HDACs and the PI3K-Akt-mTOR pathway inhibition in a Pten deficient model of prostate cancer. <i>Oncotarget</i> , 2013, 4, 2225-2236.	0.8	64
2892	Epigenetic therapy in urologic cancers: an update on clinical trials. <i>Oncotarget</i> , 2017, 8, 12484-12500.	0.8	35
2893	A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. <i>Oncotarget</i> , 2017, 8, 6796-6808.	0.8	8
2894	Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression. <i>Oncotarget</i> , 2017, 8, 27966-27975.	0.8	27
2895	Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 71447-71455.	0.8	23
2896	Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. <i>Oncotarget</i> , 2017, 8, 56051-56065.	0.8	70
2897	Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. <i>Oncotarget</i> , 2017, 8, 56698-56713.	0.8	95
2898	Vinculin and filamin-C are two potential prognostic biomarkers and therapeutic targets for prostate cancer cell migration. <i>Oncotarget</i> , 2017, 8, 82430-82436.	0.8	31

#	ARTICLE	IF	CITATIONS
2899	Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness. <i>Oncotarget</i> , 2014, 5, 7357-7367.	0.8	24
2900	Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4. <i>Oncotarget</i> , 2017, 8, 66878-66888.	0.8	21
2901	Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study. <i>Oncotarget</i> , 2017, 8, 110774-110784.	0.8	8
2902	Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 10284-10293.	0.8	44
2903	Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. <i>Oncotarget</i> , 2014, 5, 9335-9348.	0.8	64
2904	Testosterone metabolites inhibit proliferation of castration- and therapy-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 16951-16961.	0.8	10
2905	Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP. <i>Oncotarget</i> , 2018, 9, 22147-22157.	0.8	13
2906	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 25586-25596.	0.8	66
2907	Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>Oncotarget</i> , 2014, 5, 12448-12458.	0.8	92
2908	A prognostic score for overall survival in patients treated with abiraterone in the pre- and post-chemotherapy setting. <i>Oncotarget</i> , 2019, 10, 5082-5091.	0.8	4
2909	Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer. <i>Oncotarget</i> , 2020, 11, 15-21.	0.8	9
2910	Nucleolin represses transcription of the androgen receptor gene through a G-quadruplex. <i>Oncotarget</i> , 2020, 11, 1758-1776.	0.8	7
2911	Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase. <i>Oncotarget</i> , 2015, 6, 10030-10044.	0.8	35
2912	Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. <i>Oncotarget</i> , 2015, 6, 12520-12528.	0.8	47
2913	Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression. <i>Oncotarget</i> , 2015, 6, 20474-20484.	0.8	20
2914	Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 18192-18205.	0.8	111
2915	Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents. <i>Oncotarget</i> , 2015, 6, 23358-23371.	0.8	79
2916	FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 29782-29794.	0.8	35

#	ARTICLE	IF	CITATIONS
2917	AR-v7 protein expression is regulated by protein kinase and phosphatase. <i>Oncotarget</i> , 2015, 6, 33743-33754.	0.8	43
2918	The promise of dual targeting Akt/mTOR signaling in lethal prostate cancer. <i>Oncotarget</i> , 2012, 3, 1483-1484.	0.8	11
2919	Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. <i>Oncotarget</i> , 2016, 7, 69397-69411.	0.8	17
2920	Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. <i>Oncotarget</i> , 2016, 7, 28891-28902.	0.8	19
2921	Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer. <i>Oncotarget</i> , 2016, 7, 35818-35831.	0.8	55
2922	Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors. <i>Oncotarget</i> , 2013, 4, 691-704.	0.8	57
2923	SSX2 regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. <i>Oncotarget</i> , 2016, 7, 50997-51011.	0.8	9
2924	Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. <i>Oncotarget</i> , 2016, 7, 40690-40703.	0.8	12
2925	Medical management of metastatic prostate cancer. <i>Australian Prescriber</i> , 2018, 41, 154-159.	0.5	11
2926	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6
2927	Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms. , 2020, 3, 742-761.		13
2928	Immunobiology and immunotherapy in genitourinary malignancies. <i>Annals of Translational Medicine</i> , 2016, 4, 270-270.	0.7	14
2929	Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer. <i>Annals of Translational Medicine</i> , 2016, 4, S64-S64.	0.7	1
2930	Restoration of FKBP51 protein promotes the progression of castration resistant prostate cancer. <i>Annals of Translational Medicine</i> , 2019, 7, 729-729.	0.7	13
2931	Analysis of novel enzalutamide-resistant cells: upregulation of testis-specific Y-encoded protein gene promotes the expression of androgen receptor splicing variant 7. <i>Translational Cancer Research</i> , 2020, 9, 6232-6245.	0.4	2
2932	Towards understanding androgen receptor-independent prostate cancer: an evolving paradigm. <i>Translational Cancer Research</i> , 2020, 9, 415-417.	0.4	2
2933	Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target. <i>Current Medicinal Chemistry</i> , 2019, 26, 6053-6073.	1.2	7
2934	Androgen Receptor Gene Rearrangements: New Perspectives on Prostate Cancer Progression. <i>Current Drug Targets</i> , 2013, 14, 441-449.	1.0	31

#	ARTICLE	IF	CITATIONS
2935	Actions of Estrogenic Endocrine Disrupting Chemicals on Human Prostate Stem/Progenitor Cells and Prostate Carcinogenesis. <i>Open Biotechnology Journal</i> , 2016, 10, 76-97.	0.6	7
2936	Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2016, 36, 5719-5730.	0.5	10
2937	Consequences of an Early PSA Response to Enzalutamide Treatment for Japanese Patients with Metastatic Castration-resistant Prostate Cancer. <i>Anticancer Research</i> , 2016, 36, 6141-6150.	0.5	21
2938	Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. <i>Anticancer Research</i> , 2016, 36, 6439-6448.	0.5	10
2939	Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy. <i>Anticancer Research</i> , 2017, 37, 3717-3722.	0.5	18
2940	Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11191.	0.5	8
2941	Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 737-745.	3.9	6
2942	The changing role of radium-223 in metastatic castrate-resistant prostate cancer: has the EMA missed the mark with revising the label?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 63, 170-182.	0.4	7
2943	Acute coronary syndromes in oncology: conservative or invasive strategies? Case study and literature review. <i>OnCOREview</i> , 2018, 8, 5-10.	0.1	1
2944	Assessing the Population Impact of Published Intervention Studies. <i>NAM Perspectives</i> , 2015, 5, .	1.3	1
2945	Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours. <i>Health Technology Assessment</i> , 2013, 17, 1-386.	1.3	32
2946	TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. <i>Health Technology Assessment</i> , 2016, 20, 1-288.	1.3	29
2947	Development of an immunofluorescent AR-V7 circulating tumor cell assay – A blood-based test for men with metastatic prostate cancer. <i>Journal of Circulating Biomarkers</i> , 2020, 9, 13-19.	0.8	7
2948	Imaging for Metastasis in Prostate Cancer: A Review of the Literature. <i>Frontiers in Oncology</i> , 2020, 10, 55.	1.3	46
2949	Cardiovascular Complications of Prostate Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2020, 11, 555475.	1.6	14
2950	Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2015, 7, 2290-2308.	1.7	51
2951	Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. <i>Journal of Health Economics and Outcomes Research</i> , 2018, 6, 1-14.	0.6	2
2952	Assessment of biochemical recurrence of prostate cancer (Review). <i>International Journal of Oncology</i> , 2019, 55, 1194-1212.	1.4	14

#	ARTICLE	IF	CITATIONS
2953	A randomized phase III trial of personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel. <i>Oncology Reports</i> , 2020, 45, 159-168.	1.2	17
2954	Androgen receptor and prostate cancer. <i>AIMS Molecular Science</i> , 2016, 3, 280-299.	0.3	22
2955	Future perspectives of prostate cancer therapy. <i>Translational Andrology and Urology</i> , 2012, 1, 19-32.	0.6	18
2956	Current clinical challenges in prostate cancer. <i>Translational Andrology and Urology</i> , 2013, 2, 122-36.	0.6	34
2957	Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression. <i>Translational Andrology and Urology</i> , 2013, 2, 202-211.	0.6	93
2958	Decoding the androgen receptor splice variants. <i>Translational Andrology and Urology</i> , 2013, 2, 178-186.	0.6	115
2959	Novel non-AR therapeutic targets in castrate resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2013, 2, 265-77.	0.6	4
2960	Sequence of treatment in locally advanced and metastatic renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2015, 4, 310-25.	0.6	16
2961	Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2015, 4, 355-64.	0.6	19
2962	Mechanisms of resistance in castration-resistant prostate cancer (CRPC). <i>Translational Andrology and Urology</i> , 2015, 4, 365-80.	0.6	310
2963	Chemotherapy for advanced cancers. <i>Annals of Palliative Medicine</i> , 2014, 3, 203-28.	0.5	11
2964	Immunotherapy in metastatic prostate cancer. <i>Indian Journal of Urology</i> , 2016, 32, 271.	0.2	6
2965	More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 99.	0.8	4
2966	Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 341.	0.8	9
2967	Chemotherapy and its evolving role in the management of advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 334.	0.8	19
2968	Improving intermittent androgen deprivation therapy: lessons learned from basic and translational research. <i>Asian Journal of Andrology</i> , 2014, 16, 505.	0.8	4
2969	Treatment sequencing in metastatic castrate-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 426.	0.8	41
2970	Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 387.	0.8	43

#	ARTICLE	IF	CITATIONS
2971	Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells. <i>Asian Journal of Andrology</i> , 2016, 18, 607.	0.8	48
2972	DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 533.	0.8	18
2973	Genomic predictors for treatment of late stage prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 586.	0.8	7
2974	Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 580.	0.8	38
2975	Personalized prostate cancer care: from screening to treatment. <i>Asian Journal of Andrology</i> , 2016, 18, 505.	0.8	8
2976	Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 270.	0.8	15
2977	PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. <i>Asian Journal of Andrology</i> , 2018, 20, 173.	0.8	5
2978	External validation and newly development of a nomogram to predict overall survival of abiraterone-treated, castration-resistant patients with metastatic prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 184.	0.8	9
2979	The path forward in prostate cancer therapeutics. <i>Asian Journal of Andrology</i> , 2018, 20, 213.	0.8	3
2980	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 12.	0.8	5
2981	Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 131.	0.8	6
2982	Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer. <i>Indian Journal of Nuclear Medicine</i> , 2020, 35, 299.	0.1	16
2983	Neoadjuvant therapy in high-risk prostate cancer. <i>Indian Journal of Urology</i> , 2020, 36, 251.	0.2	6
2984	Quadriplegia secondary to abiraterone-induced severe hypokalemia. <i>South Asian Journal of Cancer</i> , 2019, 08, 139-144.	0.2	3
2985	Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, 1.	0.6	68
2986	Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05). <i>Cancer Research and Treatment</i> , 2018, 50, 1252-1259.	1.3	27
2987	Management of Severe Cushing Syndrome Induced by Adrenocortical Carcinoma with Abiraterone Acetate: A Case Report. <i>AACE Clinical Case Reports</i> , 2016, 2, e337-e341.	0.4	11
2988	Androgen Receptor Signaling in Prostate Cancer: New Twists for an Old Pathway. <i>Journal of Steroids & Hormonal Science</i> , 2012, 01, .	0.1	3

#	ARTICLE	IF	CITATIONS
2989	New Molecular Targets in Metastatic Prostate Cancer. <i>Journal of Cancer Therapy</i> , 2016, 07, 388-401.	0.1	2
2990	Hormonal therapy and chemotherapy for advanced prostate cancer. <i>Journal of the Korean Medical Association</i> , 2015, 58, 30.	0.1	3
2991	How Precisely Can Prostate Cancer Be Managed?. <i>International Neurourology Journal</i> , 2016, 20, S120-130.	0.5	10
2992	Is there still a place for docetaxel rechallenge in prostate cancer?. <i>World Journal of Clinical Oncology</i> , 2015, 6, 99.	0.9	17
2993	Post-docetaxel options for further survival benefit in metastatic castration-resistant prostate cancer: Questions of choice. <i>Canadian Urological Association Journal</i> , 2013, 7, S11-7.	0.3	12
2994	Optimal management of patients receiving cabazitaxel-based chemotherapy. <i>Canadian Urological Association Journal</i> , 2013, 7, S18-24.	0.3	5
2995	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. <i>World Journal of Men's Health</i> , 2020, 38, 151.	1.7	7
2996	Brain metastases in patient with prostate cancer found in 18F-choline PET/CT. <i>Nuclear Medicine Review</i> , 2015, 18, 39-41.	0.3	9
2997	End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review. <i>World Journal of Methodology</i> , 2014, 4, 123.	1.1	1
2998	Skeletal metastasis: treatments, mouse models, and the Wnt signaling. <i>Chinese Journal of Cancer</i> , 2013, 32, 380-396.	4.9	30
2999	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	2.3	943
3000	Identifying Differentially Expressed Genes and Small Molecule Drugs for Prostate Cancer by a Bioinformatics Strategy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5281-5286.	0.5	17
3001	Abiraterone for Treatment of Metastatic Castration-resistant Prostate Cancer: a Systematic Review and Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 1313-1320.	0.5	14
3002	Lenalidomide in Treating Patients with Castration-Resistant Prostate Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 3969-3972.	0.5	2
3003	Single-cell analyses of circulating tumor cells. <i>Cancer Biology and Medicine</i> , 2015, 12, 184-92.	1.4	24
3004	Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. <i>ELife</i> , 2017, 6, .	2.8	32
3005	Diethylstilbestrol in the Treatment of Castration-resistant Prostate Cancer: A Lower-middle-income Country Experience. <i>Cureus</i> , 2019, 11, e4470.	0.2	3
3006	Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. <i>In Vivo</i> , 2021, 35, 3509-3519.	0.6	5

#	ARTICLE	IF	CITATIONS
3007	Prostate Cancer: Advanced and Metastatic Disease. UNIPA Springer Series, 2021, , 805-821.	0.1	0
3008	Comparative pathology of dog and human prostate cancer. Veterinary Medicine and Science, 2022, 8, 110-120.	0.6	11
3009	Canadian Urologic Association best practice report: Bone health in prostate cancer. Canadian Urological Association Journal, 2021, 15, 375-382.	0.3	3
3010	Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell, 2021, 39, 1464-1478.e8.	7.7	98
3012	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. EBioMedicine, 2021, 72, 103625.	2.7	23
3013	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors. Advanced Materials, 2022, 34, e2100096.	11.1	24
3014	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncology, 2022, 18, 35-45.	1.1	4
3015	Antiproliferative, proapoptotic, and tumor-suppressing effects of the novel anticancer agent alsevirone in prostate cancer cells and xenografts. Archiv Der Pharmazie, 2021, , e2100316.	2.1	1
3016	Hormonal Therapy in Metastatic Prostate Cancer. Trk ceroloji Seminerleri/Turkish Urology Seminars, 2010, 1, 195-200.	0.0	0
3018	Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2011, 13, 785-786.	0.8	3
3019	Paradigm Shift in the Concept of Hormonal Milieu of Prostate Cancer. , 0, , .		0
3020	Advanced Models for Target Validation & Drug Discovery in Prostate Cancer. , 0, , .		0
3021	Abstract B237: Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.. , 2011, , .		0
3023	Development of Novel Secondary Hormonal Therapies for Castrate-Resistant Prostate Cancer. , 0, , .		0
3024	Abiraterone acetate. Journal of Postgraduate Medicine, 2012, 58, 203-206.	0.2	2
3025	Resistance to Chemical Castration: Second-Line Hormonal Treatment. , 2012, , 251-259.		0
3026	Targeted Therapies and Vaccination. , 2012, , 261-275.		0
3027	The Androgen Receptor in Castration-Resistant Prostate Cancer: Still a Clinical Opportunity?. Journal of Cancer Science & Therapy, 2012, 01, .	1.7	2

#	ARTICLE	IF	CITATIONS
3028	Castrate Resistant Metastatic Prostate Cancer: Options for a Patient in 2012. Open Journal of Urology, 2012, 02, 210-215.	0.0	0
3029	Management of Prostate Cancer: EAU Guidelines on Screening, Diagnosis and Treatment. , 2012, , 299-326.		1
3030	Experimental therapeutics in prostate cancer: where are we now and where do we need to go. Asian Journal of Andrology, 2012, 14, 421-422.	0.8	0
3031	New Developments in Prostate Cancer Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 309-313.	1.8	0
3032	Clinical Management of Elderly Patientsâ€™™ Metastatic Prostate Cancer: Other Treatments and Supportive Care. , 2013, , 203-216.		0
3033	New Treatment Developments Applied to Elderly Patients. , 2013, , 217-227.		0
3034	Androgen Deprivation in Elderly Prostate Cancer Patients: Side Effects and Their Prevention. , 2013, , 77-90.		0
3035	Clinical Management of Elderly Patients with Metastatic Prostate Cancer Chemotherapy. , 2013, , 179-201.		0
3036	Genitourinary Cancer. , 2013, , 247-292.		1
3037	Urologische oncologie. , 2013, , 529-564.		0
3038	Assessment of Treatment Outcomes Following Prostate Cancer Therapy. , 2013, , 943-949.		0
3039	Chemotherapy and Novel Systemic Approaches in the Treatment of Metastatic Castration Resistant Prostate Cancer. , 2013, , 901-923.		0
3041	Recent Advances in Cancer Treatment. , 2013, , 25-35.		0
3042	The Effect of AR Overexpression on Androgen Signaling in Prostate Cancer. , 2013, , 187-200.		1
3044	Androgen Receptor Regulation of Serum Response Factor Signaling in Prostate Cancer. , 2013, , 257-271.		0
3045	Early vs. Delayed Hormonal Treatment in Locally Advanced or Asymptomatic Metastatic Prostatic Cancer Patient Dilemma: A Review. Journal of Steroids & Hormonal Science, 2013, 01, .	0.1	0
3046	Metastatic castration-resistant prostate cancer: The emerging continuum of care. Canadian Urological Association Journal, 2013, 7, S3.	0.3	1
3047	Nonhormone Therapy for Metastatic Castration-Resistant Prostate Cancer: Chemotherapy, Bone-Targeted Treatments, and Others. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e161-e165.	1.8	0

#	ARTICLE	IF	CITATIONS
3048	Scaffold attachment factor B1: an intrinsic inhibitor of androgen receptor downregulated in prostate cancer. <i>Asian Journal of Andrology</i> , 2013, 15, 703-704.	0.8	1
3050	Response as a Measure of Treatment Efficacy in Clinical Trials: Should RECIST Be Abandoned?. , 2014, , 91-100.		0
3051	Impact of initial time to prostate-specific antigen nadir on survival in prostate cancer with bone metastasis initially treated with maximum androgen blockade therapy. <i>Journal of Cancer Research & Therapy</i> , 2013, 1, 201-207.	0.1	1
3052	Defining Clinical Endpoints in Castration-Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , 187-199.	0.0	0
3054	Bone-Targeted Therapy: Rationale and Current Status. <i>Current Clinical Urology</i> , 2014, , 139-153.	0.0	0
3055	Prostate Cancer in Older Adults. , 2014, , 273-288.		0
3056	Functional and metabolic complications of androgen deprivation therapy. <i>World Journal of Clinical Urology</i> , 2014, 3, 227.	0.0	0
3057	Prostatakarzinom. , 2014, , 513-676.		0
3060	Evidence-Based Therapeutic Approaches for mCRPC Patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development. <i>Current Clinical Urology</i> , 2014, , 321-327.	0.0	0
3061	Prostate Cancer Vaccines Generated with the Disruptive RNActive® Technology Follow the Path Paved by Sipuleucel-T and Prostavac-VF. , 2014, , 155-169.		0
3062	Management of Patients with Prostate Cancer. , 2014, , 17-47.		0
3064	Clinical Trials of Low-Dose Metronomic Chemotherapy in Castration-Resistant Prostate Cancer. , 2014, , 119-134.		1
3065	Phase II Targeted Treatments. <i>Current Clinical Urology</i> , 2014, , 177-186.	0.0	0
3066	Androgen Receptor Biology in Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , 67-75.	0.0	0
3067	Review of novel therapeutic medicines targeting androgen signaling in castration-resistant prostate cancer. <i>World Journal of Clinical Urology</i> , 2014, 3, 264.	0.0	0
3068	Geriatric considerations in the treatment of advanced prostate cancer. <i>F1000prime Reports</i> , 2014, 6, 33.	5.9	4
3071	Liver Metastases from Prostate Cancer. , 2015, , 183-206.		0
3072	Metastatic Castrate-resistant Prostate Cancer: When and How to Treat?. <i>The Journal of Oncopathology</i> , 2014, 1, 33-43.	0.1	0

#	ARTICLE	IF	CITATIONS
3073	Macroscopic Extramedullary Hematopoiesis Resembling Hepatic Metastases in Prostate Cancer. Journal of Cytology & Histology, 2015, 06, .	0.1	0
3074	Targeted Therapies for Prostate Cancer. Current Clinical Pathology, 2015, , 229-248.	0.0	0
3077	Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer. Asian Journal of Andrology, 2015, 17, 936.	0.8	1
3078	Comparative Effectiveness Research in Urologic Cancers. Cancer Treatment and Research, 2015, 164, 221-235.	0.2	0
3080	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
3081	Development of Severe Hypophosphatemia from Acquired Fanconi Syndrome during Treatment with Abiraterone. Journal of Case Reports and Studies, 2015, 2, .	0.0	0
3082	Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France.. Journal of Clinical Oncology, 2015, 33, 264-264.	0.8	0
3083	How to approach castration-resistant prostate cancer?. Marmara Medical Journal, 2015, 28, 24.	0.2	1
3084	Metastatic prostate cancer and spinal cord compression. , 2015, , 155-164.		0
3086	Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer?. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6167-6169.	0.5	0
3087	Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer. Urology Annals, 2016, 8, 123.	0.3	3
3088	Prostate Cancer in the Elderly. , 2016, , 63-72.		0
3089	Targeting of Steroid Hormone Receptor Function in Breast and Prostate Cancer. Endocrinology, 2016, , 1-21.	0.1	0
3090	Rapid bench to bed in management of metastatic prostate cancer. Indian Journal of Urology, 2016, 32, 255.	0.2	0
3091	Switching of GnRH Agent from Agonist to Antagonist in Patients with Castration-Resistant Prostate Cancer. Open Journal of Urology, 2016, 06, 190-198.	0.0	0
3092	Experience with abiraterone acetate in the treatment of metastatic prostate cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2016, 5, 61.	0.0	0
3093	Bone Preservation Strategies for Men on Androgen Deprivation Therapy. , 2016, , 231-257.		0
3094	Sequencing Therapies in Metastatic Castration-Resistant Prostate Cancer. , 2016, , 215-230.		0

#	ARTICLE	IF	CITATIONS
3095	Assessing the utility of cabazitaxel in mCRPC. Canadian Urological Association Journal, 2016, 10, 111.	0.3	0
3096	Abiraterone: A Review of its Pharmacokinetic, Pharmacodynamic Profile and Clinical Efficacy. Urology & Nephrology Open Access Journal, 2016, 3, .	0.1	0
3097	The Emerging Role of PARP Inhibitors in the Treatment of Prostate Cancer. , 0, , .		0
3098	Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation. Translational Cancer Research, 2016, 5, S529-S531.	0.4	0
3100	Bone-Targeted Agents. , 2017, , 181-192.		0
3102	Bone Metastases from Prostate Cancer: Hormonal Therapy. , 2017, , 105-120.		0
3103	Bone-Seeking Radionuclide for Therapy. , 2017, , 193-207.		0
3104	Chapter 1 Prostate Cancer: An Introduction. Traditional Herbal Medicines for Modern Times, 2016, , 1-16.	0.1	0
3106	Exceptional response after metronomic chemotherapy and palliative radiotherapy in castration-resistant prostate cancer: A case report. European Journal of Medical Case Reports, 0, , 135-139.	0.0	0
3107	Chemotherapy and Androgen Receptor-Directed Treatment of Castration Resistant Metastatic Prostate Cancer. , 2017, , 327-342.		0
3108	Combination of Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced and Localized Prostate Cancer. , 2017, , 217-230.		0
3109	Targeting the Androgen Receptor Signaling Axis. , 2017, , 134-153.		0
3110	Bone Target Therapy in Urologic Malignancies. , 2017, , 1-16.		0
3111	Long term response with abiraterone without lhrh analogs in metastatic castration resistant prostate cancer. Clinical Case Reports and Reviews, 2017, 3, .	0.1	0
3112	Drug interaction (39. Drug interaction in prostate cancer therapy). Okayama Igakkai Zasshi, 2017, 129, 131-136.	0.0	0
3113	Drug therapy methods in patients with metastatic castration-resistant prostate cancer: Role of somatostatin analogues. Onkologiya Zhurnal Imeni P A Gertsena, 2017, 6, 76.	0.0	0
3115	Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology. Korean Journal of Medicine, 2017, 92, 124-141.	0.1	2
3116	Chemotherapy With Androgen Deprivation for Hormone-Na~ve Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 11-15.	0.1	0

#	ARTICLE	IF	CITATIONS
3118	Epidemiology and Etiology. Molecular Pathology Library, 2018, , 13-26.	0.1	0
3119	The Role of Androgen Receptor in Prostate Cancer. Molecular Pathology Library, 2018, , 345-365.	0.1	1
3120	The Cell Cycle and Androgen Signaling Interactions in Prostate Cancer. Molecular Pathology Library, 2018, , 381-404.	0.1	1
3121	Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer. Onkourologiya, 2018, 13, 85-90.	0.1	1
3122	Applying precision medicine approach to metastatic castration-resistant prostate cancer: urgent education need on genomic oncology. , 2018, 02, .		0
3123	Investigation in silico the interaction of oxazoliny derivatives of [17(20)E]-21-norpregnene with androgen receptor. Biomedical Chemistry Research and Methods, 2018, 1, e00008.	0.1	0
3124	Alternative Antiandrogen Therapy for CRPC. , 2018, , 215-223.		0
3125	PSMA-Based Therapy of Metastasized Castrate-Resistant Prostate Cancer. , 2018, , 451-464.		0
3126	Prostate Gland Pathology. , 2018, , 267-395.		0
3127	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2018, , 1-14.		0
3128	Side Effects of Medical Cancer Therapy in Genitourinary Malignancies. , 2018, , 179-212.		0
3129	Optimization of Sequential AR Targeted Therapy for CRPC. , 2018, , 225-229.		0
3130	New Targeted Approach to CRPC. , 2018, , 375-385.		0
3131	Abiraterone Acetate Therapy for mCRPC in Japanese Men. , 2018, , 241-247.		0
3132	Therapy Monitoring of Oncologic Disease in the Abdomen (Including PET/CT). IDKD Springer Series, 2018, , 35-47.	0.8	0
3133	Detection of Circulating Tumor Cells in Castration-Resistant Prostate Cancer. , 2018, , 299-305.		0
3134	Synthesis and Binding of a Novel PSMA-specific Conjugate. Anticancer Research, 2018, 38, 1531-1537.	0.5	2
3137	Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy. Urologie Pro Praxi, 2018, 19, 61-63.	0.0	0

#	ARTICLE	IF	CITATIONS
3138	Osteoporosis in oncology. Bol ¹ , Sustavy, Pozvono ¹ nik, 2018, 8, 101-110.	0.1	0
3139	Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research, 2018, 7, 1135-1142.	0.4	2
3141	Is age the limitation of metastatic treatment prostate cancer?. Onkologie (Czech Republic), 2018, 12, 224-230.	0.0	0
3143	Androgen Deprivation Therapy for Advanced Prostate Cancer. , 2019, , 1-22.		0
3144	Uroonkologie beim ¹ Älteren Patienten. Springer Reference Medizin, 2019, , 1-10.	0.0	0
3145	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
3148	Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. Onkourologiya, 2019, 14, 139-149.	0.1	2
3149	Radionuclide therapy with radium-223 chloride. A few strokes to the patient ¹ 's portrait. Onkourologiya, 2019, 14, 87-94.	0.1	0
3150	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 241-253.		0
3151	Androgen Deprivation Therapy for Advanced Prostate Cancer. , 2019, , 255-276.		0
3153	Nanoparticles as theranostic vehicles in prostate cancer. Annals of Translational Medicine, 2019, 7, S29-S29.	0.7	1
3154	The Treatment of Metastatic and Castration-Resistant Prostate Cancer Patients in Korea. The Korean Journal of Urological Oncology, 2019, 17, 48-59.	0.1	0
3155	Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.. Journal of Clinical Oncology, 2019, 37, e16555-e16555.	0.8	1
3156	The role of ARTAs in treating metastatic castration-resistant prostate cancer. Urologie Pro Praxi, 2019, 20, 62-65.	0.0	0
3159	Factores predictivos del s ¹ ndrome de retirada de abiraterona. Actas Urol ³ gicas Espa [±] olas, 2019, 43, 300-304.	0.3	1
3161	Immunotherapy Landscape in ¹ Prostate Cancer: Successes, Failures and Promises. Annals of Urologic Oncology, 2019, , 1-18.	0.0	0
3163	Miscellaneous Metastases. , 2020, , 289-299.		0
3164	Possibilities of treatment of patients with castrationrefractory prostate cancer using enzalutamide. Meditsinskiy Sovet, 2019, , 176-180.	0.1	0

#	ARTICLE	IF	CITATIONS
3165	Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1497-1504.	2.3	1
3166	A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Cureus</i> , 2020, 12, e6806.	0.2	3
3167	Intracrine androgen biosynthesis and drug resistance. , 2020, 3, 912-929.		1
3169	The Current Status of Metastatic Castration-Resistant Prostate Cancer Management. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 11-17.	0.1	0
3170	Actualización del protocolo de manejo del cáncer de próstata resistente a la castración metastásico de la Asociación Andaluza de Urología. <i>Actas Urológicas Españolas</i> , 2020, 44, 125-130.	0.3	0
3172	Prostate Cancer Lymphangitic Pulmonary Carcinomatosis. <i>Clinical Nuclear Medicine</i> , 2020, 45, 727-729.	0.7	0
3173	Efficacy of abiraterone combined with flutamide on prostate cancer patients and its effect on serum miR-493-5p and miR-195-5p. <i>Oncology Letters</i> , 2020, 20, 1922-1930.	0.8	4
3174	New Androgen Receptor Axis-Targeted Agents in the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer: From Bench to Clinical Trials. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 99-108.	0.1	0
3175	Management of Patients With Advanced Prostate Cancer: Establishment of Treatment Guidelines Through Prostate Cancer Summit (PCAS) 2016 Composed of Korean Prostate Cancer Experts. <i>The Korean Journal of Urological Oncology</i> , 2020, 18, 124-139.	0.1	0
3177	Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies. <i>Cancers</i> , 2021, 13, 5417.	1.7	34
3178	Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. <i>Prostate International</i> , 2021, 10, 50-55.	1.2	3
3179	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era. <i>Cancer Medicine</i> , 2021, 10, 7909-7920.	1.3	2
3180	Identification of DNA Damage Repair-Associated Prognostic Biomarkers for Prostate Cancer Using Transcriptomic Data Analysis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11771.	1.8	6
3181	Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1584-1594.	3.3	24
3183	Choice of treatment options for metastatic hormone-sensitive prostate cancer. <i>Meditsinskiy Sovet</i> , 2020, , 90-99.	0.1	0
3184	The Estimate of Cytokines and Fibroblast Growth Factors in Patients with Breast Cancer. <i>Journal of Zankoy Sulaimani - Part A</i> , 2020, 22, 9-16.	0.1	0
3185	Novel therapeutic compounds for prostate adenocarcinoma treatment. <i>Medicine (United States)</i> , 2020, 99, e23768.	0.4	2
3186	Efficacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer. <i>Meditsinskiy Sovet</i> , 2020, , 70-82.	0.1	0

#	ARTICLE	IF	CITATIONS
3187	Abiraterone acetate plus prednisone/prednisolone in hormone-sensitive and castration-resistant metastatic prostate cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2021, 6, 41-49.	0.4	1
3188	More Than Androgens: Hormonal and Paracrine Signaling in Prostate Development and Homeostasis. , 2020, , 195-223.		0
3189	Alpha-therapy using radium-223 chloride in patients with castration-resistant prostate cancer. From clinical researches to routine practice. <i>Onkourologiya</i> , 2020, 15, 84-92.	0.1	0
3190	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study. <i>Investigative and Clinical Urology</i> , 2020, 61, 588.	1.0	4
3191	Sequential Treatment with Abiraterone and Enzalutamide in Swedish Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Universal Journal of Oncology</i> , 2020, 02, .	0.0	0
3192	A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer. <i>South Asian Journal of Cancer</i> , 2020, 09, 23-26.	0.2	1
3193	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
3194	Androgen Signaling in Metastatic Bone Disease. , 2020, , 305-314.		0
3195	Decreased biochemical progression in patients with castration-resistant prostate cancer using a novel mefenamic acid anti-inflammatory therapy: A randomized controlled trial. <i>Oncology Letters</i> , 2020, 19, 4151-4160.	0.8	6
3196	Papel del Índice neutrófilo/linfocito en pacientes con cáncer de próstata resistente a castración metastásicos tratados en primera línea con abiraterona. <i>Actas Urológicas Españolas</i> , 2020, 44, 164-171.	0.3	1
3197	Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting. <i>Prostate</i> , 2021, , .	1.2	2
3198	Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology. <i>Pharmacogenomics</i> , 2021, 22, 1237-1250.	0.6	1
3200	Mechanistic Insights into the Selective Dual BET and PLK1 Inhibitory Activity of a Novel Benzamide Compound in Castration-Resistant Prostate Cancer. <i>Chemistry and Biodiversity</i> , 2021, 18, e2100519.	1.0	1
3202	Pharmacoeconomic aspects of using enzalutamide for treatment of patients with nonmetastatic castration-resistant prostate cancer. <i>Onkourologiya</i> , 2020, 16, 82-96.	0.1	0
3203	Synthesis and Evaluation of \pm -Asaronol Esters with LDH and GABAA Receptor Modulation as Anticonvulsant Agents. <i>Letters in Drug Design and Discovery</i> , 2020, 17, 891-904.	0.4	3
3204	Uroonkologie beim Älteren Patienten. , 2014, , 317-326.		0
3205	Prostatakarzinom. , 2014, , 513-676.		0
3207	Abiraterone acetate and acute leukemia: a casual association?. <i>Anti-Cancer Drugs</i> , 2021, 32, 102-104.	0.7	2

#	ARTICLE	IF	CITATIONS
3208	Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives. <i>Current Drug Therapy</i> , 2020, 15, 168-180.	0.2	0
3210	Cabazitaxel (jevtana): a novel agent for metastatic castration-resistant prostate cancer. <i>P and T</i> , 2012, 37, 440-8.	1.0	16
3211	The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients. <i>P and T</i> , 2012, 37, 453-63.	1.0	1
3212	LHRH Agonists for the Treatment of Prostate Cancer: 2012. <i>Reviews in Urology</i> , 2012, 14, 1-12.	0.9	34
3213	The 2011 Gordon Wilson Lecture: overcoming resistance to targeted cancer drugs. <i>Transactions of the American Clinical and Climatological Association</i> , 2012, 123, 114-23; discussion 123-5.	0.9	10
3214	Endocrine manipulations in cancer prostate: A review. <i>Indian Journal of Endocrinology and Metabolism</i> , 2012, 16, S199-204.	0.2	1
3215	Abiraterone (zytiga), a novel agent for the management of castration-resistant prostate cancer. <i>P and T</i> , 2013, 38, 23-6.	1.0	13
3217	Management of metastatic castration-resistant prostate cancer. <i>European Urological Review</i> , 2011, 6, 90-96.	0.0	1
3218	Abiraterone for the Treatment of Advanced Prostate Cancer. <i>The International Journal of Targeted Therapies in Cancer</i> , 2012, 1, 40-42.	0.0	1
3219	Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options. <i>P and T</i> , 2014, 39, 130-43.	1.0	9
3221	Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasis. <i>American Journal of Clinical and Experimental Urology</i> , 2013, 1, 30-8.	0.4	3
3222	Splicing variants of androgen receptor in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2013, 1, 18-24.	0.4	8
3223	Wnt signaling in castration-resistant prostate cancer: implications for therapy. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 27-44.	0.4	46
3224	Revisiting nomenclature for the description of prostate cancer androgen-responsiveness. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 121-6.	0.4	1
3225	Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 92-101.	0.4	18
3226	PI-3 kinase p110 β : a therapeutic target in advanced prostate cancers. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 188-98.	0.4	16
3227	(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 72-82.	1.0	16
3229	Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer. <i>American Health and Drug Benefits</i> , 2015, 8, 185-95.	0.5	15

#	ARTICLE	IF	CITATIONS
3230	Drug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies. American Journal of Clinical and Experimental Urology, 2015, 3, 64-76.	0.4	49
3231	Potential role of CXCR3 in proliferation and invasion of prostate cancer cells. International Journal of Clinical and Experimental Pathology, 2015, 8, 8091-8.	0.5	10
3232	The HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells. American Journal of Cancer Research, 2015, 5, 3198-209.	1.4	4
3233	Translating insights of AR signaling from mouse models. Translational Andrology and Urology, 2013, 2, 197-201.	0.6	0
3234	Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients. Translational Andrology and Urology, 2013, 2, 92-3.	0.6	1
3235	Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clinical Biochemist Reviews, 2016, 37, 3-15.	3.3	265
3236	Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy. American Health and Drug Benefits, 2017, 10, 143-153.	0.5	20
3238	Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide. American Health and Drug Benefits, 2017, 10, 296-303.	0.5	20
3239	Prostate Cancer Academy 2017 Summaries. Reviews in Urology, 2017, 19, 252-260.	0.9	2
3240	A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients. International Journal of Hematology-Oncology and Stem Cell Research, 2018, 12, 4-7.	0.3	1
3241	Liquid Biopsy in Thyroid Cancer: New Insight. International Journal of Hematology-Oncology and Stem Cell Research, 2018, 12, 235-248.	0.3	25
3242	Immune modulatory functions of EZH2 in the tumor microenvironment: implications in cancer immunotherapy. American Journal of Clinical and Experimental Urology, 2019, 7, 85-91.	0.4	14
3243	Differential expression profiles of circRNAs in human prostate cancer based on chip and bioinformatic analysis. International Journal of Clinical and Experimental Pathology, 2020, 13, 1045-1052.	0.5	5
3244	Targeting treatment options for castration-resistant prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 101-120.	0.4	4
3245	Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer. American Health and Drug Benefits, 2021, 14, 15-20.	0.5	5
3246	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer-a narrative review. Translational Andrology and Urology, 2021, 10, 3188-3198.	0.6	1
3247	Dysregulated androgen synthesis and anti-androgen resistance in advanced prostate cancer. American Journal of Clinical and Experimental Urology, 2021, 9, 292-300.	0.4	0
3248	Mechanisms, Challenges, and Opportunities in Combined Radiation and Hormonal Therapies. Seminars in Radiation Oncology, 2022, 32, 76-81.	1.0	2

#	ARTICLE	IF	CITATIONS
3249	Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study. <i>BMC Medical Research Methodology</i> , 2021, 21, 263.	1.4	12
3250	rAAV-delivered PTEN therapeutics for prostate cancer. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 27, 122-132.	2.3	8
3251	Disparities in germline testing among racial minorities with prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 403-410.	2.0	22
3252	HER3 Is an Actionable Target in Advanced Prostate Cancer. <i>Cancer Research</i> , 2021, 81, 6207-6218.	0.4	25
3253	Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	2
3254	Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 5830.	1.7	19
3255	Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. <i>Urology</i> , 2022, 161, 50-58.	0.5	2
3256	Kastrationsresistentes fortgeschrittenes Prostatakarzinom: Viele innovative Substanzen. , 0, , .		0
3257	Progress in Clinical Application of Abiraterone in the Treatment of mCRPC. <i>Advances in Clinical Medicine</i> , 2021, 11, 5507-5513.	0.0	0
3258	Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. <i>Health Services and Outcomes Research Methodology</i> , 2022, 22, 317-331.	0.8	4
3260	Target delivery of photo-triggered nanocarrier for externally activated chemo-photodynamic therapy of prostate cancer. <i>Materials Today Chemistry</i> , 2022, 23, 100688.	1.7	11
3261	Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. <i>Minerva Urology and Nephrology</i> , 2022, 73, .	1.3	4
3262	Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3188-3198.	0.6	3
3263	Metastatic Prostate Cancer: Treatment Options. <i>Oncology</i> , 2022, 100, 48-59.	0.9	47
3264	An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13519.	1.8	13
3265	Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 293-301.	2.0	12
3266	A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	3
3267	Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling. <i>Prostate</i> , 2022, 82, 505-516.	1.2	9

#	ARTICLE	IF	CITATIONS
3268	Risk of Fatigue and Anemia in Patients With Prostate Cancer Treated With Novel Oral Anti-androgens: A Meta-Analysis of Randomized Controlled Trials. <i>Cureus</i> , 2022, 14, e21560.	0.2	0
3269	RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition. <i>Oncogene</i> , 2022, 41, 852-864.	2.6	18
3270	<i>RB1</i>, Cancer Lineage Plasticity, and Therapeutic Resistance. <i>Annual Review of Cancer Biology</i> , 2022, 6, 201-221.	2.3	5
3272	Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. <i>Cancers</i> , 2022, 14, 440.	1.7	20
3273	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 503.	1.7	21
3274	HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 667-676.	1.9	5
3275	Ethnic Pharmacogenomic Differences in the Management of Asian Patients with Metastatic Prostate Cancer. <i>Cancers</i> , 2022, 14, 407.	1.7	5
3276	Early prostate specific antigen decline and its velocity are independent predictive factors for outcomes of mCRPC patients treated with abiraterone acetate. <i>Military Medical Research</i> , 2022, 9, 5.	1.9	0
3277	Distribution and Effects of Estrogen Receptors in Prostate Cancer: Associated Molecular Mechanisms. <i>Frontiers in Endocrinology</i> , 2021, 12, 811578.	1.5	11
3278	Prognostic significance of risk stratification in CHARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer. <i>Prostate International</i> , 2022, 10, 7-13.	1.2	4
3279	High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer. <i>Asian Journal of Andrology</i> , 2022, 24, 147.	0.8	5
3280	Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 789319.	1.6	9
3282	Association of Novel Androgen Receptor Axis-Targeted Therapies With Diarrhea in Patients With Prostate Cancer: A Bayesian Network Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 800823.	1.2	2
3283	MiR-182-5p Modulates Prostate Cancer Aggressive Phenotypes by Targeting EMT Associated Pathways. <i>Biomolecules</i> , 2022, 12, 187.	1.8	7
3284	SU086, an inhibitor of HSP90, impairs glycolysis and represents a treatment strategy for advanced prostate cancer. <i>Cell Reports Medicine</i> , 2022, 3, 100502.	3.3	18
3285	Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1549-1559.	3.2	24
3286	Advances with androgen deprivation therapy for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1015-1033.	0.9	10
3287	PP2A promotes apoptosis and facilitates docetaxel sensitivity via the PP2A/pâ€‘eIF4B/XIAP signaling pathway in prostate cancer. <i>Oncology Letters</i> , 2022, 23, 101.	0.8	5

#	ARTICLE	IF	CITATIONS
3288	Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 314-319.	2.0	6
3289	Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT + ⁶⁸ Docetaxel. <i>Cancers</i> , 2022, 14, 815.	1.7	3
3290	Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	1.4	7
3291	Current and Emerging Therapies for Neuroendocrine Prostate Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3292	Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer. <i>Cancer Informatics</i> , 2022, 21, 117693512210870.	0.9	3
3293	Round up. <i>Indian Journal of Urology</i> , 2022, 38, 85.	0.2	0
3294	Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial. <i>BMC Cancer</i> , 2022, 22, 177.	1.1	2
3295	Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. <i>ChemistrySelect</i> , 2022, .	0.7	3
3296	Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients. <i>Translational Andrology and Urology</i> , 2022, 11, 202-212.	0.6	5
3297	Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer. <i>Nutrients</i> , 2022, 14, 851.	1.7	17
3298	⁶⁸ Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263132.	2.8	5
3299	Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. <i>Frontiers in Pharmacology</i> , 2022, 13, 843110.	1.6	3
3300	Is Low-Dose Abiraterone for Prostate Cancer An Attractive Strategy for Limited Resource Settings?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2022, 43, 040-046.	0.1	1
3301	History of androgens and androgen action. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101629.	2.2	4
3302	Application of Surface-Enhanced Raman Spectroscopy to Guide Therapy for Advanced Prostate Cancer Patients. <i>ACS Sensors</i> , 2022, 7, 827-838.	4.0	7
3304	Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review. <i>Cancers</i> , 2022, 14, 1792.	1.7	15
3305	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC. <i>Cancers</i> , 2022, 14, 1696.	1.7	10
3306	Prostate Cancer and Sleep Disorders: A Systematic Review. <i>Cancers</i> , 2022, 14, 1784.	1.7	5

#	ARTICLE	IF	CITATIONS
3307	Clinical Outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant Prostate Cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy. <i>Anticancer Research</i> , 2022, 42, 2123-2130.	0.5	3
3308	Treatment Outcomes in Neuroendocrine Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 2167-2176.	0.5	7
3309	Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	3
3310	Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). , 2022, 10, e004198.		19
3311	Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan. <i>Frontiers in Oncology</i> , 2022, 12, 822375.	1.3	2
3312	Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	2.0	5
3313	Androgen-targeting therapeutics mitigate the adverse effect of <sc>GnRH</sc> agonist on the risk of neurodegenerative disease in men treated for prostate cancer. <i>Cancer Medicine</i> , 2022, , .	1.3	4
3314	Identification of a Steroid Hormone-Associated Gene Signature Predicting the Prognosis of Prostate Cancer through an Integrative Bioinformatics Analysis. <i>Cancers</i> , 2022, 14, 1565.	1.7	4
3315	Characterization of long-term survivors of primary metastatic prostate cancer patients in Norway. <i>Acta Oncol</i> ³gica, 2022, 61, 615-618.	0.8	0
3316	Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers. <i>Research and Reports in Urology</i> , 2022, Volume 14, 87-108.	0.6	13
3317	Androgen Deprivation Therapy in High-Risk Localized and Locally Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 1803.	1.7	5
3318	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. <i>ESMO Open</i> , 2022, 7, 100431.	2.0	1
3319	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. <i>Cell Reports</i> , 2022, 39, 110595.	2.9	25
3320	Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation. <i>Pathology Research and Practice</i> , 2022, 233, 153851.	1.0	15
3321	Onco-hypertension: An Emerging Specialty. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 477-489.e1.	0.6	11
3322	Design, Synthesis, and Biological Evaluation of 1-(Indolizin-3-yl)ethan-1-ones as CBP Bromodomain Inhibitors for the Treatment of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 785-810.	2.9	23
3323	The value of anticancer drugs â€” a regulatory view. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 207-215.	12.5	14
3324	Structure-based discovery of selective CYP17A1 inhibitors for Castration-resistant prostate cancer treatment. <i>Biology Methods and Protocols</i> , 2022, 7, bpab026.	1.0	13

#	ARTICLE	IF	CITATIONS
3325	Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. <i>Nuklearmedizin - NuclearMedicine</i> , 2022, 61, 25-32.	0.3	6
3326	The Anti-Proliferative Activity of Secondary Metabolite from the Marine <i>Streptomyces</i> sp. against Prostate Cancer Cells. <i>Life</i> , 2021, 11, 1414.	1.1	9
3327	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile. <i>Life</i> , 2022, 12, 48.	1.1	49
3328	The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. <i>Clinical Cancer Research</i> , 2022, 28, 860-869.	3.2	4
3329	Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 778758.	1.5	7
3330	Insights of RKIP-Derived Suppression of Prostate Cancer. <i>Cancers</i> , 2021, 13, 6388.	1.7	6
3331	Novel lipid mediators contributing to androgen receptor therapy resistance in prostate cancer. <i>EBioMedicine</i> , 2021, 74, 103696.	2.7	0
3333	Redox-responsive nanoparticles enhance radiation therapy by altering multifaceted radio-resistance mechanisms in human castration-resistant prostate cancer cells and xenografts. <i>Radiotherapy and Oncology</i> , 2022, 170, 213-223.	0.3	8
3334	Management challenges and therapeutic advances in congenital adrenal hyperplasia. <i>Nature Reviews Endocrinology</i> , 2022, 18, 337-352.	4.3	34
3335	Management of prostate cancer by targeting 3 β HSD1 after enzalutamide and abiraterone treatment. <i>Cell Reports Medicine</i> , 2022, 3, 100608.	3.3	11
3336	Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1127-1134.	3.0	11
3337	LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 778-784.	2.0	7
3338	OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer. <i>Scientific Reports</i> , 2022, 12, 6094.	1.6	6
3339	Acute coronary syndrome in patients with cancer. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 275-290.	0.6	4
3340	Hormone Treatment of Prostate Cancer. <i>Urologic Clinics of North America</i> , 2022, 49, 309-321.	0.8	1
3354	Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. <i>Journal of Medical Economics</i> , 2022, 25, 583-590.	1.0	2
3355	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). <i>Journal of Clinical Oncology</i> , 2022, 40, 3301-3309.	0.8	14
3357	WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?. <i>Acta Clinica Croatica</i> , 2019, 58, 36-41.	0.1	0

#	ARTICLE	IF	CITATIONS
3358	Ascending flaccid paralysis secondary to hypokalemia in a cancer patient using abiraterone – a case report. <i>Current Drug Safety</i> , 2022, 17, .	0.3	1
3362	Endocrine manipulations in cancer prostate: A review. <i>Indian Journal of Endocrinology and Metabolism</i> , 2012, 16, 199.	0.2	1
3364	Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.. <i>Cancer Health Disparities</i> , 2020, 4, .	0.5	0
3365	Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.. <i>Clinical Advances in Hematology and Oncology</i> , 2022, 20, 227-238.	0.3	0
3367	Mechanisms of Resistance to Second-Generation Antiandrogen Therapy for Prostate Cancer: Actual Knowledge and Perspectives. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 25.	1.3	10
3368	Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 871259.	1.6	2
3369	Impact of Novel Hormonal Agents (Abiraterone, Enzalutamide) on the Development of Visceral and/or Brain Metastases in Patients With Bone-metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
3370	Comprehensive analysis of the associations between clinical factors and outcomes by machine learning, using post marketing surveillance data of cabazitaxel in patients with castration-resistant prostate cancer. <i>BMC Cancer</i> , 2022, 22, 470.	1.1	1
3371	Protein kinase C δ in cancer: a contextual balance of time and signals. <i>Trends in Cell Biology</i> , 2022, 32, 1023-1034.	3.6	5
3372	Lower Fracture Rates in Patients Treated with Radium-223, Abiraterone or Enzalutamide, When Given Concurrently with Bone Health Agents: A Real-World Analysis. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 399-403.	0.9	4
3373	Real-world cabazitaxel use and outcomes in metastatic castrate-resistant prostate cancer: the impact of response to first ARPI. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	0
3374	Sex steroid hormones in urinary exosomes as biomarkers for the prediction of prostate cancer. <i>Clinica Chimica Acta</i> , 2022, 531, 389-398.	0.5	6
3375	ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer. <i>Nature Communications</i> , 2022, 13, 2282.	5.8	34
3376	Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. <i>Cancers</i> , 2022, 14, 2219.	1.7	5
3377	The Novel Function of Unsymmetrical Chiral CCN Pincer Nickel Complexes as Chemotherapeutic Agents Targeting Prostate Cancer Cells. <i>Molecules</i> , 2022, 27, 3106.	1.7	2
3378	Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. <i>CNS Drugs</i> , 2022, 36, 419-449.	2.7	6
3379	Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management. <i>Current Opinion in Urology</i> , 2022, 32, 283-291.	0.9	4
3380	Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer. <i>Scientific Reports</i> , 2022, 12, 7319.	1.6	1

#	ARTICLE	IF	CITATIONS
3381	Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer. <i>Oncogene</i> , 2022, 41, 3251-3262.	2.6	6
3382	Pharmacoeconomic evaluation of using enzalutamide for treatment of patients with metastatic hormone-sensitive prostate cancer. <i>Onkourologiya</i> , 2022, 18, 90-105.	0.1	0
3383	Combining Real-World and Randomized Control Trial Data Using Data-Adaptive Weighting via the On-Trial Score. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 408-420.	0.6	2
3384	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. <i>European Journal of Cancer</i> , 2022, 170, 296-304.	1.3	14
3385	Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
3386	Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review. <i>Cancers</i> , 2022, 14, 2470.	1.7	4
3387	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0
3388	Metronomic Chemotherapy in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2853.	1.0	6
3389	Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial. <i>European Urology Open Science</i> , 2022, 41, 16-23.	0.2	3
3390	Neutropenia, neutrophilia, and neutrophilâ€”lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211000.	1.4	4
3391	Current Trends in Advanced Prostate Cancer Medical Setting. <i>Proceedings of the Latvian Academy of Sciences</i> , 2022, 76, 168-180.	0.0	0
3392	PTENâ€”PI3K pathway alterations in advanced prostate cancer and clinical implications. <i>Prostate</i> , 2022, 82, .	1.2	20
3393	Prostate Cancer Treatment: ¹⁷⁷ Lu-PSMA-617 Considerations, Concepts, and Limitations. <i>Journal of Nuclear Medicine</i> , 2022, 63, 823-829.	2.8	6
3395	Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2022, 5, 667-90.	0.9	8
3396	Metastasis Model to Test the Role of Notch Signaling in Prostate Cancer. <i>Methods in Molecular Biology</i> , 2022, , 221-233.	0.4	1
3397	Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy. <i>In Vivo</i> , 2022, 36, 1841-1846.	0.6	1
3399	Proteome profiling of enzalutamideâ€”resistant cell lines and serum analysis identified <i>ALCAM</i> as marker of resistance in castrationâ€”resistant prostate cancer. <i>International Journal of Cancer</i> , 0, , .	2.3	3
3401	Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castrationâ€”resistant prostate cancer. <i>Prostate</i> , 2022, 82, 1284-1292.	1.2	2

#	ARTICLE	IF	CITATIONS
3402	Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. <i>BJUI Compass</i> , 0, , .	0.7	1
3403	Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	0.8	1
3404	Usefulness of serum CCL2 as prognostic biomarker in prostate cancer: a long-term follow-up study. <i>Japanese Journal of Clinical Oncology</i> , 0, , .	0.6	3
3405	Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	12
3406	Cell Line Characteristics Predict Subsequent Resistance to Androgen Receptor-Targeted Agents (ARTA) in Preclinical Models of Prostate Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
3407	Liquid biopsy as a cancer biomarker-potential, and challenges. , 2022, , 203-244.		0
3408	The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3409	Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?. <i>Actas Urológicas Españolas (English Edition)</i> , 2022, , .	0.2	0
3410	PD-L1 Up-Regulation in Prostate Cancer Cells by <i>Porphyromonas gingivalis</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	12
3411	Concurrent Androgen Deprivation Therapy for Prostate Cancer Improves Survival for Synchronous or Metachronous Non-Small Cell Lung Cancer: A SEER Medicare Database Analysis. <i>Cancers</i> , 2022, 14, 3206.	1.7	4
3412	Simultaneous Determination of Steroids and Glucocorticoids in Human Urine by Ultra-High-Performance Liquid Chromatography Tandem Mass Spectrometry (UPLC-MS/MS). <i>Analytical Letters</i> , 2023, 56, 148-165.	1.0	1
3413	An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective. <i>BMC Health Services Research</i> , 2022, 22, .	0.9	0
3414	Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice. , 2022, 39, .		5
3415	The Role of Curcumin in Prostate Cancer Cells and Derived Spheroids. <i>Cancers</i> , 2022, 14, 3348.	1.7	12
3416	Bone health assessment with dual energy X-ray absorptiometry in men with high-risk prostate carcinoma commencing adjuvant androgen deprivation therapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 0, , .	0.3	0
3417	Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. <i>European Urology Oncology</i> , 2022, 5, 494-502.	2.6	21
3418	Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
3419	Phase Ib Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3979-3989.	3.2	8

#	ARTICLE	IF	CITATIONS
3420	The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
3421	Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series. <i>Histopathology</i> , 2022, 81, 246-254.	1.6	6
3422	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. <i>ESMO Open</i> , 2022, 7, 100518.	2.0	10
3423	Increasing the efficacy of abiraterone - from pharmacokinetics, through therapeutic drug monitoring to overcoming food effects with innovative pharmaceutical products. <i>European Journal of Pharmaceutical Sciences</i> , 2022, 176, 106254.	1.9	3
3424	Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer. <i>Annals of the Academy of Medicine, Singapore</i> , 2015, 44, 397-405.	0.2	7
3425	Current and emerging therapies for neuroendocrine prostate cancer. , 2022, 238, 108255.		13
3426	Diffuse Synaptophysin Expression in Aggressive Recurrent Castration-Resistant Acinar (Usual) Prostate Cancer: Case Report and Review of Prostatic Neuroendocrine Tumors. <i>AJSP Review and Reports</i> , 2020, 25, 114-122.	0.0	0
3428	Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic. <i>American Journal of Men's Health</i> , 2022, 16, 155798832211155.	0.7	1
3429	The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8535.	1.8	9
3430	Patterns of structural variation define prostate cancer across disease states. <i>JCI Insight</i> , 2022, 7, .	2.3	3
3431	Reformation of the chondroitin sulfate glyocalyx enables progression of AR-independent prostate cancer. <i>Nature Communications</i> , 2022, 13, .	5.8	4
3432	Factors influencing survival in metastatic castration-resistant prostate cancer therapy. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1061-1079.	1.1	2
3433	The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients. <i>Translational Andrology and Urology</i> , 2022, 11, 1169-1176.	0.6	0
3434	Androgen receptor axis-targeted agents are not superior to conventional hormonal therapy for treatment of metastatic prostate cancer. <i>Oncology Letters</i> , 2022, 24, .	0.8	0
3435	Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 1139-1145.	1.3	2
3436	The Overall Survival and Safety of Men with Metastatic Hormone-Sensitive Prostate Cancer Treated with Combination Therapy of Novel Androgen Receptor Antagonists and Androgen-Deprivation Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	0
3437	Resistance to prostate cancer treatments. <i>IUBMB Life</i> , 2023, 75, 390-410.	1.5	4
3439	Bone-only oligometastatic prostate cancer: can SABR improve outcomes? A single-center experience. <i>Radiation Oncology Journal</i> , 2022, 40, 192-199.	0.7	1

#	ARTICLE	IF	CITATIONS
3440	Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormones. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	0
3441	The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128951.	1.0	3
3442	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
3443	AR Structural Variants and Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2022, , 195-211.	0.8	2
3444	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
3445	Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemo-naïve patients with metastatic castration-resistant prostate cancer. <i>Investigative and Clinical Urology</i> , 2022, 63, 546.	1.0	1
3446	Androgen receptor in breast cancer: The "5W" questions. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	10
3447	Novel AR/AR-V7 and Mnk1/2 Degradar, VNPP433-3 rd : Molecular Mechanisms of Action and Efficacy in AR-Overexpressing Castration Resistant Prostate Cancer In Vitro and In Vivo Models. <i>Cells</i> , 2022, 11, 2699.	1.8	8
3448	Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. <i>European Urology</i> , 2023, 83, 15-26.	0.9	22
3449	Predictive factors for the effectiveness of novel androgen receptor axis-targeted agents in patients with metastatic prostate cancer. <i>International Journal of Urology</i> , 0, , .	0.5	1
3450	Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. <i>Prostate</i> , 2022, 82, 1483-1490.	1.2	4
3451	Investigation into the Optimal Strategy of Radium-223 Therapy for Metastatic Castration-Resistant Prostate Cancer. <i>Radiation</i> , 2022, 2, 273-284.	0.6	3
3452	PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures. <i>Cancers</i> , 2022, 14, 4751.	1.7	4
3453	Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. <i>Research and Reports in Urology</i> , 0, Volume 14, 339-350.	0.6	8
3455	Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 4714.	1.7	0
3456	Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes. <i>Communications Medicine</i> , 2022, 2, .	1.9	2
3457	Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer. <i>Medical Science Monitor</i> , 0, 28, .	0.5	1
3458	Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 743-750.	2.0	7

#	ARTICLE	IF	CITATIONS
3459	Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1 <i>H</i> -pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 13074-13093.	2.9	2
3460	Metastatic prostate cancer gets into the biomarker era. <i>Canadian Urological Association Journal</i> , 2022, 16, 333.	0.3	0
3461	Emerging hormonal agents for the treatment of prostate cancer. <i>Expert Opinion on Emerging Drugs</i> , 2022, 27, 301-309.	1.0	2
3462	UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	0
3463	Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study. <i>Anticancer Research</i> , 2022, 42, 4857-4866.	0.5	0
3464	Remission of progressive metastatic castration-resistant prostate cancer during abiraterone therapy following unilateral adrenalectomy for a functioning adrenal adenoma. <i>BMJ Case Reports</i> , 2022, 15, e251036.	0.2	1
3465	Modern paradigms for prostate cancer detection and management. <i>Medical Journal of Australia</i> , 2022, 217, 424-433.	0.8	13
3466	A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications. <i>European Journal of Medicinal Chemistry Reports</i> , 2022, 6, 100084.	0.6	2
3467	EFFECT OF NEW ANDROGEN RECEPTOR AXIS-TARGETED AGENTS ON SURVIVAL OF CASTRATION-RESISTANT PROSTATE CANCER. <i>Japanese Journal of Urology</i> , 2021, 112, 207-214.	0.0	0
3468	A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	8
3470	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
3471	Application of support vector machine algorithm for early differential diagnosis of prostate cancer. <i>Data Science and Management</i> , 2023, 6, 1-12.	4.1	7
3472	Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. <i>British Journal of Cancer</i> , 0, , .	2.9	1
3473	The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 4877.	1.7	12
3474	Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3476	Impact of treatment on elder-relevant physical function and quality of life outcomes in older adults with metastatic castration-resistant prostate cancer. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101395.	0.5	2
3477	2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2022, 16, E506-15.	0.3	4
3478	Perioperative morbidity of radical prostatectomy after intensive neoadjuvant androgen blockade in men with high-risk prostate cancer: results of phase II trial compared to a control group. <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	2

#	ARTICLE	IF	CITATIONS
3480	A COP1-GATA2 axis suppresses AR signaling and prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	5
3481	Repression of <i>SLC22A3</i> by the AR/YAP1/TAZ axis in enzalutamide-resistant castration-resistant prostate cancer. FEBS Journal, 2023, 290, 1645-1662.	2.2	2
3482	Juglone promotes antitumor activity against prostate cancer via suppressing glycolysis and oxidative phosphorylation. Phytotherapy Research, 2023, 37, 515-526.	2.8	3
3483	In Silico Identification of Promising New Pyrazole Derivative-Based Small Molecules for Modulating CRMP2, C-RAF, CYP17, VEGFR, C-KIT, and HDAC Application towards Cancer Therapeutics. Current Issues in Molecular Biology, 2022, 44, 5312-5351.	1.0	3
3484	Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. Expert Review of Anticancer Therapy, 2022, 22, 1163-1175.	1.1	6
3485	Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2. Frontiers in Oncology, 0, 12, .	1.3	5
3486	The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations. Expert Review of Clinical Pharmacology, 2022, 15, 1293-1304.	1.3	0
3487	UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways. Cancer Letters, 2023, 553, 215994.	3.2	2
3488	Ginsenoside compound K suppresses tumour growth in the 22Rv1 xenograft model and inhibits androgenic responses via the transcriptional mechanism in human prostate cancer cells. FEBS Journal, 2023, 290, 1840-1854.	2.2	2
3489	Long Term Use and Risk of Major Adverse Cardiac Events: Comparing Enzalutamide and Abiraterone in Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer. International Journal of Cancer, 0, , .	2.3	1
3490	Cardiovascular complications of treatment for prostate cancer. British Journal of Hospital Medicine (London, England: 2005), 2022, 83, 1-12.	0.2	3
3491	SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXR±/FOXM1 pathway independently of REV-ERBs. Cell Death and Disease, 2022, 13, .	2.7	7
3492	Utilization Trends of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer in Quebec. Current Oncology, 2022, 29, 8626-8637.	0.9	2
3493	Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors. Current Opinion in Supportive and Palliative Care, 2022, 16, 223-229.	0.5	2
3494	A population-based study of factors associated with systemic treatment in advanced prostate cancer decedents. Cancer Medicine, 0, , .	1.3	3
3495	Potential target identification for osteosarcoma treatment: Gene expression re-analysis and drug repurposing. Gene, 2023, 856, 147106.	1.0	0
3496	Guidelines on Management of Prostate Cancer. Annals of the Academy of Medicine, Singapore, 2013, 42, 190-199.	0.2	9
3497	A Phase I Study of Capiwasertib in Combination With Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2023, 21, 278-285.	0.9	4

#	ARTICLE	IF	CITATIONS
3498	Current Developments in Cellular Therapy for Castration Resistant Prostate Cancer: A Systematic Review of Clinical Studies. <i>Cancers</i> , 2022, 14, 5719.	1.7	2
3499	Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. <i>Current Oncology</i> , 2022, 29, 9511-9524.	0.9	3
3500	The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer. <i>British Journal of Cancer</i> , 2023, 128, 918-927.	2.9	4
3501	A Comprehensive Overview of Small-Molecule Androgen Receptor Degraders: Recent Progress and Future Perspectives. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 16128-16154.	2.9	10
3502	Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?. <i>Cancers</i> , 2022, 14, 6071.	1.7	7
3503	The impact of locoregional treatments for metastatic castration resistant prostate cancer on disease progression: real life experience from a multicenter cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2024, 27, 89-94.	2.0	3
3504	The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 4183-4192.	1.1	1
3505	Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database. <i>World Journal of Oncology</i> , 2022, 13, 350-358.	0.6	0
3506	The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications. <i>Nature Reviews Urology</i> , 2023, 20, 265-278.	1.9	10
3507	TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer. <i>Oncogene</i> , 2023, 42, 559-571.	2.6	4
3508	Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	0
3509	Examining the Effect of PARP-1 Inhibitors on Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells. <i>Methods in Molecular Biology</i> , 2023, , 329-335.	0.4	2
3510	Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
3511	Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer. <i>Biomedicines</i> , 2022, 10, 3262.	1.4	2
3512	AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer. <i>Oncogenesis</i> , 2023, 12, .	2.1	4
3513	<sc>YAP</sc> antagonizes <sc>TEAD</sc>'s mediated <sc>AR</sc> signaling and prostate cancer growth. <i>EMBO Journal</i> , 2023, 42, .	3.5	5
3514	Abiraterone and Docetaxel Treatments Increase Phospho-PTEN Expression in Metastatic Prostate Cancer Cells. , 2023, 13, 6-10.		0
3515	Prevalence and Causes of Discontinuation of Androgen Receptor Inhibitors in Advanced Prostate Cancer Patients and Analysis of Physician Management to Increase Duration of Therapy. <i>Urology</i> , 2023, 173, 142-148.	0.5	1

#	ARTICLE	IF	CITATIONS
3516	Molecular Mechanisms of Noncoding RNA in the Occurrence of Castration-Resistant Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1305.	1.8	2
3517	How to Improve the Quality of Life of Patients with Prostate Cancer Treated with Hormone Therapy?. <i>Research and Reports in Urology</i> , 0, Volume 15, 9-26.	0.6	1
3518	Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?. <i>Future Oncology</i> , 0, , .	1.1	0
3519	STAT3 signaling in prostate cancer progression and therapy resistance: An oncogenic pathway with diverse functions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114168.	2.5	3
3520	Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. <i>European Journal of Medicinal Chemistry</i> , 2023, 247, 115077.	2.6	8
3521	Hydroxylation and lyase reactions of steroids catalyzed by mouse cytochrome P450 17A1 (Cyp17a1). <i>Journal of Inorganic Biochemistry</i> , 2023, 240, 112085.	1.5	6
3522	Androgen-Independent Prostate Cancer Is Sensitive to CDC42-PAK7 Kinase Inhibition. <i>Biomedicines</i> , 2023, 11, 101.	1.4	2
3523	Enzalutamide or Abiraterone Acetate With Prednisone in the Treatment of Metastatic Castration-resistant Prostate Cancer in Real-life Clinical Practice: A Long-term Single Institution Experience. <i>Anticancer Research</i> , 2023, 43, 463-471.	0.5	1
3524	Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials. <i>Current Opinion in Urology</i> , 2023, 33, 219-229.	0.9	3
3525	Niclosamide in prostate cancer: An inhibitor of AR-V7, a mitochondrial uncoupler, or more?. <i>Cancer Treatment and Research Communications</i> , 2023, 35, 100685.	0.7	0
3526	Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer. <i>ELife</i> , 0, 12, .	2.8	6
3527	AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2046.	1.8	12
3528	Effects of In-office Dispensing by Single-specialty Urology Practices on Management of Advanced Prostate Cancer. <i>Urology Practice</i> , 2023, 10, 230-235.	0.2	1
3529	Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. <i>World Journal of Men's Health</i> , 2023, 41, 769.	1.7	10
3530	IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms. <i>Journal of Advanced Research</i> , 2023, 54, 195-210.	4.4	2
3531	State-Of-The-Art Treatment in Castration-Resistant Prostate Cancer. <i>European Medical Journal Oncology</i> , 0, , 10-105.	0.0	0
3532	Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). <i>Journal of Clinical Oncology</i> , 2023, 41, 3608-3615.	0.8	2
3533	Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1887-1893.	3.2	1

#	ARTICLE	IF	CITATIONS
3534	Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. <i>Annals of Oncology</i> , 2023, 34, 557-563.	0.6	10
3535	Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer. <i>Biomarker Research</i> , 2023, 11, .	2.8	0
3536	Activity and safety of KEES - an oral multi-drug chemo-hormonal metronomic combination regimen in metastatic castration-resistant prostate cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
3537	Current therapy and drug resistance in metastatic castration-resistant prostate cancer. <i>Drug Resistance Updates</i> , 2023, 68, 100962.	6.5	30
3538	Cancer stem cell in prostate cancer progression, metastasis and therapy resistance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2023, 1878, 188887.	3.3	7
3539	Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. <i>Oncogene</i> , 2023, 42, 926-937.	2.6	12
3540	Mechanisms of Prostate Cancer Cells Survival and Their Therapeutic Targeting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2939.	1.8	5
3541	Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3083.	1.8	6
3542	Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2023, 12, 8251-8266.	1.3	1
3543	Circular RNAs in Prostate Cancer: Is it Time to Further Explore Liquid Biopsies?. <i>Mini-Reviews in Medicinal Chemistry</i> , 2023, 23, .	1.1	0
3544	Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site. <i>Journal of Biological Chemistry</i> , 2023, 299, 102999.	1.6	4
3545	Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer. <i>Cancer Treatment Reviews</i> , 2023, 115, 102524.	3.4	4
3546	Bayesian Machine Learning Enables Identification of Transcriptional Network Disruptions Associated with Drug-Resistant Prostate Cancer. <i>Cancer Research</i> , 2023, 83, 1361-1380.	0.4	3
3547	Preclinical models of prostate cancer " modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo. <i>Nature Reviews Urology</i> , 2023, 20, 480-493.	1.9	5
3548	Differential adoption of castration-resistant prostate cancer treatment across facilities in a national healthcare system. <i>Cancer Medicine</i> , 2023, 12, 6945-6955.	1.3	0
3549	miR-29a-5p modulates ferroptosis by targeting ferritin heavy chain FTH1 in prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2023, 652, 6-13.	1.0	4
3550	Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer. <i>Biology Bulletin</i> , 2022, 49, 2285-2297.	0.1	0
3551	Bone Metastases and Health in Prostate Cancer: From Pathophysiology to Clinical Implications. <i>Cancers</i> , 2023, 15, 1518.	1.7	7

#	ARTICLE	IF	CITATIONS
3552	Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
3553	Vaccines as treatments for prostate cancer. <i>Nature Reviews Urology</i> , 2023, 20, 544-559.	1.9	8
3554	Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain. <i>Journal of Health Economics and Outcomes Research</i> , 0, , 1-14.	0.6	0
3555	Development and validation of a survival nomogram and calculator for male patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate and/or enzalutamide. <i>BMC Cancer</i> , 2023, 23, .	1.1	0
3556	Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. <i>European Urology</i> , 2023, 83, 571-579.	0.9	3
3557	A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC-MS/MS. <i>Prostate</i> , 2023, 83, 759-764.	1.2	0
3558	Advances in Molecular Imaging and Therapy and Its Impact in Oncologic Imaging. <i>IDKD Springer Series</i> , 2023, , 31-45.	0.8	0
3559	Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 2324-2335.	3.2	7
3560	Role of Androgen Receptor-Targeted Agents in Localized Prostate Cancer. <i>Acta Clinica Croatica</i> , 2022, , .	0.1	0
3561	HOXB3 drives WNT-activation associated progression in castration-resistant prostate cancer. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	0
3562	Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592311528.	1.4	2
3563	Toward Precision Medicine: Development and Validation of A Machine Learning Based Decision Support System for Optimal Sequencing in Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, e2111-e218.e4.	0.9	0
3564	Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). <i>Journal of Clinical Oncology</i> , 2023, 41, 3352-3362.	0.8	4
3565	Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. <i>Journal of Personalized Medicine</i> , 2023, 13, 608.	1.1	1
3566	Cancer-associated fibroblast-secreted glucosamine alters the androgen biosynthesis program in prostate cancer via HSD3B1 upregulation. <i>Journal of Clinical Investigation</i> , 2023, 133, .	3.9	8
3567	Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3568	Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer. <i>Oncologist</i> , 2023, 28, 465-473.	1.9	3
3569	Cardiovascular Complications in Patients with Prostate Cancer: Potential Molecular Connections. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6984.	1.8	5

#	ARTICLE	IF	CITATIONS
3570	External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 2736-2746.	0.8	3
3571	The clinical and biochemical significance of 11-oxygenated androgens in human health and disease. <i>European Journal of Endocrinology</i> , 2023, 188, R98-R109.	1.9	8
3572	Hormonal Therapies for Patients with Advanced Prostate Cancer. <i>European Medical Journal</i> (Chelmsford, England), 0, , 39-51.	3.0	0
3573	Abiraterone-Induced Endocrinopathies. , 2023, 1, .		1
3574	Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials. <i>Clinical Cancer Research</i> , 2023, 29, 2426-2434.	3.2	2
3575	Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer. <i>Prostate</i> , 0, , .	1.2	1
3576	Hormonal therapy. , 2023, , 161-204.		0
3584	Therapeutic applications of the prostate cancer epigenome. , 2023, , 301-337.		0
3600	Models of multidisciplinary management. , 2024, , 39-44.		0
3601	Case Report: Long-term complete response to PSMA-targeted radioligand therapy and abiraterone in a metastatic prostate cancer patient. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
3605	Management of bone metastasis in prostate cancer. <i>Journal of Bone and Mineral Metabolism</i> , 2023, 41, 317-326.	1.3	2
3621	Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide. <i>Clinical Pharmacokinetics</i> , 0, , .	1.6	1
3627	Androgen Receptor in Health and Disease. , 2023, , 21-75.		0
3643	Targeting sex steroid biosynthesis for breast and prostate cancer therapy. <i>Nature Reviews Cancer</i> , 2023, 23, 686-709.	12.8	1
3648	En bloc resection of bladder tumors (ERBT) revisited 12 years after reintroduction: too good to be further ignored. <i>World Journal of Urology</i> , 2023, 41, 2577-2582.	1.2	0
3654	Androgen Receptor Signaling: A Central and Evolving Theme in Prostate Cancer Treatment. , 2023, , 1-29.		0
3658	Metastatic Prostate Cancer. , 2023, , 241-255.		0
3666	Therapeutic, diagnostic and prognostic values of TRIM proteins in prostate cancer. <i>Pharmacological Reports</i> , 2023, 75, 1445-1453.	1.5	1

#	ARTICLE	IF	CITATIONS
3668	Overcoming resistance in prostate cancer with targeted and small molecule-based therapies. , 2024, , 255-287.		0
3669	Androgen receptor-dependent mechanisms mediating therapy resistance in prostate cancer. , 2024, , 57-84.		0
3681	Case Study #8: Alpha-Therapy with Radium-223 Dichloride for Metastatic Castration-Resistant Prostate Cancer. , 2023, , 387-405.		0
3695	Beta-blocker adjunct therapy as a prospective anti-metastatic with cardio-oncologic regulation. Clinical and Experimental Metastasis, 2024, 41, 9-24.	1.7	0
3699	Therapy of Castration-Resistant Prostate Cancer: Where Is the Place of 225Ac-PSMA?. , 2024, , 255-265.		0
3735	Urologische Tumoren. , 2024, , 239-274.		0